




上海君实生物醫藥科技股份有限公司 Shanghai Junshi Biosciences Co., Ltd.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

Stock code: 1877



2026

INTERIM REPORT

* For identification purpose only

CONTENTS

2	Corporate Information
4	Highlights
8	Management Discussion and Analysis
40	Other Information
63	Report on Review of Condensed Consolidated Financial Statements
64	Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income
66	Condensed Consolidated Statement of Financial Position
68	Condensed Consolidated Statement of Changes in Equity
70	Condensed Consolidated Statement of Cash Flows
72	Notes to the Condensed Consolidated Financial Statements
103	Definitions



CORPORATE INFORMATION

EXECUTIVE DIRECTORS

Mr. Xiong Jun (*Chairman and Legal Representative*)
 Dr. Li Ning (*Vice Chairman*)
 Dr. Zou Jianjun (*Chief Executive Officer and General Manager*)
 Mr. Li Cong (*Co-Chief Executive Officer*)
 Mr. Zhang Zhuobing
 Dr. Wang Gang
 Dr. Li Xin

NON-EXECUTIVE DIRECTORS

Dr. Yao Sheng¹
 Mr. Tang Yi

INDEPENDENT NON-EXECUTIVE DIRECTORS

Mr. Zhang Chun²
 Dr. Feng Xiaoyuan
 Mr. Li Zhongxian³
 Ms. Lu Kun
 Dr. Yang Jin
 Mr. Chen Liang⁴

AUDIT COMMITTEE

Mr. Li Zhongxian³ (*Chairman*)
 Mr. Tang Yi
 Mr. Chen Liang⁴
 Mr. Zhang Chun²

NOMINATION COMMITTEE

Dr. Feng Xiaoyuan (*Chairman*)
 Mr. Xiong Jun
 Ms. Lu Kun

REMUNERATION AND APPRAISAL COMMITTEE

Mr. Li Zhongxian³ (*Chairman*)
 Mr. Xiong Jun
 Dr. Zou Jianjun
 Dr. Feng Xiaoyuan
 Dr. Yang Jin
 Mr. Zhang Chun²

STRATEGIC AND ESG COMMITTEE⁵

Mr. Xiong Jun (*Chairman*)
 Dr. Zou Jianjun
 Dr. Wang Gang
 Dr. Feng Xiaoyuan
 Mr. Li Zhongxian³
 Mr. Zhang Chun²

COMPLIANCE COMMITTEE

Ms. Lu Kun (*Chairman*)
 Mr. Li Zhongxian³
 Mr. Chen Liang⁴
 Mr. Zhang Chun²

JOINT COMPANY SECRETARIES

Mr. Wang Zhengyu
 Ms. Lai Siu Kuen

AUTHORIZED REPRESENTATIVES

Mr. Wang Zhengyu
 Ms. Lai Siu Kuen

REGISTERED ADDRESS, HEADQUARTERS AND PRINCIPAL PLACE OF BUSINESS IN THE PRC

Level 4, No. 987 Cai Lun Road,
 China (Shanghai) Pilot Free Trade Zone,
 the PRC

CORPORATE INFORMATION

PRINCIPAL PLACE OF BUSINESS IN HONG KONG UNDER PART 16 OF THE COMPANIES ORDINANCE

Room 1918, 19/F, Lee Garden One
33 Hysan Avenue
Causeway Bay
Hong Kong

H SHARE REGISTRAR

Tricor Investor Services Limited
17/F, Far East Finance Centre
16 Harcourt Road
Hong Kong

LEGAL ADVISERS

Jones Day (as to Hong Kong law)
Jia Yuan Law Offices (as to PRC law)

AUDITOR

Deloitte Touche Tohmatsu
Registered Public Interest Entity Auditors

LISTING

H Shares on the Hong Kong Stock Exchange
(Stock code: 01877)
A Shares on the STAR Market
(Stock code: 688180)

NUMBER OF SHARES (AS AT THE DATE OF THIS REPORT)

1,026,689,871 Shares
(including 260,295,700 H Shares and
766,394,171 A Shares)

BOARD LOT OF H SHARES

200 H Shares

COMPANY'S WEBSITE

www.junshipharma.com

INVESTOR RELATIONS

Corporate press releases, financial reports and other investor information of the Group are available on the Company's website

- 1 Resigned from his position as deputy general manager of the Company and director of Suzhou Junao Precision Medicine Co., Ltd.* (蘇州君奧精準醫學有限公司), a subsidiary of the Company, and was re-designated from an executive Director to a non-executive Director with effect from 5 June 2026.
- 2 Retired from the position of independent non-executive Director and member of the Audit Committee, Remuneration and Appraisal Committee, Strategic and ESG Committee and Compliance Committee with effect from 26 June 2026.
- 3 Appointed as the chairman of the Audit Committee and Remuneration and Appraisal Committee and a member of the Strategic and ESG Committee on 26 June 2026.
- 4 Elected as an independent non-executive Director and appointed as a member of the Audit Committee and Compliance Committee on 26 June 2026.
- 5 The Strategic Committee was adjusted to the Strategic and ESG Committee on 13 March 2026.

HIGHLIGHTS

FINANCIAL HIGHLIGHTS

- As at 30 June 2026, total revenue of the Group was approximately RMB1,696 million for the Reporting Period, representing an increase of approximately 45% compared to the corresponding period in 2025, which was mainly due to the increase in revenue from sales of pharmaceutical products, in particular the domestic sales revenue of our core product TUOYI® (toripalimab, JS001) was approximately RMB1,299 million, representing an increase of approximately 36% compared to the corresponding period in 2025. In addition, revenue related to out-licensing also increased approximately RMB152 million, representing an increase of approximately 149% compared to the corresponding period in 2025.
- Total R&D expenses of the Group were approximately RMB644 million for the Reporting Period, which was primarily used to advance the construction of our R&D technology platforms, explore potential drug targets and advance our clinical pipelines steadily and efficiently.
- Profit attributable to owners of the Company increased to RMB26 million for the Reporting Period, representing an increase of approximately RMB439 million compared to the corresponding period in 2025. During the Reporting Period, when excluding the effects of share-based payment, profit attributable to owners of the Company increased to RMB153 million, representing an increase of approximately RMB566 million compared to the corresponding period in 2025.
- During the Reporting Period, net cash inflow from financing activities was approximately RMB1,643 million, which fully covered the cash outflows in operating and investing activities, leading to an increase in bank balances and cash. A successful issuance of the 2026 first tranche of technology innovation bonds generated a net cash inflow of approximately RMB1,000 million for the Group.
- As at 30 June 2026, the aggregate balance of bank balances and cash and financial products of the Group was approximately RMB3,670 million, providing a relatively sufficient cash position to support the Group's development.

HIGHLIGHTS

BUSINESS HIGHLIGHTS

During the Reporting Period, staying focused on the “unmet medical needs” and our goal of “improving quality, reducing cost and enhancing efficiency”, we continued to ensure all-rounded, high-quality compliance, and made breakthrough progress in discovery, clinical development and commercialization of innovative drugs and business operations with accelerating international development. The following achievements and milestones were attained:

- Our innovative R&D field has expanded from monoclonal antibodies to the research and development of various drug modalities, including small molecules drugs, ADC, bi-specific or multi-specific antibodies, fusion protein, nucleic acid drugs and vaccines, as well as the exploration of next-generation innovative therapies including those for cancer and autoimmune diseases. As of the date of this report, a total of four drugs (TUOYI®, JUNMAIKANG (君邁康®), MINDEWEI (民得維®) and JUNSHIDA (君適達®)) have been commercialized, five products are in the stage of phase III clinical studies (including two products in the stage of NDA acceptance), and various innovative drugs that are competitive in the international market are undergoing accelerated clinical trials.
 - In February 2026, the indications of toripalimab for the first-line treatment of NPC and the first-line treatment of ESCC were approved for marketing in Oman and Qatar.
 - In March 2026, the NDA for JS001sc (toripalimab injection (subcutaneous injection)) for 12 indications in the treatment of tumors has been accepted by the NMPA.
 - In April 2026, the indication expansion of toripalimab for the first-line treatment of ESCC was approved for marketing in Singapore.
 - In May 2026, the sNDA for the new indication of TUOYI® (拓益®) in combination with disitamab vedotin for the treatment for patients with HER2-expressing (which is defined as achieving score of 1+, 2+ or 3+ in HER2 immunohistochemistry test) locally advanced or metastatic UC was approved by the NMPA.
 - In May 2026, the phase III clinical study of TUOYI® in combination with chemotherapy as perioperative treatment for resectable stage II-III NSCLC patients met primary endpoint in the final analysis. In July 2026, the supplemental application for the indication of TUOYI® in combination with chemotherapy as perioperative treatment for resectable stage II-III NSCLC patients was accepted.

HIGHLIGHTS

- In May 2026, the indications of toripalimab for the first-line and second-line or later treatment of NPC were approved for marketing in Malaysia and South Africa.
- In June 2026, the indications of toripalimab for the first-line treatment of NPC and first-line treatment of ESCC were approved for marketing in Peru.
- In June 2026, the indications of toripalimab for the first-line and second-line or later treatment of NPC were approved for marketing in Brazil.
- External collaborations
 - In June 2026, Shanghai JunTop Biosciences Co., Ltd.* (“**JunTop Biosciences**”), a controlling subsidiary of the Company, reached a collaborative agreement with the Institute of Microbiology, Chinese Academy of Sciences. JunTop Biosciences was granted the exclusive global license rights for quadrivalent recombinant dengue vaccine.
 - In June 2026, the Company entered into a license agreement with Fosun Wanbang, a wholly-owned subsidiary of Fosun Pharma. The Company granted Fosun Wanbang the right to develop, register, manufacture and commercialize Roconkibart (“**JS005**” or “**anti-IL-17A monoclonal antibody**”) in the Greater China region. Under the agreement, the Company will receive an upfront payment of RMB215 million, which shall be non-deductible and non-refundable, and will be eligible to receive milestone payments for product development and sales of RMB1,125 million, as well as double-digit tiered royalties based on net sales in the Greater China region.
- Other significant event
 - From November 2025 to March 2026, Mr. Xiong Jun, one of the controlling shareholders and actual controllers, and the chairman of the Board of the Directors of the Company, increased his shareholding of the Company by 3,259,495 A shares and H shares in aggregate, accounting for 0.32% of the total share capital of the Company, with a total transaction amount of RMB100,638,052.19.

HIGHLIGHTS

IFRS

	For the six months ended 30 June		
	2026	2025	Changes
	RMB'000	RMB'000	%
	(Unaudited)	(Unaudited)	
Operating results			
Revenue	1,696,211	1,168,384	45
Gross Profit	1,279,431	924,025	38
Research and development expenses	(643,935)	(744,931)	(14)
Selling and distribution expenses	(507,169)	(487,343)	4
Administrative expenses	(279,359)	(208,761)	34
Loss for the period	(36,986)	(466,409)	(92)
Profit (loss) for the period attributable to owners of the Company	25,501	(413,431)	(106)
Total comprehensive expense for the period	(34,995)	(482,325)	(93)
Total comprehensive income (expense) for the period attributable to owners of the Company	27,492	(429,347)	(106)
Earning (loss) per share			
– Basic (RMB yuan)	0.02	(0.42)	NA
– Diluted (RMB yuan)	0.02	(0.42)	NA

	At	At	Changes
	30 June	31 December	%
	2026	2025	
	RMB'000	RMB'000	
	(Unaudited)	(Audited)	
Financial position			
Non-current assets	9,012,239	7,941,280	13
Current assets	5,205,246	4,457,704	17
Total assets	14,217,485	12,398,984	15
Non-current liabilities	5,125,896	3,513,755	46
Current liabilities	2,924,205	2,811,979	4
Total liabilities	8,050,101	6,325,734	27
Net assets	6,167,384	6,073,250	2

MANAGEMENT DISCUSSION AND ANALYSIS

OVERVIEW

Business Review

We have all-rounded capabilities in innovative drug discovery and development, clinical research on a global scale, and large-scale production capacity for commercialization across the entire industry chain, with an aim to become an innovative pharmaceutical company that operates “in China, for global”. Adhering to the corporate values of being quality-oriented, realistic and pragmatic, and maintaining integrity and compliance in our pursuit of excellence, we are committed to developing first-in-class or best-in-class drugs by way of original innovation and co-development. Our innovation field has continued to expand from monoclonal antibodies to various drug modalities, including small molecules, antibody-drug conjugates (ADCs), bi-specific or multi-specific antibodies, fusion protein, nucleic acid drugs and vaccines, as well as the next-generation innovative therapies including those for cancer and autoimmune diseases.

With our outstanding capacity for innovative drug discovery, strong biotechnology R&D capability and large-scale production capacity, we have successfully developed a drug candidate portfolio with tremendous market potential and a well-structured research pipeline. Our core product, toripalimab (trade name: TUOYI® (拓益®)/LOQTORZI®, i.e. JS001), has 13 indications approved in Chinese Mainland, and has received marketing approval in over 50 countries and regions including China, the United States and the European Commission, achieving continuous growth in the revenue from sales of pharmaceutical products. We also efficiently advance our R&D pipeline. As of the date of this report, five products are in the stage of phase III clinical studies, including two products in the stage of NDA acceptance. Meanwhile, we are rapidly advancing clinical trials for multiple innovative drugs that are competitive in the international market, including the anti-PD-1/VEGF bispecific antibody (JS207), EGFR/HER3 ADC (JS212) and the PD-1/IL-2 bifunctional fusion protein (JS213), and actively exploring multiple combination regimens with a focus on the next-generation IO in combination with ADC therapy, so as to maximize synergistic effects across the pipeline and drive more promising products into registration clinical trials.

In the first half of 2026, the Company recorded revenue of RMB1,696 million, representing a year-on-year increase of approximately 45%. The domestic sales revenue of our core product, toripalimab, was approximately RMB1,299 million, representing a year-on-year increase of approximately 36%. Profit attributable to owners of the Company increased to RMB26 million. When excluding the effects of share-based payments, profit attributable to owners of the Company increased to RMB153 million. Our operation quality continued to improve. As of the end of the Reporting Period, the aggregate balance of bank balances and cash and financial products of the Company was approximately RMB3,670 million, indicating a sufficient reserve of funds.

In the first half of 2026, we stayed focused on our goal of “improving quality, reducing cost and enhancing efficiency” and continued to ensure all-rounded, high-quality compliance. While controlling different kinds of costs, we made various major achievements in commercialization, R&D of drugs, global expansion, business operations and other aspects, which are summarized as follows:

MANAGEMENT DISCUSSION AND ANALYSIS

Continuously improved our commercialization capability and steadily enhanced our income-generating capacity

During the Reporting Period, the cohesion and professionalism of our commercialization team continued to improve, and we recorded continuous growth in the revenue from sales of our core product, toripalimab, achieving the domestic sales revenue of RMB1,299 million, representing a year-on-year increase of approximately 36%.

From 1 January 2026, TUOYI®, with two new indications, and JUNSHIDA (君適達®) were included in the NRDL. JUNSHIDA is the only domestically developed PCSK9-targeted drug in the new edition of the NRDL for statin-intolerant patients. In May 2026, the sNDA for the indication of TUOYI® in combination with disitamab vedotin for the treatment for patients with HER2-expressing locally advanced or metastatic UC was approved by the NMPA, thus further expanding the future market of TUOYI® in UC.

As of the date of this report, four commercialized products of the Company, namely TUOYI®, JUNMAIKANG (君邁康®), MINDEWEI (民得維®) and JUNSHIDA, are included in the NRDL. TUOYI® has 13 indications approved in Chinese Mainland, 12 of which are included in the NRDL, and it is the only anti-PD-1 monoclonal antibody included in the NRDL for the treatment of renal carcinoma, TNBC and melanoma.

With the expansion of our approved products, the improved accessibility driven by insurance coverage, the enhanced diversity of the product portfolio and the commercialization efforts in global markets, our commercial competitiveness continues to strengthen, and our income-generating capacity has steadily improved. At the same time, the Company has persistently implemented the action plan for “Enhancing Quality and Efficiency with a Focus on Return” by strengthening our control over expenses as well as our resource allocation. Moving forward, the Company will continue to promote cost reduction and efficiency enhancement, optimize our business structure, improve operational efficiency, expand market channels, and strengthen cost control and internal management, so as to further solidify our income-generating capability.

Efficiently pushed forward R&D to develop innovative drugs that are competitive in the international market, with a focus on the next-generation IO in combination with ADC therapy

During the Reporting Period, the Company realized full-process tracking management for R&D projects, covering from project initiation to application. The efficiency of clinical R&D continuously improved, with over 700 subjects enrolled in clinical studies. The Company actively shared its innovative achievements. From the beginning of the Reporting Period to the date of this report, our products have been featured in over 125 journal publications in total, with a combined impact factor of over 950, and over 70 research findings have been presented at international academic conferences.

We have a professional and experienced team in R&D, and place strong emphasis on our innovative pipelines. In respect of early-stage R&D, we have integrated the laboratories in Wujiang, Suzhou and Zhangjiang, Shanghai to set up the Innovation Research Institute, which concentrates resources and operates in a unified manner. We have established the “molecule discovery” platform, promoted the early-stage project launch in R&D pipeline, actively facilitated the project launch and implementation for lean management projects, optimized procedures, accelerated domestic substitution, introduced AI technologies for efficiency improvement, and continued to optimize R&D expenses. In respect of clinical R&D, we have implemented the “open R&D management”, reviewed R&D pipelines regularly, and devoted resources to more promising projects based on factors such as overall competitive landscape, R&D progress and combination strategies of our products. Meanwhile, by exploring design for R&D innovation plans, making categorized procurement and adopting other methods, we have improved R&D efficiency and controlled our costs. During the Reporting Period, we commenced over 85 clinical studies, and had established a well-structured research pipeline portfolio.

MANAGEMENT DISCUSSION AND ANALYSIS

We have actively developed globally competitive innovative drugs, accelerated the clinical trials for several innovative drugs, such as JS207 (PD-1/VEGF bispecific antibody), JS212 (EGFR/HER3 bispecific ADC) and JS213 (PD-1/IL-2 bifunctional fusion protein), and are proactively exploring different combined applications.

- For JS207, the phase II clinical studies are underway, including exploration of its combination with chemotherapy, monoclonal antibody, ADCs and other drugs in multiple tumor types. The phase II clinical study of JS207 in combination with JS212 is underway. In October 2025, the IND application for phase II/III clinical study comparing JS207 to nivolumab for the neoadjuvant treatment of patients with stage II/III, resectable, actionable genomic aberration (AGA)-negative, NSCLC was approved by the FDA.
- The IND application for JS212 was approved by the NMPA and the FDA. A phase I/II clinical study of JS212 evaluating the safety, tolerability, pharmacokinetics and preliminary efficacy of JS212 in patients with advanced solid tumors is underway. The phase II clinical trial on application of JS207 in combination with JS212 is underway.
- As of the date of this report, the phase I clinical studies of JS213 are underway simultaneously overseas and in China.

We focus on the development of the next-generation IO in combination with ADC therapy. We have carried out or planned to commence the phase II clinical trials of JS212 in combination with various IO drugs such as JS207, JS213 and toripalimab for different tumors. We proactively initiate wide deployment in multiple disciplines and multiple combined drug applications aiming to make a breakthrough in innovation of the next-generation cancer treatment.

With the continuous improvement of clinical research design and technology, our early-stage clinical studies are not limited to dose finding but also include diverse explorations, such as combined cohort investigations and validation of target indications. Once a signal is identified, we may then directly engage with regulatory authorities to communicate and prepare for pivotal registrational studies. We will accelerate the advancement of clinical studies of high-potential pipelines, and push more pipelines into pivotal registrational clinical studies.

Accelerated international expansion, with our core product being approved in six continents across the world, supported by the production capacity in two major production bases

During the Reporting Period, positive progress was made for the overseas market expansion for toripalimab, with accelerating marketing application and collaborations in various countries and regions, and the global commercialization network has gradually expanded. As of the date of this report, we have been cooperating on the commercialization with partners including Coherus, Hikma, Dr. Reddy's and LEO Pharma in over 80 countries. Toripalimab achieved presence in six continents across the world. It has been approved for marketing in over 50 countries and regions including Chinese Mainland, Hong Kong SAR, China, the United States, the EU, India, the UK, Jordan, Australia, Singapore, the UAE, Kuwait, Pakistan, Canada, Bahrain, Oman, Qatar, Malaysia, South Africa, Peru, Brazil, Saudi Arabia, Thailand and Vietnam, and has its marketing applications submitted/accepted in various countries/regions. We and our partners are actively promoting the marketing application and commercialization process for toripalimab within their cooperation territories, and actively exploring the possibility of marketing more indications in certain regions.

MANAGEMENT DISCUSSION AND ANALYSIS

We support gradual business expansion with adequate production capacity and high-quality production system. At present, we have two commercial production bases:

- With a fermentation capacity of 4,500L (9*500L), Wujiang production base in Suzhou has obtained GMP certifications and approvals from various countries and regions, including Chinese Mainland, Hong Kong SAR, China, the United States, the EU, the UK, Australia, Singapore, India, Jordan, the UAE, Kuwait, Pakistan, Canada, Bahrain, Oman and Qatar, and is responsible for the commercial supply of toripalimab for overseas markets;
- Shanghai Lingang production base has a production capacity of 42,000L (21*2,000L), and has obtained GMP certification from the NMPA to produce commercial batches of toripalimab injection jointly with Wujiang production base in Suzhou, and supports the clinical trials of our drug candidates and future production of commercial batches.

As at the date of this report, Suzhou Union Biopharm Co., Ltd.* (蘇州眾合生物醫藥科技有限公司) passed two on-site inspections by the FDA (first inspection conducted in 2023, second inspection conducted in 2025), demonstrating that the high-quality production and manufacturing system of the Company continues to gain international recognition. The Company will continue to promote the in-depth integration and all-rounded optimization of production system. Based on market insights and its own development strategies, the Company reasonably allocates production resources, and conducts scientific planning on production capacity allocation. Leveraging the synchronized operation of the two production bases, the Company has established a large-scale, highly cost-efficient production system to ensure stable product supply and fulfill the growing market demand.

Continued to enhance our operations, and facilitated high-quality, sustainable corporate development

During the Reporting Period, we continued to enhance our compliance operations, quality management, talent development, cost control and other aspects to ensure our high-quality, sustainable development against the backdrop of stringent regulation in the pharmaceutical industry.

In respect of compliance operations, maintaining integrity and compliance is the fundamental rule of our operations. Upholding a corporate culture of operation compliance as always, we build a comprehensive compliance system at a high standard, strictly complying with relevant national laws and regulations and the regulatory policies of the pharmaceutical industry, and providing patient-centered treatment options which have better efficacy and greater cost-effectiveness. We encourage our employees to comply with laws and regulations related to the products or services of the Company as well as the highest standards of business and personal ethics. During the Reporting Period, we continued to adhere to our business philosophy of integrity and compliance. We took practical actions to prevent legal risk, organized comprehensive self-inspection on compliance operation, and enhanced awareness on anti-unfair competition. Meanwhile, in order to further increase the standardization level, transparency and efficiency of academic meeting management of the Company, we implemented strict management over academic meetings, thereby ensuring the compliance of different academic activities. Moreover, we enhanced our management over pharmaceutical sales representatives, and arranged comprehensive trainings and appraisals in respect of product knowledge, illness knowledge, compliance requirement and other aspects for all sales representatives. Against the backdrop of stringent regulation in the pharmaceutical industry, we will continue to build a compliance culture of “innovation-driven, academic promotion” and optimize our compliance system of “full-process guidance and supervision” to enhance the quality and efficiency of our operations and management, establish a comprehensive compliance management system and facilitate high-quality and sustainable development.

MANAGEMENT DISCUSSION AND ANALYSIS

In respect of quality management, we have established and continuously improved the quality audit mechanism which combines both internal and external audits. During the Reporting Period, we underwent external inspections/audits for five times. The Group, including the two major production bases, underwent official inspection by Kazakhstan and Iraq, on-site inspection and inspection for pharmaceutical product manufacturing license by the Shanghai Medical Products Administration, covering Marketing Authorization Holder (MAH) management system, organizational structure, production management, quality management, laboratory management, supplier management, materials and warehousing management, equipment management, drug safety, and pharmacovigilance. All entities have successfully passed the inspections/audits and are in compliance with the relevant standards of the quality management systems.

In respect of talent development, we attach great importance to talent cultivation and development, striving to establish a diversified, professional, interdisciplinary talent system, and promote the concurrent development of talent and organization. As of the end of the Reporting Period, the Group's number of employees was 3,055, among which 607 employees are responsible for R&D of drugs. We attach importance to the career development of our employees, and implemented a unified performance management system that combines competitiveness, fairness and motivation of remuneration system. We protect the rights and interests of our employees in career development by building a job position hierarchy system, and provide a clear and reasonable career path and platform for our employees. We formulate and implement staff training system, systematically integrate internal and external learning resources, expand training modes, and continuously promote the establishment of learning culture organization, aiming to improve the all-rounded abilities of our employees. We also encourage all employees to participate in industry training and professional certification. For employees who have obtained professional title certificates, we provide them with support in applying for relevant government subsidies or bonuses. Furthermore, for outstanding R&D talents within the Company, we actively apply for national, municipal, and district-level talent programs, helping employees gain more tangible support in various aspects while they diligently dedicate themselves to their work.

In respect of cost control, the Company has implemented strict budget management across all departments, strengthened resource focus, and continued to improve operational efficiency. At the same time, we maintain visionary deployment in cutting-edge therapeutic areas and additional drug candidates. Our R&D team regularly conducts systematic review on our R&D pipelines and formulates reasonable R&D plans based on the comprehensive evaluation on factors such as competitive landscape, R&D progress and combination strategies of our products to enhance capital efficiency and devote resources to more promising R&D projects. We will actively pursue drug R&D, optimize our business structure, improve operational efficiency, and expand market channels, while continuously enhancing cost control and internal management to facilitate comprehensive improvement in operational quality and overall competitiveness.

Product Pipelines

Our products concentrate on self-developed biological products with original innovation. At the same time, through co-development, formation of joint ventures, license-in and other means, we obtained the licenses of drugs or platform technologies that synergized with our own original product pipeline, so as to further expand our product pipeline. As of the date of this report, a total of four drugs (TUOYI®, JUNMAIKANG (君邁康®), MINDEWEI (民得維®) and JUNSHIDA (君適達®)) have been commercialized. Our innovative field has continued to expand from monoclonal antibodies to the research and development of more drug modalities, including small molecule drugs, ADCs, bi-specific or multi-specific antibodies, fusion protein, nucleic acid drugs and vaccines, as well as the exploration of next-generation innovative therapies including those for cancer and autoimmune diseases.

MANAGEMENT DISCUSSION AND ANALYSIS



Key Projects Entering the Clinical R&D Stage (As of 14 August 2026)



MANAGEMENT DISCUSSION AND ANALYSIS

Our Core Products

TUOYI®/LOQTORZI® (toripalimab, JS001)

- *Milestones and achievements of commercialization*

During the Reporting Period, TUOYI® recorded domestic sales revenue of approximately RMB1,299 million, representing a year-on-year increase of approximately 36%, which demonstrated our positive progress in sales. The Company's self-developed product, toripalimab is the first domestic anti-PD-1 monoclonal antibody successfully launched in China, and is also the first innovative biological drug independently developed and manufactured in China that was approved for marketing by the FDA, addressing various malignant tumors. It was granted the "China Patent Gold Award", the highest award in the patent field nationally, and has been supported by two National Major Science and Technology Projects for "Major New Drugs Development" during the "Twelfth Five-Year Plan" and "Thirteenth Five-Year Plan" periods.

As of the date of this report, toripalimab has 13 indications approved in Chinese Mainland:

- treatment for unresectable or metastatic melanoma after failure of standard systemic therapy (December 2018);
- treatment for recurrent/metastatic NPC after failure of at least two lines of prior systemic therapy (February 2021);
- treatment for locally advanced or metastatic UC that failed platinum-containing chemotherapy or progressed within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy (April 2021);
- in combination with cisplatin and gemcitabine as the first-line treatment for patients with locally recurrent or metastatic NPC (November 2021);
- in combination with paclitaxel and cisplatin as the first-line treatment for patients with unresectable locally advanced/recurrent or distant metastatic ESCC (May 2022);
- in combination with pemetrexed and platinum as the first-line treatment in recombinant humanized EGFR mutation-negative and anaplastic lymphoma kinase (ALK) mutation-negative, unresectable, locally advanced or metastatic non-squamous NSCLC (September 2022);
- in combination with chemotherapy as perioperative treatment and subsequently, monotherapy as adjuvant therapy for the treatment of adult patients with resectable stage IIIA-IIIB NSCLC (December 2023);
- in combination with axitinib for the first-line treatment of patients with medium to high risk unresectable or metastatic RCC (April 2024);
- in combination with etoposide plus platinum for the first-line treatment of ES-SCLC (June 2024);

MANAGEMENT DISCUSSION AND ANALYSIS


- in combination with paclitaxel for injection (albumin-bound) for the first-line treatment of recurrent or metastatic TNBC with a well-validated test to evaluate PD-L1 positive (CPS $\geq$ 1) (June 2024);
- in combination with bevacizumab for the first-line treatment of patients with unresectable or metastatic HCC (March 2025);
- first-line treatment of unresectable or metastatic melanoma (April 2025);
- in combination with disitamab vedotin for the first-line treatment of HER2-expressing locally advanced or metastatic UC (May 2026).

In addition, toripalimab has been recommended and recognized by 20 definitive guidelines both domestically and internationally. It is the first domestic anti-PD-1 monoclonal antibody to be recommended by the three major definitive guidelines: the CSCO, the NCCN, and the ESMO. Under the latest 2025 CSCO Clinical Guidelines for the Diagnosis and Treatment of Cancer, a number of toripalimab treatment regimens have been included in more than ten guidelines, with a comprehensive coverage of therapeutic areas such as NPC, head and neck cancer, NSCLC, SCLC, breast cancer, oesophageal cancer, liver cancer, biliary tract malignancies, colorectal cancer, renal cancer, UC, and melanoma. Toripalimab secured several Grade I recommendations, which further reinforced its clinical standing in cancer therapies and continued to facilitate the transformative immuno-oncology clinical practices in China.

As of the date of this report, 13 indications of TUOYI® have been approved for marketing in Chinese Mainland, of which 12 indications have been included in the NRDL, and TUOYI® is the only anti-PD-1 monoclonal antibody in the NRDL for the treatment of renal cancer, TNBC and melanoma. The approvals for new indications and the inclusion of new indications of TUOYI® in the NRDL will further expand the coverage of patients with various types of cancers who may gain benefits, reduce the medical burden for patients and their families, and improve the accessibility and affordability of TUOYI® among patients.

In terms of international layout, as of the date of this report, toripalimab achieved presence in six continents across the world. It has been approved for marketing in over 50 countries and regions worldwide, such as China, the United States and the European Commission, and its marketing applications have been submitted/accepted in various countries and regions. We have been cooperating on the commercialization with partners including Coherus, Hikma, Dr. Reddy's and LEO Pharma in over 80 countries. We and our partners are actively promoting the marketing application process for toripalimab within their cooperation territories, and actively exploring the possibility of marketing more indications in certain regions.

MANAGEMENT DISCUSSION AND ANALYSIS



- *Milestones and achievements of clinical development*

Over 40 clinical studies covering more than 15 indications in respect of toripalimab have been conducted in China, the United States, Europe, Southeast Asia and other regions. Among the pivotal registered clinical studies, the Company has actively deployed perioperative treatment/postoperative adjuvant treatment for various types of tumors in addition to the extensive layout of toripalimab for the first-line treatment of multiple tumor types, to promote the application of cancer immunotherapy in the early treatment of cancer patients.

Progress of clinical trials and registration in China:

- In May 2026, the sNDA for the new indication of TUOYI® in combination with disitamab vedotin for the treatment for patients with HER2-expressing (which is defined as achieving score of 1+, 2+ or 3+ in HER2 immunohistochemistry test) locally advanced or metastatic UC was approved by the NMPA.
- In May 2026, the phase III clinical study of TUOYI® in combination with chemotherapy as perioperative treatment for resectable stage II-III NSCLC patients met primary endpoint in the final analysis. In July 2026, the supplemental application for the indication of TUOYI® in combination with chemotherapy as perioperative treatment for resectable stage II-III NSCLC patients was accepted.

MANAGEMENT DISCUSSION AND ANALYSIS

Global registration progress:

- In February 2026, the indications of toripalimab for the first-line treatment of NPC and the first-line treatment of ESCC were approved for marketing in Oman and Qatar.
- In April 2026, the indication expansion of toripalimab for the first-line treatment of ESCC was officially approved for marketing in Singapore.
- In May 2026, the indications of toripalimab for the first-line and second-line or later treatment of NPC were approved for marketing in Malaysia and South Africa.
- In June 2026, the indications of toripalimab for the first-line treatment of NPC and the first-line treatment of ESCC were officially approved for marketing in Peru.
- In June 2026, the indications of toripalimab for the first-line and second-line or later treatment of NPC were approved for marketing in Brazil.
- In July 2026, the indications of toripalimab for the first-line treatment of ESCC and second-line or later treatment of NPC were approved for marketing in Saudi Arabia.
- In July 2026, the indications of toripalimab for the first-line and second-line or later treatment of NPC were approved for marketing in Thailand.
- In July 2026, the 3 indications of toripalimab for the first-line and second-line or later treatment of NPC and first-line treatment of ESCC were approved for marketing in Vietnam.

- *Publication of academic results*

- Our innovative products have achieved numerous remarkable academic results. From the beginning of the Reporting Period to the date of this report, toripalimab has been featured in over 120 journal publications in total, with a combined impact factor over 930, and its research findings have been published in international authoritative journals such as the *New England Journal of Medicine* (NEJM) and the *Annals of Oncology*, and presented at international academic conferences such as AACR Annual Meeting and the ASCO Annual Meeting for multiple times, with oral presentations made in various academic conferences.

MANAGEMENT DISCUSSION AND ANALYSIS

Recombinant humanized anti-PD-1/VEGF bispecific antibody (JS207)

JS207 is a recombinant humanized anti-PD-1/VEGF bispecific antibody self-developed by the Company, mainly used for the treatment of advanced malignant tumors. JS207 can simultaneously bind to PD-1 and VEGFA with high affinity, effectively block the binding of PD-1 to PD-L1 and PD-L2 while inhibiting the binding of VEGF to its receptor. JS207 has the efficacy properties of both immunotherapeutic drugs and anti-angiogenic drugs. Through neutralization of VEGF, JS207 can inhibit the proliferation of vascular endothelial cells, improve the tumor microenvironment, and increase the infiltration of cytotoxic T lymphocytes in the tumor microenvironment, thus achieving better anti-tumor activity.

JS207 is designed based on the high-affinity, clinically proven and differentiated anti-PD-1 drug toripalimab as the backbone. The anti-PD-1 moiety of JS207 adopts a Fab structure to maintain binding affinity to PD-1 and thereby attain better enrichment in the tumor microenvironment. The anti-VEGF moiety has a binding affinity for human vascular endothelial growth factor that is comparable to that of bevacizumab. In non-clinical in vitro cytological tests, compared with the combination of an anti-PD-1/PD-L1 monoclonal antibody and a VEGF monoclonal antibody, a bispecific antibody simultaneously targeting PD-1/PD-L1 and VEGF demonstrated significantly enhanced PD-1 antigen binding and internalization, and synergistic enhancement of the NFAT signaling pathway, thereby better activating immune cells in the tumor microenvironment.

- *Publication of academic results*
 - In April 2026, the results of the phase II clinical study of JS207 in combination with JS007 (anti-CTLA-4 monoclonal antibody) for the first-line treatment of advanced HCC (code: JS207-006-II-HCC) were presented in form of poster presentation (Abstract No. : #CT159) at the 2026 AACR Annual Meeting. The study results showed that: the drug combination therapy exhibited strong antitumor activity. 26 patients received treatment of JS207 in combination with JS007 (3 mg/kg Q6W for 2-week treatment, and 1 mg/kg Q6W (i.e. recommended dose) thereafter). Among 22 efficacy-evaluable patients, the ORR of combined treatment reached 45.5%, while DCR reached 86.4%. In respect of safety profile, the drug combination therapy was well tolerated. No dose-limiting toxicity (DLT) was observed during the safety run-in period. The incidence of grade 3 or higher TRAEs was only 19.2%. There were no TEAEs leading to death.
 - In April 2026, the results of the phase II clinical study of JS207 in combination with chemotherapy for the first-line treatment of microsatellite stable or mismatch repair proficient (MSS/pMMR) metastatic colorectal cancer (mCRC) (code: JS207-007-II-CRC) were presented for the first time in form of poster presentation (Abstract No. : #CT152) at the 2026 AACR Annual Meeting. The study results showed that: JS207 in combination with chemotherapy for the first-line treatment of MSS/pMMR mCRC exhibited positive efficacy signal. Among 31 efficacy-evaluable patients, 22 patients achieved partial response (PR) and 8 patients achieved stable disease (SD). ORR reached 71.0%, while DCR was 96.8%. In respect of safety profile, it was well tolerated in general. No dose-limiting toxicity was observed during the safety run-in period. The incidence of grade 3 or higher treatment-related adverse events (TRAEs) was 40.6%. Only one (3.1%) patient encountered grade 3 or higher immune-related adverse events (irAEs). There were no TEAEs leading to death.

MANAGEMENT DISCUSSION AND ANALYSIS

As of the date of this report, JS207 is in the phase II clinical study stage, and the exploration of its combination with chemotherapy, monoclonal antibodies, ADCs and other drugs in various tumors is underway. The phase II clinical trial of JS207 in combination with JS212 is underway. In addition, in October 2025, the IND application for an open-label, two-arm, randomized, active-controlled, phase II/III clinical study comparing JS207 to nivolumab for the neoadjuvant treatment of patients with stage II/III, resectable, actionable genomic aberration (AGA)-negative, NSCLC was approved by the FDA. Upon further data collection, the Company will make plans for subsequent registrational clinical studies based on the clinical data and its communication with regulators.

EGFR/HER3 bispecific antibody-drug conjugate (JS212)

JS212 is a recombinant humanized epidermal growth factor receptor (EGFR) and HER3 bispecific antibody drug conjugate (ADC) that is mainly used for the treatment of advanced malignant solid tumor. EGFR and HER3 are highly expressed in a variety of tumor cells, such as lung cancer, colorectal cancer and head and neck cancer etc. There is interaction in signaling pathway between EGFR and HER3. They jointly facilitate the proliferation, survival, migration and angiogenesis of tumor cells. In addition, HER3 is involved in the drug-resistance mechanisms of various anti-tumor drugs (including EGFR-targeted drugs and chemotherapy etc.). Comparing to single-target ADC drugs, JS212 can suppress tumors by binding to EGFR or HER3, and is expected to be effective on a wider range of tumors and overcome drug resistance. According to pre-clinical studies, with JS212 having high affinity and specific binding to EGFR and HER3, it exhibits significant anti-tumor effect in various animal models. Meanwhile, JS212 has a favorable and acceptable safety profile.

In January 2025, the IND application for JS212 was accepted by the NMPA. It was approved by the NMPA in March 2025. In December 2025, the IND application of JS212 for the treatment of advanced solid tumors was approved by the FDA.

- *Publication of academic results*

- In April 2026, the pre-clinical study results of JS212 were presented in the form of a poster presentation at the 2026 AACR Annual Meeting (Abstract No. : #1715). The study results showed that: JS212 binds to tumor cells expressing EGFR and/or HER3 with high affinity, exhibiting superior and broad-spectrum anti-tumor activity, favorable tolerability, and desirable pharmacokinetic profiles in pre-clinical evaluations. In multiple cell line-derived xenograft (CDX) models, JS212 demonstrated superior anti-tumor activity compared to similar drugs. JS212 also showed efficacy in CDX models resistant to Osimertinib, Patritumab-deruxtecan and BL-B01D1;
- In April 2026, the results of a first-in-human (FIH) clinical study of JS212 for the treatment of advanced solid tumors (code: JS212-001-I/II) were presented in the form of a poster presentation at the 2026 AACR Annual Meeting (Abstract No. : #CT128). The study results showed that: JS212 monotherapy was generally well tolerated in the treatment of advanced solid tumors, and demonstrated encouraging anti-tumor activity across multiple dose levels (even as low as 1.8 mg/kg). Notably, in the 4.2 mg/kg and 4.6 mg/kg dose groups, the ORRs reached 44.4% and 50.0%, respectively, with a disease control rate (DCR) of 100.0% in both groups. The ORRs in patients with HER2-negative breast cancer (BC) and esophageal squamous cell carcinoma (ESCC) reached 50.0% and 38.9%, respectively, exhibiting favorable development potential. In respect of safety profile, it was well tolerated in general, and the maximum tolerated dose (MTD) was not reached. The incidence of grade 3 or higher treatment-related adverse events (TRAEs) was 31.7%, with no TRAEs leading to death. The common grade 3 or higher TRAEs, with an incidence of 5% or greater, included neutropenia (19.0%), leukopenia (14.3%) and thrombocytopenia (7.9%). Based on the comprehensive safety, efficacy and pharmacodynamic biomarker data, the recommended phase II dose (RP2D) for JS212 monotherapy was to be determined to be 4.6 mg/kg Q3W.

MANAGEMENT DISCUSSION AND ANALYSIS

As of the date of this report, JS212 is in the phase II clinical study stage, and the exploration of its combination with PD-1/VEGF bispecific antibody (JS207), anti-PD-1 monoclonal antibody (toripalimab), PD-1/IL-2 bifunctional fusion protein (JS213), 3rd EGFR TKI (JS111) and other drugs in various tumors has been initiated or planned, actively advancing a comprehensive layout of multiple combination regimens in diverse fields.

Plans and Progress of JS207 and JS212 Major Phase II Clinical Studies



	■ Study treatment	■ Indications	■ Anticipated sample size
JS207	JS207 + Chemo (China)	Resectable Stage II -III / Unresectable Stage III NSCLC	88
	JS207 + Chemo (Global)	Resectable Stage II -III NSCLC	200
	JS207 + Chemo (China)	1L EGFR / ALK Wild Type NSCLC	84
	JS207 + CTLA4 (China)	1L HCC	72
	JS207 + Chemo ± DKK1 / JS207 + CTLA4 (China)	Advanced CRC	120
	JS207 + Nectin-4 ADC / JS207 + Chemo (China)	1L TNBC	60
JS207 + JS212	JS207 + JS212 / JS207 + Chemo (China)	AGA+ NSCLC After TKI Failure	72
	JS207 + JS212 ± Chemo (China)	1L/2L AGA – NSCLC	426
	JS212 + JS207 + Chemo (China)	Advanced CRC	80
	JS207 + JS212 (China)	TNBC	102
JS212	JS212 + 3rd EGFR TKI (China)	1L/2L AGA+ NSCLC	35
	JS212 + PD-1 monoclonal antibody ± Chemo (China)	1L ESCC	280
	JS212 + Chemo ± Bevacizumab (China)	2L CRC	80
	JS212 ± PD-1/IL-2 / PD-1/IL-2 monotherapy (China)	2L CRC, UC, CRPC, Melanoma	319
	JS212 monotherapy (China)	Advanced Solid Tumors	126

* As of 14 August 2026, more than 617 subjects had been enrolled in Phase II clinical study of JS207 and Phase II clinical study of JS212; Previously, nearly 100 subjects had been enrolled in Phase I clinical study of JS207.

PD-1/IL-2 bifunctional antibody fusion protein (JS213)

JS213 is a PD-1 and IL-2 bifunctional antibody fusion protein, which is mainly used for the treatment of advanced malignant tumors. In view of the co-expression of PD-1 and IL-2 in the tumor microenvironment, the fusion protein can selectively activate the IL-2 signaling pathway by binding to the IL-2 receptor while blocking the PD-1 pathway, thereby strengthening the anti-tumor immune responses. The combination therapy with PD-(L)1 and IL-2 has shown potential efficacy in a variety of tumor types. Compared with combination therapy, JS213 as a single agent targeting both PD-1 and IL-2 pathways, may be more effective in activating the tumor immune microenvironment and thus enhancing anti-tumor activity. Pre-clinical results showed that, JS213 preferentially stimulated the expansion of tumor-infiltrating CD8+ T cells, with little effect on T cells and natural killer (NK) cells in the peripheral blood, and showed good efficacy and safety in both anti-PD-1 monoclonal antibody-sensitive or -resistant mouse tumor models.

MANAGEMENT DISCUSSION AND ANALYSIS

In June 2025, the preliminary data from the overseas phase I first-in-human (FIH) study of JS213 was presented for the first time at the 2025 ASCO Annual Meeting. The study was an open-label, dose-escalation, phase I FIH study (NCT06092580). The dose escalation phase aimed to evaluate the safety and preliminary efficacy of AWT020 monotherapy in patients with advanced/metastatic cancer who had failed prior standard treatments or are intolerant to them, with key endpoints including safety, maximum tolerated dose (MTD), the recommended phase II dose (RP2D), pharmacokinetics (PK), pharmacodynamics, immunogenicity and anti-tumor response.

In November 2025, at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) held in 2025, the latest results of the overseas phase I clinical study of JS213 were presented in the form of a poster presentation (Abstract No. : #595). The results of the initial dose escalation phase were reported at the SITC meeting. As of 19 June 2025, 25 patients received JS213 treatment at doses of 0.3, 0.6 and 1 mg/kg, including priming regimens with a 0.3 mg/kg step dose.

- Preliminary PK analysis showed that the exposure of JS213 was approximately proportional to dose.
- Among the 20 patients with evaluable efficacy, the ORR was 35% and the DCR was 75%. Among the seven patients with partial responses (PR), one was refractory to prior anti-PD-1 therapy, three had developed secondary resistance to anti-PD-(L)1 therapies, and the remaining three were anti-PD-(L)1-naïve. Among the eight patients who achieved stable disease (SD), tumor shrinkage was observed in patients with thymic carcinoma, neuroendocrine renal carcinoma, mesothelioma and non-clear cell renal cell carcinoma, providing preliminary evidence of JS213's broad-spectrum anti-tumor activity.
- The safety profile was manageable with most of the TRAEs being low grade. The most common TRAEs were arthralgia (50%), fatigue (35%), rash (35%), nausea (31%) and hypothyroidism (23%). No patient experienced vascular leak syndrome.

In June 2026, at the ASCO Annual Meeting, the updated results from the dose-escalation phase of the phase I first-in-human (FIH) study of JS213 in advanced solid tumors were presented in the form of a poster presentation (Abstract No. : #2528). The results showed that among the 28 evaluable patients with solid tumors who had received multiple lines of therapy, the overall ORR was 25% and the DCR reached 60.7%. Among the patients resistant to prior anti-PD-1 therapy (n=10), the ORR was 35.7% and the DCR was 57.1%. In respect of safety profile, most TRAEs were low grade, with the most common TRAEs including arthralgia (50%), rash (35%), fatigue (35%) and nausea (32.5%). No patients experienced vascular leak syndrome.

As of the date of this report, the phase I clinical studies of JS213 are underway simultaneously overseas and in China.

Tifcemalimab (TAB004/JS004)

Tifcemalimab is the world's first-in-human recombinant humanized anti-tumor anti-BTLA monoclonal antibody specific to B- and T-lymphocyte attenuator (BTLA) independently developed by us. BTLA is expressed in the T lymphocyte, B lymphocyte, and dendritic cell subpopulations. In 2005, the interaction between BTLA and its ligand, herpes virus entry mediator (HVEM), was discovered. HVEM, a tumor necrosis factor (TNF) receptor, is extensively expressed in the hematopoietic system and has been confirmed as the ligand of BTLA. By binding with BTLA, tifcemalimab blocks the HVEM-BTLA interaction, thereby obstructing the BTLA-mediated inhibitory signal pathways and activating the tumor-specific lymphocytes.

MANAGEMENT DISCUSSION AND ANALYSIS

Tifcemalimab in combination with toripalimab has commenced phase III clinical studies. The JUSTAR-001 study is a randomized, double-blind, placebo-controlled, international multi-regional phase III clinical study, and is aimed to evaluate the efficacy and safety of tifcemalimab in combination with toripalimab compared to toripalimab alone and compared to placebo as consolidation therapy used in LS-SCLC patients without disease progression following chemoradiotherapy. As the first confirmatory study of a monoclonal antibody targeting BTLA, this study plans to recruit about 756 subjects around the world. As of the date of this report, this study has been carried out in more than 200 centers across 15 countries/regions, and has enrolled more than 730 patients, and enrollment is underway. It is expected to complete patient enrollment by 2026.

We believe that tifcemalimab in combination with toripalimab is a promising anti-tumor treatment strategy, which is expected to increase patients' response to immunotherapy and expand the range of potential beneficiaries. We will continue to facilitate patient enrollment, and promote the commercialization of Tifcemalimab across the world.

- *Publication of academic results*

The preliminary clinical study results of tifcemalimab alone or in combination with toripalimab have been presented at various international medical conferences. The combination demonstrated good safety profiles and encouraging efficacy in patients with lung cancer, relapsed/refractory (R/R) lymphoma, and immune-refractory advanced solid tumors who have failed multiple lines of therapy. In 2025, two study results of tifcemalimab in combination with toripalimab on lung cancer were selected for oral presentations at the Japanese Society of Medical Oncology (JSMO) Annual Meeting and the World Conference on Lung Cancer (WCLC). The preliminary results of such combined therapy in combination with chemotherapy for the perioperative treatment of resectable locally advanced thoracic esophageal squamous cell carcinoma were published for the first time at the 2025 ESMO Annual Meeting, with the updated research results presented at the 2026 ASCO Annual Meeting. In addition, various study results of tifcemalimab have been published in international journals.

In June 2026, the phase II clinical study (BT-NICE study) evaluating the efficacy and safety of tifcemalimab in combination with toripalimab and chemotherapy for the perioperative treatment of resectable locally advanced thoracic esophageal squamous cell carcinoma (ESCC) was successfully selected for a poster presentation at the 2026 ASCO Annual Meeting (Abstract No. : #4087). The study results showed that after neoadjuvant treatment with such combination therapy, the objective response rate (ORR) reached 96.0%, and all patients achieved R0 resection (complete tumor resection with negative margins). The pathological complete response (pCR) rate was 40.0%, the major pathological response (MPR) rate was 56.0%, and the 1-year relapse-free survival (RFS) rate and overall survival (OS) rate were 96% and 100%, respectively. In respect of safety profile, it was well tolerated in general. The most common TEAEs included alopecia, vomiting, neutropenia and lymphopenia. Grade 3 TEAEs occurred in 20% (5/25) of patients, with no grade 4-5 TEAEs or treatment-related deaths reported. No patients experienced treatment-related surgical delays, and no deaths occurred within 30 days.

MANAGEMENT DISCUSSION AND ANALYSIS

Other Products That Have Been Commercialized or Are in Later Stages of Clinical R&D

MINDEWEI (民得維®) (Deuremidevir Hydrobromide Tablets, code: JT001/VV116)

MINDEWEI is a new oral nucleoside analog antiviral drug, which can be non-covalently bound to the active center of RdRp of SARS-CoV-2 in the form of nucleoside triphosphate, directly inhibiting the activity of RdRp of the virus and blocking the replication of virus, thus realizing the antiviral effect. Pre-clinical studies have shown that MINDEWEI exhibited significant antiviral effects against both the original COVID-19 strain and mutant strains, including Omicron, and exhibited no genetic toxicity. MINDEWEI was jointly developed by Shanghai Institute of Materia Medica, Chinese Academy of Sciences* (中國科學院上海藥物研究所), Wuhan Institute of Virology, Chinese Academy of Sciences* (中國科學院武漢病毒研究所), Xinjiang Technical Institute of Physics and Chemistry, Chinese Academy of Sciences* (中國科學院新疆理化技術研究所), Central Asian Center of Drug Discovery and Development of Chinese Academy of Sciences* (中國科學院中亞藥物研發中心)/China-Uzbekistan Medicine Technical Park (the Belt and Road Joint Laboratory of the Ministry of Science and Technology)* (中烏醫藥科技城(科技部“一帶一路”聯合實驗室)), Lingang Laboratory* (臨港實驗室), Suzhou Vigonvita Biomedical Co., Ltd.* (蘇州旺山旺水生物醫藥有限公司) and the Company.

On 28 January 2023, the marketing of MINDEWEI for the treatment of adult patients with mild to moderate COVID-19 was conditionally approved by the NMPA. In January 2025, such indication was approved by the NMPA for conversion from conditional approval to regular approval. MINDEWEI was included in the scope of provisional medical insurance reimbursement in January 2023, and has been officially included in the NRDL since January 2024.

After MINDEWEI was marketed, the Company actively established a commercialization team, continuously explores sales models, continues to expand the coverage of MINDEWEI in hospitals and departments, expands e-commerce channels, and further improves the accessibility of MINDEWEI. As of the end of the Reporting Period, MINDEWEI had been used in more than 2,000 medical institutions, including community healthcare service centers, secondary hospitals and tertiary hospitals, covering all provinces in the territory.



MANAGEMENT DISCUSSION AND ANALYSIS

JUNMAIKANG (君邁康®) (adalimumab, UBP1211)

JUNMAIKANG is an adalimumab jointly developed by us, Mabwell (Shanghai) Bioscience Co., Ltd.* (邁威(上海)生物科技股份有限公司) and its subsidiaries. As our third commercialized product, JUNMAIKANG received support from the national “Major New Drug Development”, a major scientific and technological project, during the “Twelfth Five-Year Plan”, which brings new treatment options for Chinese patients at large with autoimmune disease after its launch. In March 2022, the marketing of JUNMAIKANG for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriasis was approved by the NMPA, with the first prescription issued in May 2022. In November 2022, the supplemental application for five additional indications of JUNMAIKANG for the treatment of Crohn’s disease, uveitis, polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis and pediatric Crohn’s disease was approved by the NMPA.



JUNSHIDA (君適達®) (ongeriximab, JS002)

JUNSHIDA is a recombinant humanized anti-PCSK9 monoclonal antibody independently developed by us. In October 2023, we signed an agreement with Bochuang Pharmaceuticals, pursuant to which we granted Bochuang Pharmaceuticals an exclusive license to conduct R&D on, manufacture and commercialize JUNSHIDA for the licensed purposes and within Chinese Mainland. Bochuang Pharmaceuticals will be responsible for the subsequent commercialization of JUNSHIDA in Chinese Mainland and will make corresponding milestone payments and sales commissions to the Company.

In October 2024, the NDA for JUNSHIDA as the treatment for adult patients with primary hypercholesterolemia (non-familial) and mixed dyslipidemia was approved for marketing by the NMPA.

In May 2025, the two sNDAs for JUNSHIDA for: 1) adult patients with heterozygous familial hypercholesterolemia (HeFH); 2) alone or in combination with ezetimibe, in adult patients with non-familial hypercholesterolemia and mixed dyslipidemia who are statin-intolerant or statins contraindicated, were approved. Ongeriximab became the first domestic PCSK9-targeted drug approved for statin-intolerant patients.

In December 2025, JUNSHIDA was successfully included in Category B of the NRDL as the only domestic PCSK9-targeted drug in the new edition of NRDL for statin-intolerant patients. The new edition of the NRDL officially came into effect on 1 January 2026.

MANAGEMENT DISCUSSION AND ANALYSIS

The significant lipid-lowering effects of JUNSHIDA have been demonstrated in multiple phase III clinical studies. The study results of JUNSHIDA were frequently published in international academic journals and presented at international academic conferences:

- In February 2025, the full text of the latest data from the phase III clinical study of ongericimab for the treatment for adult patients with HeFH (code: JS002-005) was published in *Atherosclerosis*, the official journal of the European Atherosclerosis Society (EAS), which demonstrated the potent lipid-lowering effects and favorable tolerability of ongericimab.
- In June 2025, the full results of the phase III clinical study of ongericimab for the treatment of primary hypercholesterolemia and mixed dyslipidemia in which statins are not tolerated (code: JS002-007) were published in *Atherosclerosis*, which for the first time announced the lipid-lowering efficacy and safety data of ongericimab in the Chinese population with statin intolerance. The results showed that, compared with placebo, the ongericimab subcutaneous injection (150 mg every 2 weeks (Q2W)) significantly reduced the low-density lipoprotein cholesterol (LDL-C) level by 66.2%, for a 12-week treatment, with steady reduction up to the 52nd week. At the same time, it also demonstrated significant improvements in other lipid parameters. Ongericimab has a favorable overall safety profile, with the incidence of TEAEs being comparable to that of the placebo group during the double-blind trial.



Recombinant humanized anti-IL-17A monoclonal antibody (Roconkibart injection, JS005)

JS005 is a specific anti-IL-17A monoclonal antibody developed independently by us. In June 2026, we entered into an agreement with Fosun Wanbang* (復星萬邦), granting Fosun Wanbang the rights to develop, register, manufacture and commercialize JS005 in the Greater China region. We received a non-deductible and non-refundable upfront payment of RMB215 million, and are eligible to receive development and sales milestone payments of up to RMB1,125 million, as well as tiered royalties based on a double-digit percentage of net sales in the Greater China region.

MANAGEMENT DISCUSSION AND ANALYSIS

In pre-clinical studies, JS005 has shown efficacy and safety comparable to those of anti-IL-17 monoclonal antibodies that have been marketed. Data from pre-clinical study fully depicts that JS005 has a clear target, definite efficacy, good safety profile, stable production process and controllable product quality. At the 2023 American College of Rheumatology (ACR) Annual Meeting, we announced the results of the phase Ib/II clinical study of JS005 for the treatment for patients with moderate to severe psoriasis for the first time. The study results showed that, JS005 has a good safety profile in the treatment for patients with moderate to severe plaque psoriasis. Compared with placebo, JS005 significantly improved the psoriasis area and severity index of patients ($p < 0.0001$).

In September 2025, JS005 achieved positive results in a multi-center, randomized, double-blind, parallel, placebo-controlled pivotal registrational phase III clinical study (code: JS005-005-III-PsO) for the treatment of moderate to severe plaque psoriasis. Both the co-primary endpoints and key secondary endpoints showed statistically significant and clinically meaningful improvements.

In December 2025, the NDA of JS005 for the treatment of moderate to severe plaque psoriasis in patients was accepted by the National Medical Products Administration.

In June 2026, the results of two clinical studies of JS005 were successfully selected for presentations at the European Congress of Rheumatology (EULAR 2026), including a phase III study of JS005 for the treatment of moderate to severe plaque psoriasis and a phase II study of JS005 for the treatment of active ankylosing spondylitis (AS). These studies demonstrated favorable efficacy and safety profiles of JS005 in Chinese patients with nail psoriasis and patients with active AS. As of the date of this report, all participants in the phase II clinical study of JS005 for the treatment of active ankylosing spondylitis (AS) have completed study follow-up.

PD-1 monoclonal antibody subcutaneous injection formulation (JS001sc)

JS001sc injection is a subcutaneous injection formulation developed by the Company on the basis of TUOYI®, our marketed product. The pre-clinical in vivo pharmacodynamics showed that JS001sc exhibited significant anti-tumor effect in animal models by subcutaneous injection. At the dose level of 0.3mg/kg, the anti-tumor effect of JS001sc administered by subcutaneous injection was comparable to that of toripalimab administered by intravenous injection, with no significant difference. In addition, animals had a good tolerance to JS001sc.

In April 2024, the results of the first-in-human (FIH) study of JS001sc were successfully selected for a presentation at the 2024 AACR and firstly published with a poster presentation (Abstract No. : #CT113), becoming the first domestic anti-PD-1 monoclonal antibody subcutaneous injection to publish clinical study data. JS001sc in combination with gemcitabine and cisplatin (GP regimen) for the treatment of recurrent or metastatic NPC (RM-NPC) demonstrated safety and clinical efficacy similar to that of the toripalimab intravenous (IV) formulation. The exposure of JS001sc (360mg, Q3W) was comparable to that of the IV regimen (240mg, Q3W). JS001sc has a good safety profile, and no new safety signals have been identified.

In November 2025, a multi-center, open-label, randomized controlled phase III clinical study to compare JS001sc and toripalimab injection (TUOYI®) in combination with chemotherapy for the first-line treatment of recurrent or metastatic non-squamous NSCLC has met the primary endpoints.

MANAGEMENT DISCUSSION AND ANALYSIS

In March 2026, the phase III clinical study of JS001sc in combination with chemotherapy for the first-line treatment of non-squamous NSCLC was successfully selected for an oral presentation at the 2026 European Lung Cancer Congress (ELCC 2026). The study results showed that the drug exposure of toripalimab subcutaneous injection was non-inferior to that of the intravenous formulation of toripalimab, with comparable clinical efficacy and safety profiles, potentially offering patients a more convenient new option for immunotherapy.

In March 2026, the NDAs for JS001sc for 12 indications in the treatment of tumors have been accepted by the NMPA, marking the first domestic anti-PD-1 monoclonal antibody subcutaneous formulation to enter the marketing application stage.

Recombinant humanized anti-Claudin18.2 monoclonal antibody-MMAE conjugate (JS107)

JS107 is a recombinant humanized anti-Claudin18.2 monoclonal antibody-MMAE (Monomethyl auristatin E) conjugate for injection developed independently by the Company. It is an antibody drug conjugate (ADC) targeting tumor-related protein Claudin18.2, and is intended to be used for the treatment of advanced malignant tumors, such as gastric cancer and pancreatic cancer. JS107 can bind to Claudin18.2 on the surface of tumor cells, enter into tumor cells through endocytosis, and release the small molecule toxin MMAE, which has demonstrated strong lethality to tumor cells. JS107 also retained antibody-dependent cellular cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) effects, further killing tumor cells. Furthermore, due to the cell permeability of MMAE, JS107 can mediate indiscriminate killing of other tumor cells by way of its bystander effect, thereby improving the efficacy of treatment and inhibiting tumor recurrence. The pre-clinical in vivo pharmacodynamics showed that JS107 exhibits significant anti-tumor effect. As of the date of this report, two phase III clinical studies of JS107 have been initiated, including a multi-center, randomized, placebo-controlled, open-label phase III clinical study of JS107 comparing the efficacy and safety of treatment of physician's choice for the second-line or later treatment of Claudin18.2 positive advanced gastric or G/GEJA, as well as a multi-center, randomized, placebo-controlled, open-label phase III clinical study of JS107 in combination with toripalimab and chemotherapy comparing the efficacy and safety of sintilimab in combination with chemotherapy as the first-line treatment for Claudin18.2-positive advanced gastric or gastroesophageal junction adenocarcinoma.

In April 2025, the data from a phase I clinical study of JS107 as a monotherapy or in combination with other therapies in patients with advanced solid tumors (code: #CT010) was presented in the form of oral presentation at the AACR Annual Meeting. This study was the first to report the clinical benefits of the Claudin18.2 ADC combination therapy as the first-line treatment for patients with advanced G/GEJA. The results showed that, among patients with Claudin18.2-positive advanced G/GEJA, JS107 as a monotherapy or in combination with toripalimab and XELOX (capecitabine + oxaliplatin) demonstrated significant anti-tumor efficacy, especially in patients with high Claudin18.2 expression, which achieved a high remission rate with an ORR of 81.0%, along with a good tolerance and a manageable safety profile, demonstrating the good development potential of the JS107 combination therapy.

MANAGEMENT DISCUSSION AND ANALYSIS

In December 2025, the updated results from a phase I clinical study of JS107 in combination with toripalimab and chemotherapy as the first-line treatment of advanced G/GEJA (code: #LBA5) was selected at the ESMO Asia Congress 2025 for oral presentation. The results showed that, for patients with advanced G/GEJA over-expressing Claudin18.2, JS107 in combination with toripalimab + XELOX as the first-line treatment demonstrated significant anti-tumor efficacy, with an ORR of 86.7%, a DCR of 100% and a mPFS of 11.14 months, achieving a higher remission rate and promising improvement in survival with a manageable safety profile. Moreover, when compared with the JS107 2 mg/kg + 100% XELOX regimen, the recommended dose (i.e. the 2 mg/kg + 75% XELOX group) showed a more significant trend of therapeutic benefits with an ORR of 87.5%, while the mPFS was not reached and the six-month PFS rate was 85.9%.

Other Products in Early Stages of R&D

Recombinant humanized anti-CD20/CD3 bispecific antibody (JS203)

JS203 is a recombinant humanized anti-CD20/CD3 bispecific antibody self-developed by the Company. CD20 is a B lymphocyte restricted differentiation antigen and one of the most successful targets for B-cell lymphoma treatment. CD3 is an important marker on the surface of T cell. The main mechanism of T cell engaging bispecific antibodies is using CD3 as a mediator to activate T cells to specifically attack tumor cells. JS203 consists of anti-CD20 segment and anti-CD3 segment. By associating and activating lymphoma cells (binding to CD20) and T cells (binding to CD3), JS203 can enable T cells to kill lymphoma cells effectively. Pre-clinical in vivo pharmacodynamics shows that JS203 has a significant anti-tumor effect. In addition, JS203 is well tolerated by animals. As of the date of this report, the phase II clinical study of JS203 is underway. It is expected that a pivotal registrational clinical trial will commence in 2026.

In April 2025, the preliminary results of a phase I clinical study of JS203 in patients with relapsed or refractory ("R/R") B-cell non-Hodgkin lymphoma ("B-NHL") were presented in the form of poster presentation (Abstract No. : #CT025) for the first time at the AACR Annual Meeting. The results showed that, after pretreatment with rituximab, JS203 administered with step-up dosing (SUD) demonstrated a good overall safety profile. JS203 demonstrated promising anti-tumor efficacy in patients with CD20-positive R/R B-NHL, with efficacy signals observed in the group with lower dose. In particular, in patients with DLBCL treated with JS203 30mg, the ORR reached 80% and the CRR was 40%. Due to limited follow-up time, the median duration of response (DoR) has not yet been reached, demonstrating the therapeutic potential of JS203 for patients with CD20-positive relapsed or refractory B-cell non-Hodgkin lymphoma, and is expected to provide a potential new treatment option for patients with malignant lymphoma.

In December 2025, the updated results of the phase I clinical study of JS203 for the treatment of patients with R/R B-NHL were presented in the form of poster presentation (Abstract No. : #1957) at the 67th ASH Annual Meeting held in 2025. The results showed that, for JS203 monotherapy at RP2D dosage administered with step-up dosing to 30 mg for the treatment of patients with CD20-positive R/R B-NHL, the ORR reached 72.4%. In particular, in patients with DLBCL, the ORR was 69.7%, the CRR was 39.4%, and there was persistent relief. Meanwhile, the overall safety profile was manageable. The incidence of cytokine release syndrome (CRS) was only 27.3%, and there was no incidence of immune effector cell-associated neurotoxicity syndrome (ICANS).

MANAGEMENT DISCUSSION AND ANALYSIS

FUTURE AND PROSPECTS

We see it as our mission to benefit patients with world-class and trustworthy innovative drugs, striving to become an innovative pharmaceutical enterprise that operates “in China, for global” for the benefit of human health.

In respect of R&D of drugs, we will continue to advance the construction of our R&D technology platforms, and maintain ongoing track and exploratory research on potential drug targets, with the goal of developing innovative drugs with unique therapeutic advantages. Meanwhile, we will also continue to efficiently advance our clinical pipeline, accelerate clinical trials of innovative drugs that are competitive in the international market, and actively explore dynamic combination therapy regimens to maximize pipeline synergies. Based on our independent R&D capabilities, we will also consider introducing product pipelines with synergistic effects to our existing portfolio through licensing-in and other methods, so as to stay on the forefront of developing innovative drugs.

As for production and manufacturing, we uphold quality as our foundation, and will continue to optimize production processes, enhance technical capabilities and strengthen quality control measures. We will also facilitate the in-depth integration and comprehensive upgrade of our production system, and will establish a scalable production system with significant cost advantages, thus effectively ensuring the stable supply of the Company’s products to meet growing market demand.

In respect of commercialization, we will maintain comprehensive and high-quality compliance, further refine the establishment of our commercialization team, and continuously enhance their product knowledge and disease expertise. In addition, we will promote our products to offer greater coverage and faster accessibility for patients in collaboration with partners worldwide.

In terms of international expansion, we will continue to deepen our global commercial footprint. Leveraging our commercialization partnerships with partners such as Coherus, Hikma, Dr. Reddy’s and LEO Pharma in over 80 countries, we will further accelerate the regulatory filings and commercial launch of toripalimab in these contracted territories, while continuously expanding into overseas commercial markets.

FINANCIAL REVIEW

1. Revenue

As at 30 June 2026, total revenue of the Group was approximately RMB1,696 million, representing an increase of approximately 45% compared to the corresponding period in 2025, which includes: (i) revenue from pharmaceutical products of approximately RMB1,407 million, increased by approximately 33% compared to the corresponding period in 2025, which was mainly due to improvement in sales efficiency of the commercialization team and approval of more indications for TUOYI®; (ii) revenue related to out-licensing agreements of approximately RMB254 million; and (iii) revenue from technical services and others of approximately RMB35 million.

During the Reporting Period, the domestic sales revenue of TUOYI® was approximately RMB1,299 million, representing an increase of approximately 36% compared to the corresponding period in 2025.

MANAGEMENT DISCUSSION AND ANALYSIS

2. R&D Expenses

R&D expenses mainly include clinical research and technical service expenses, staff salary and welfare expenses, share-based payment expenses, depreciation and amortization expenses and other operating expenses.

During the Reporting Period, R&D expenses were approximately RMB644 million, which decreased by approximately RMB101 million as compared to the corresponding period in 2025, representing a decrease of approximately 14%. R&D expenses included clinical research and technical service expenses of approximately RMB361 million, staff salary and welfare expenses of approximately RMB170 million, share-based payment expenses of approximately RMB61 million, depreciation and amortization expenses of approximately RMB34 million and other operating expenses of approximately RMB18 million. In particular, clinical research and technical service expenses, staff salary and welfare expenses, depreciation and amortization expenses and other operating expenses decreased by approximately 28%, 3%, 29% and 14% respectively, while share-based payment expenses increased by approximately 100% as compared to the corresponding period in 2025 due to the implementation of the Company's 2025 A Share Option Incentive Scheme and 2025 H Share Option Incentive Scheme.

The decrease in R&D expenses was mainly due to the Group's continued optimization of R&D resource allocation and improvement in operational efficiency.

3. Selling and Distribution Expenses

Selling and distribution expenses mainly include staff salary and welfare expenses, expenses for marketing and promotion activities, share-based payment expenses and other operating expenses.

During the Reporting Period, selling and distribution expenses amounted to approximately RMB507 million, which increased by approximately RMB20 million as compared to the corresponding period in 2025, representing an increase of approximately 4%. Selling and distribution expenses included staff salary and welfare expenses of approximately RMB317 million, expenses for marketing and promotion activities of approximately RMB164 million, share-based payment expenses of approximately RMB7 million and other operating expenses of approximately RMB19 million. In particular, staff salary and welfare expenses, share-based payment expenses and other operating expenses increased by approximately 28%, 100% and 50% respectively, while expenses for marketing and promotion activities decreased by 27% as compared to the corresponding period in 2025.

During the Reporting Period, the Group's selling and distribution expenses remained relatively stable overall. The increase was mainly due to the expansion of the sales team, which resulted in an increase in staff salary and welfare expenses. Meanwhile, the Group continued to optimize its market promotion activities and enhance the efficiency of resource allocation, resulting in a decrease in expenses for marketing and promotion activities as compared to the corresponding period in 2025.

MANAGEMENT DISCUSSION AND ANALYSIS

4. Administrative expenses

Administrative expenses mainly include administrative staff cost, share-based payment expenses, depreciation and amortization expenses, ordinary operating expenses and other miscellaneous expenses.

During the Reporting Period, administrative expenses amounted to approximately RMB279 million, which increased by approximately RMB70 million as compared to the corresponding period in 2025, representing an increase of approximately 34%. Administrative expenses included administrative staff cost of approximately RMB102 million, share-based payment expenses of approximately RMB54 million, depreciation and amortization expenses of approximately RMB53 million, ordinary operating expenses of approximately RMB51 million and other miscellaneous expenses of approximately RMB19 million. In particular, administrative staff cost, share-based payment expenses and ordinary operating expenses increased by approximately 20%, 100% and 8% respectively, while depreciation and amortization expenses and other miscellaneous expenses decreased by 5% and 6% respectively as compared to the corresponding period in 2025.

The increase in administrative expenses was mainly due to the implementation of the Company's 2025 A Share Option Incentive Scheme and 2025 H Share Option Incentive Scheme, resulting in the recognition of share-based payment expenses during the Reporting Period.

5. Liquidity and Capital Resources

As at 30 June 2026, the aggregate balance of bank balances and cash and financial products of the Group was approximately RMB3,670 million, increased by RMB475 million compared to the balance of 31 December 2025, which ensured that our cash position remained relatively sufficient to support the Group's development. The Group's financial products were mainly investments with original maturities of no more than 3 months and low risk; the fair value of these low-risk investments was approximately RMB951 million.

During the Reporting Period, net cash inflow from financing activities was approximately RMB1,643 million, and net cash outflow from operating activities was approximately RMB63 million, and net cash outflow from investing activities was approximately RMB1,442 million (including cash outflow in acquisition of the financial products), resulting in an increase of RMB112 million in bank balances and cash from 31 December 2025 after considering the foreign exchange rate change effect.

The Group manages its capital to ensure that entities in the Group will be able to continue as a going concern while maximizing the return to its stakeholders and maintaining an adequate capital structure. The Group's overall strategy remained unchanged throughout the year.

The capital structure of the Group consists of net debts, which includes borrowings, lease liabilities and other financial liabilities, net of bank balances and cash, and equity of the Group, comprising issued share capital, other reserves and non-controlling interests. The management of the Group will regularly review the capital structure on a continuous basis, considering the cost of capital and the risk associated with the capital, so as to better control and reduce the cost of capital.

MANAGEMENT DISCUSSION AND ANALYSIS

6. Non-IFRS Measures

To supplement the Group's consolidated financial statements which are prepared in accordance with the IFRS, the Company has provided adjusted profit (loss) for the period (excluding effects from non-cash related items and one-off events which include, but not limited to, depreciation and amortization expenses, share-based payment expenses and net exchange gains or losses), as additional financial measures, which are not required by, nor presented in accordance with, the IFRS. The Company believes that the non-IFRS financial measures are useful for understanding and assessing underlying business performance and operating trends, and that the Company's management and investors may benefit from referring to these non-IFRS financial measures in assessing the Group's financial performance by eliminating the impacts of certain unusual and non-recurring items that the Group does not consider indicative of the performance of the Group's business. However, the presentation of these non-IFRS financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with the IFRS. You should not view the non-IFRS financial results on a stand-alone basis or as a substitute for results under the IFRS, or as being comparable to results reported or forecasted by other companies.

Non-IFRS adjusted profit (loss) for the period:

	For the six months ended 30 June	
	2026	2025
	<i>RMB'000</i>	<i>RMB'000</i>
IFRS loss for the period	(36,986)	(466,409)
Add:		
Depreciation and amortization expenses	157,637	163,307
Share-based payment expenses	128,376	—
Net exchange losses	32,771	203
Adjusted profit (loss) for the period	281,798	(302,899)

MANAGEMENT DISCUSSION AND ANALYSIS

DIVIDENDS

No dividends were paid, declared or proposed during the six months ended 30 June 2026 and 2025.

EARNINGS (LOSS) PER SHARE

The calculation of the basic and diluted earnings (loss) per share attributable to owners of the Company is based on the following data:

Profit (loss)

	For the six months ended 30 June	
	2026	2025
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
Profit (loss) for the period attributable to owners of the Company for the purpose of basic and diluted earnings (loss) per share	25,501	(413,431)

Number of shares

	For the six months ended 30 June	
	2026	2025
	(Unaudited)	(Unaudited)
Weighted average number of ordinary shares for the purpose of basic and diluted earnings (loss) per share	1,025,874,000	987,365,713

In June 2025, the Company issued 41,000,000 ordinary shares (H Shares). The weighted average number of ordinary shares for the purpose of basic loss per share for the six months ended 30 June 2025 has been adjusted for the issuance of new H shares.

The computation of diluted earnings per share for the six months ended 30 June 2026 does not assume the exercise of the Company's outstanding A share options and H share options. These share options were not dilutive as their exercise prices were higher than the Company's average share price during the six months ended 30 June 2026.

MANAGEMENT DISCUSSION AND ANALYSIS

INTERESTS IN JOINT VENTURES

	As at 30 June 2026 <i>RMB'000</i> (Unaudited)	As at 31 December 2025 <i>RMB'000</i> (Audited)
Cost of investments in joint ventures	586,900	267,500
Share of post-acquisition losses	(89,488)	(59,022)
	497,412	208,478

During the period ended 30 June 2026, the Group formed a new joint venture entity with investment cost of RMB290,000,000 and RMB29,400,000 was further injected to an existing joint venture.

TRADE AND BILL RECEIVABLES

The balance of trade and bill receivables increased from approximately RMB507 million as at 31 December 2025, to approximately RMB744 million as at 30 June 2026, representing an increase of 47%. This increase was mainly due to the Group recognizing an upfront payment receivable of approximately RMB214 million on June 30, 2026 from an out-licensing agreement as at 30 June 2026.

	As at 30 June 2026 <i>RMB'000</i> (Unaudited)	As at 31 December 2025 <i>RMB'000</i> (Audited)
Trade receivables	748,895	507,476
Bills receivables	–	302
Less: Allowance for credit losses	(5,141)	(1,031)
	743,754	506,747

The Group allows a normal credit period of 30 to 60 days (31 December 2025: 30 to 60 days) to its trade customers.

MANAGEMENT DISCUSSION AND ANALYSIS

The following is an analysis of trade receivables by age (net of allowance for credit losses) presented based on invoice dates, which approximated the revenue recognition date, at the end of the Reporting Period.

	As at 30 June 2026 RMB'000 (Unaudited)	As at 31 December 2025 RMB'000 (Audited)
0 to 90 days	706,437	490,887
91 to 180 days	26,833	5,078
Over 180 days	10,484	10,782
	743,754	506,747

OTHER FINANCIAL ASSETS

The balance of other financial assets increased from approximately RMB1,982 million as at 31 December 2025, to approximately RMB2,899 million as at 30 June 2026, representing an increase of 46%. This increase was mainly due to increases in investments in financial products, listed equity investments and unlisted preference shares.

	As at 30 June 2026 RMB'000 (Unaudited)	As at 31 December 2025 RMB'000 (Audited)
Current assets		
Financial assets measured at FVTPL		
– Financial products	963,885	600,782
Non-current assets		
Financial assets measured at FVTPL		
– Unlisted equity investments in partnership	237,353	226,708
– Unlisted equity investments	210,314	368,001
– Listed equity investments	415,768	–
– Investments in preference shares	964,150	731,060
Financial assets designated as at FVTOCI (Note)	107,757	55,787
	1,935,342	1,381,556

Note: The investments are not held for trading, instead, these are held for long-term strategic purposes. The management of the Group have elected to designate these investments in equity instruments as at FVTOCI as they believe that recognising short-term fluctuations in these investments' fair value in profit or loss would not be consistent with the Group's strategy of holding the investments for long-term purposes and realising the performance potential in the long run.

MANAGEMENT DISCUSSION AND ANALYSIS

TRADE AND OTHER PAYABLES

The balance of trade and other payables decreased from approximately RMB1,487 million as at 31 December 2025, to approximately RMB1,412 million as at 30 June 2026, representing a decrease of 5%.

	As at 30 June 2026 RMB'000 (Unaudited)	As at 31 December 2025 RMB'000 (Audited)
Trade payables	83,588	111,044
Accrued expenses in respect of		
– construction cost of properties under construction	517,189	509,233
– research and development expenses (Note a)	314,550	291,963
– selling and distribution expenses	133,247	155,430
– payables under collaboration agreement	68	55
– others	64,795	74,991
Salary and bonus payables	208,834	252,624
Other tax payables	28,082	22,377
Other payables (Note b)	61,479	69,011
	1,411,832	1,486,728
Analysed as		
– current	1,381,832	1,456,728
– non-current	30,000	30,000
	1,411,832	1,486,728

Notes:

- (a) Amounts include service fees payable to outsourced service providers including contract research organisations and clinical trial centres.
- (b) Included in the balance, amount of RMB30,000,000 (31 December 2025: RMB35,000,000) is non-trade in nature, unsecured and interest-free, and amount of RMB15,000,000 (31 December 2025: RMB15,000,000) is non-trade in nature, unsecured, and carrying interest rate of 5% (31 December 2025: 5%) per annum and will mature within one year.

MANAGEMENT DISCUSSION AND ANALYSIS

Payment terms with suppliers are mainly with credit term of 0 to 90 days (2025: 0 days to 90 days) from the time when the goods and services are received from the suppliers. The following is an aging analysis of trade payables presented based on invoice date at the end of the Reporting Period:

	As at 30 June 2026 RMB'000 (Unaudited)	As at 31 December 2025 RMB'000 (Audited)
0 to 30 days	63,282	71,167
31 to 60 days	717	1,768
61 to 180 days	2,853	16,744
Over 180 days	16,736	21,365
	83,588	111,044

INDEBTEDNESS

As at 30 June 2026, the Group had variable-rate borrowings of approximately RMB3,634 million with interest rates ranging from 2.11% to 3.05% per annum, and fixed-rate borrowings of approximately RMB2,184 million with interest rates ranging from 1.17% to 2.70% per annum.

Unsecured Bank Borrowings

As at 30 June 2026, the balance of the Group unsecured bank borrowings amounted to approximately RMB2,543 million in total and were all obtained from major domestic commercial banks. The borrowings carried interest rates ranging from 1.17% to 2.55% per annum.

During the period ended 30 June 2026, the Group repaid approximately RMB701 million in unsecured borrowings. In addition, during the period ended 30 June 2026, the Group drew down approximately RMB1,265 million in unsecured borrowings bearing interest rates ranging from 2.11% to 2.28% per annum.

MANAGEMENT DISCUSSION AND ANALYSIS

Secured Bank Borrowings

As at 30 June 2026, the balance of the Group's secured bank borrowings amounted to approximately RMB2,266 million in total and were all obtained from major domestic commercial banks. The borrowings carried interest rates ranging from 2.60% to 3.05% per annum.

During the period ended 30 June 2026, the Group repaid approximately RMB89 million in secured borrowings. In addition, during the period ended 30 June 2026, the Group drew down approximately RMB277 million in secured borrowings bearing interest rates ranging from 2.75% to 3.05% per annum.

Technology Innovation Bonds

As at 30 June 2026, the balance of the Group's other borrowings amounted to approximately RMB1,009 million in total. During the period ended 30 June 2026, the Group completed the issuance of the 2026 first tranche of technology innovation bonds and received a total proceed of RMB1,000 million. The bonds bear a fixed coupon rate of 2.7% per annum payable at the end of each year and have a term of 3+2 years, maturing in January 2031.

The Group incurred borrowings for: i) ongoing clinical trials and preclinical studies for our drug candidates and replenishment of working capital; ii) construction of Suzhou Junao Cancer Hospital; and iii) investment in funds focused on scientific and technological innovation.

As at 30 June 2026, the Group has pledged the following assets as securities for the Group's bank borrowings:

	At 30 June 2026 RMB'000 (Unaudited)	At 31 December 2025 RMB'000 (Audited)
Restricted bank deposits	20,000	20,000
Property, plant and equipment	2,474,337	2,409,148
Right-of-use assets	208,833	212,798
	2,703,170	2,641,946

The maturity profile of borrowings is as follows:

– within one year	1,398,507	1,262,590
– within a period of more than one year but not exceeding two years	1,625,880	1,139,312
– within a period of more than two years but not exceeding five years	1,799,245	708,681
– within a period of more than five years	994,244	945,615
	5,817,876	4,056,198

All borrowings are denominated in RMB as at 30 June 2026 and 31 December 2025.

MANAGEMENT DISCUSSION AND ANALYSIS

CONTRACTUAL COMMITMENTS

Capital and Other Commitments

As at 30 June 2026, the Group's capital expenditure in respect of the acquisition of property, plant and equipment and equity investments contracted for but not provided in the condensed financial statements was approximately RMB1,154 million, which decreased by 7% from RMB1,243 million as at 31 December 2025, due to the decreased capital expenditure in property, plant and equipment.

Financing Plan

The Group has obtained a credit limit of no more than RMB8,500 million to support the Group's production operations and project construction. The credit limit is valid from the date of approval by the Company at the 2025 annual general meeting to the date of the 2026 annual general meeting.

GEARING RATIO

As at 30 June 2026, the gearing ratio of the Group was 50.46%, which was calculated using interest-bearing borrowings less bank balances and cash, divided by total equity and multiplied by 100%, representing an increase of 26.38 percentage points from 24.08% as at 31 December 2025. The increase was primarily due to the increase of our long-term bank borrowings and technology innovation bonds.

SIGNIFICANT INVESTMENTS, MATERIAL ACQUISITIONS AND DISPOSALS

Save as disclosed in Note 5 and Note 26 to the condensed financial statements in this interim report, the Group did not have other significant investments, material acquisitions or disposals of subsidiaries, associates and joint ventures during the period ended 30 June 2026.

CONTINGENT LIABILITIES

As at 30 June 2026, the Group did not have any material contingent liabilities.

FUTURE PLAN FOR MATERIAL INVESTMENTS OR CAPITAL ASSETS

Save as disclosed in this interim report, the Group did not have other future plans for material investments or capital assets.

OTHER INFORMATION

RESULTS AND DIVIDENDS

The Group's profit for the Reporting Period and the state of affairs of the Group at 30 June 2026 are set out in the condensed consolidated financial statements and the accompanying notes on pages 64 to 102.

The Directors do not recommend the distribution of any interim dividend for the Reporting Period.

DIRECTORS

BOARD OF DIRECTORS

As at the end of the Reporting Period, the Board comprised 14 Directors, consisting of 7 executive Directors, 2 non-executive Directors, and 5 independent non-executive Directors. During the Reporting Period and up to the date of this interim report, the composition of the Board changed as follows:

Executive Directors

Mr. Xiong Jun (*Chairman and Legal Representative*)

Dr. Li Ning (*Vice Chairman*)

Dr. Zou Jianjun (*Chief Executive Officer and General Manager*)

Mr. Li Cong (*Co-Chief Executive Officer*)

Mr. Zhang Zhuobing

Dr. Wang Gang

Dr. Li Xin

Non-executive Directors

Dr. Yao Sheng - re-designated from an executive Director to a non-executive Director on 5 June 2026

Mr. Tang Yi

Independent Non-executive Directors

Dr. Feng Xiaoyuan

Mr. Li Zhongxian

Ms. Lu Kun

Dr. Yang Jin

Mr. Chen Liang - appointed on 26 June 2026

Mr. Zhang Chun - retirement with effect from 26 June 2026

OTHER INFORMATION

Directors' Rights to Acquire Shares or Debentures

Save as otherwise disclosed in this interim report, none of the Directors or any of their respective associates was granted by the Company or its subsidiaries any right to acquire shares in, or debentures of, the Company or its subsidiary, or had exercised any such right during the Reporting Period.

2025 A Share Option Incentive Scheme

On 2 September 2025, the Board resolved to approve the 2025 A Share Option Incentive Scheme. The 2025 A Share Option Incentive Scheme was approved and adopted by the Shareholders at the 2025 first extraordinary general meeting of the Company held on 29 September 2025.

The 2025 A Share Option Incentive Scheme is established for the purpose of further refining and enhancing the Company's long-term incentive framework. The 2025 A Share Option Incentive Scheme is designed with the primary objectives of: (i) attracting and retaining individuals possessing exceptional qualifications and capabilities; (ii) fully stimulating and maximizing the motivation and initiative of employees of the Company and its subsidiaries; and (iii) effecting a close alignment of the interests of the shareholders, the Company, and the core team members. The 2025 A Share Option Incentive Scheme is intended to promote a unified and sustained focus on the long-term development of the Company, thereby ensuring that the interests of all relevant parties are aligned. The implementation of the 2025 A Share Option Incentive Scheme shall be conducted in a manner that safeguards the legitimate rights and interests of the Shareholders and adheres to the principle that remuneration and incentives shall be commensurate with the individual contributions made by the participants to the Company.

A summary of the 2025 A Share Option Incentive Scheme is set out below:

- (a) The participants of the 2025 A Share Option Incentive Scheme may include the Directors, senior management and employees of the Company and its subsidiaries. The Board of Directors shall draft a list of eligible participants within the defined scope, which shall be verified and confirmed by the Board of Supervisors (or a supervisory authority in the case that the Board of Supervisors has been cancelled).
- (b) In the first grant under the 2025 A Share Option Incentive Scheme (the "**First Grant**") on 29 September 2025, 25,150,000 A Share Options were granted to 235 participants, including 234 participants who are employees of the Group and not connected persons of the Company, and Mr. Xiong Jun, an executive Director and a substantial shareholder.

OTHER INFORMATION

- (c) The list of participants eligible for the reserved grant (the “**Reserved Grant**”) under the 2025 A Share Option Incentive Scheme shall be determined within 12 months from the 2025 first extraordinary general meeting, otherwise such reserved grant shall lapse. The participants for the reserved grant under the 2025 A Share Option Incentive Scheme may include Directors, senior management and employees whom the Board of Directors determines to be eligible, but do not include Independent Non-executive Directors, Supervisors, Shareholders or actual controllers holding individually or collectively more than 5% of the Shares, along with their spouses, parents, and children. The criteria for determining the list of participants eligible for the Reserved Grant under the 2025 A Share Option Incentive Scheme shall be based on the same standards as those for the First Grant under the 2025 A Share Option Incentive Scheme.
- (d) The source of the underlying shares of the 2025 A Share Option Incentive Scheme shall be treasury shares and/or new A Shares to be specifically issued to the participants.
- (e) As at the date of this report, the Company has a total of 1,025,874,000 issued Shares (excluding treasury shares), comprising 765,578,300 A Shares and 260,295,700 H Shares. The number of underlying A Shares in respect of the A Share Options proposed to be granted under the 2025 A Share Option Incentive Scheme is 26,175,871, representing approximately 2.55% of the total issued Shares of the Company (excluding treasury shares) as at the date of this report, among which, (i) the first grant of A Share Options consists of 25,360,000 A Shares (the “**First Grant of A Share Options**”), representing approximately 2.47% of the total issued Shares of the Company (excluding treasury shares) and 96.88% of the total number of A Share Options under the Grant of A Share Options; (ii) the reserved grant of A Share Options consists of 815,871 A Shares (the “**Reserved Grant of A Share Options**”), representing approximately 0.08% of the total issued Shares of the Company (excluding treasury shares) and 3.12% of the total number of A Share Options under the Grant of A Share Options as at the date of this report. The total number of A Share Options to be granted under the 2025 A Share Option Incentive Scheme was adjusted from 26,175,871 to 25,965,871 pursuant to the resolution of the Board. For further details, please refer to the announcement of the Company dated 29 September 2025.
- (f) The total number of Shares to be granted to any participant under the 2025 A Share Option Incentive Scheme shall not exceed 1% of the total issued Shares of the Company (excluding treasury shares).
- (g) The validity period of the 2025 A Share Option Incentive Scheme commences on the date of the First Grant of A Share Options (i.e., 29 September 2025) and ends on the date on which all A Share Options granted to the participants have been exercised or cancelled. Such validity period shall not exceed 48 months.
- (h) The A Share Options granted to the participants are subject to different vesting periods, all calculated from the respective grant dates. The vesting periods for the First Grant of A Share Options are 12 months or 24 months from the grant date of the First Grant of A Share Options. The vesting periods for the Reserved Grant of A Share Options are 12 months or 24 months from the grant date of the Reserved Grant of A Share Options. During the vesting periods, the A Share Options granted to the participants may not be transferred, used as collateral, or used to repay debts.

OTHER INFORMATION

- (i) Upon the fulfillment of conditions of the exercise of the A Share Options, the A Share Options are exercisable in two tranches upon expiry of 12 months from the grant date.

The exercise arrangements for the First Grant of A Share Options are as follows: (1) the first exercise period (50% of the A Share Options granted) commencing from the first trading day after the expiry of the 12th month from the grant date of the First Grant of A Share Options, and ending on the last trading day of the 24th month from the grant date of the First Grant of A Share Options; (2) the second exercise period (50% of the A Share Options granted) commencing from the first trading day after the expiry of the 24th month from the grant date of the First Grant of A Share Options, and ending on the last trading day of the 36th month from the grant date of the First Grant of A Share Options.

The exercise arrangements for the Reserved Grant of A Share Options is as follows: (1) first exercise period (50% of the A Share Options granted) commencing from the first trading day after the expiry of the 12th month from the grant date of the Reserved Grant of A Share Options, and ending on the last trading day of the 24th month from the grant date of the Reserved Grant of A Share Options; (2) second exercise period (50% of the A Share Options granted) commencing from the first trading day after the expiry of the 24th month from the grant date of the Reserved Grant of A Share Options, and ending on the last trading day of the 36th month from the grant date of the Reserved Grant of A Share Options.

A Share Options for which the exercise conditions are not fulfilled during the above agreed period shall not be exercised or deferred to the next exercise period, and the relevant A Share Options of such participants shall be cancelled by the Company in accordance with the principles stipulated in the 2025 A Share Option Incentive Scheme. After the end of each exercise period of the A Share Options, the A Share Options exercisable by the participants for the current period that have not been exercised shall be terminated and cancelled by the Company.

- (j) The exercise price of A Share Options for the First Grant of A Share Options under the 2025 A Share Option Incentive Scheme is RMB46.67 per A Share. As such, the participants have the right to purchase A Shares at a price of RMB46.67 per A Share after satisfying the conditions of the grant of the A Share Options and exercise conditions. There is no amount payable on application or acceptance of the option and there is no time requirement for which payments must or may be made.

Pursuant to the STAR Market Listing Rules and the Management Measures for Share Incentives of Listed Companies* (《上市公司股權激勵管理辦法》), The exercise price of the A Share Options to be granted under the 2025 A Share Option Incentive Scheme shall not be lower than the face value of the Shares, and shall not be lower than the higher of: (1) the average trading price of the A Shares on the trading day preceding the announcement date (i.e., 2 September 2025) of the draft 2025 A Share Option Incentive Scheme, i.e., RMB46.67 per A Share; and (2) the average trading price of the Company's A Shares for the 120 trading days preceding the announcement date of the draft 2025 A Share Option Incentive Scheme, i.e., RMB37.00 per A Share.

The exercise price of the A Share Options granted in the Reserved Grant of A Share Options under the 2025 A Share Option Incentive Scheme is the same as the exercise price of the A Share Options granted in the First Grant of A Share Options, being RMB46.67 per A Share. The Board of Directors shall convene a meeting to review and approve the relevant proposals, and disclose the details of the Reserved Grant of A Share Options.

OTHER INFORMATION

- (k) The A Share Options may only be granted and exercised upon satisfaction of the relevant conditions stipulated in the 2025 A Share Option Incentive Scheme.
- (l) The requirements of black-out for the A Share Options shall be implemented in accordance with the requirements in the PRC Company Law, PRC Securities Law and other relevant laws, regulations, regulatory documents and the Articles of Association.
- (m) In the event of conversion of capital reserve into share capital, bonus issue and share split, rights issue, share consolidation and dividend distribution of the Company during the period from the date of announcement of the draft 2025 A Share Option Incentive Scheme to the completion of registration of exercise of the A Share Options by the participants, the exercise price of A Share Options and/or the number of A Shares subject to A Share Options to be granted under the grant of A Share Options should be adjusted accordingly, but no adjustments may be made to the extent that the exercise price of A Share Options would be lower than the nominal value of the A Shares.

As of 30 June 2026, the 25,150,000 A Share Options under the First Grant has been granted on 29 September 2025. In the process of registration of the A Share Options following the determination of the grant date of the First Grant under the 2025 A Share Option Incentive Scheme, nine participants waived all A Share Options they had been granted, amounting to 450,000 A Share Options in total, for personal reasons. Such A Share Options were not registered and were directly cancelled. Accordingly, the number of participants under the First Grant of A Share Options has been reduced to 226 (including 225 participants who are employees of the Group and not connected persons of the Company, and Mr. Xiong Jun, an executive Director and a substantial shareholder), and the number of A Share Options registered for the First Grant of A Share Options is 24,700,000. During the Reporting Period, no A Share Options were granted under the Reserved Grant. For further details, please refer to the Company's announcement dated 14 November 2025.

The validity period of the 2025 A Share Option Incentive Scheme commenced on the date of the First Grant of A Share Options and ends on the date on which all A Share Options granted to the participants have been exercised or cancelled. Such validity period shall not exceed 48 months. As at 30 June 2026, the maximum remaining life of the 2025 A Share Option Incentive Scheme is approximately 39 months.

OTHER INFORMATION

Details of the movements of the A Share Options during the Reporting Period are as follows:

Name or category of grantee	Date of grant ⁽¹⁾	Exercise Period ⁽²⁾	Grant Price (RMB yuan) ⁽³⁾	Movement of A Share Options during the Reporting Period						
				Number of A Share Options granted	Number of A Share Options that have not been exercised as at 31 December 2025	Granted	Exercised	Lapsed	Cancelled	Number of A Share Options that have not been exercised as at 30 June 2026
Xiong Jun (Chairman of the Board and Executive Director)	29 September 2025	29 September 2026 – 28 September 2028	46.67	8,000,000	8,000,000	–	–	–	–	8,000,000
Employees whom the Board of Directors has determined should be incentivized (225 persons)	29 September 2025	29 September 2026 – 28 September 2028	46.67	16,700,000	16,700,000	–	–	–	–	16,700,000
Total				24,700,000	24,700,000	–	–	–	–	24,700,000

Notes:

- (1) The grant of A Share Options under the First Grant was made on 29 September 2025.
- (2) The exercise arrangements for the First Grant of A Share Options are as follows: (1) the first exercise period (50% of the A Share Options granted) commencing from the first trading day after the expiry of the 12th month from the grant date of the First Grant of A Share Options, and ending on the last trading day of the 24th month from the grant date of the First Grant of A Share Options; (2) the second exercise period (50% of the A Share Options granted) commencing from the first trading day after the expiry of the 24th month from the grant date of the First Grant of A Share Options, and ending on the last trading day of the 36th month from the grant date of the First Grant of A Share Options.
- (3) The exercise arrangements for the Reserved Grant of A Share Options are as follows: (1) first exercise period (50% of the A Share Options granted) commencing from the first trading day after the expiry of the 12th month from the grant date of the Reserved Grant of A Share Options, and ending on the last trading day of the 24th month from the grant date of the Reserved Grant of A Share Options; (2) second exercise period (50% of the A Share Options granted) commencing from the first trading day after the expiry of the 24th month from the grant date of the Reserved Grant of A Share Options, and ending on the last trading day of the 36th month from the grant date of the Reserved Grant of A Share Options.
- (4) The grant price is RMB46.67 per A Share. The closing price of the A Shares immediately before the grant date is RMB41.00.
- (5) 815,871 A Share Options were reserved under the Reserved Grant. During the Reporting Period, no A Share Options were granted under the Reserved Grant.

OTHER INFORMATION

The number of A Share Options available for grant under the 2025 A Share Option Incentive Scheme as at 1 June 2026 and 30 June 2026 is 815,871 A Shares. The number of A Share Options available for grant under the 2025 A Share Option Incentive Scheme represents 0.08% of the total issued Shares (excluding treasury shares) as at the date of this report.

Further details of the 2025 A Share Option Incentive Scheme and the First Grant are set out in the circular dated 5 September 2025, the announcements dated 2 September 2025, 29 September 2025 and 14 November 2025 of the Company, and note 24 to the Unaudited Condensed Consolidated Financial Statements of this report.

2025 H Share Option Incentive Scheme

On 2 September 2025, the Board resolved to approve the 2025 H Share Option Incentive Scheme. The 2025 H Share Option Incentive Scheme was approved and adopted by the Shareholders at the 2025 first extraordinary general meeting of the Company held on 29 September 2025.

The purposes of establishing the 2025 H Share Option Incentive Scheme are: (1) to provide the Company with a flexible means of attracting, remunerating, incentivising, retaining, rewarding, compensating and/or providing benefits to the participants; (2) to align the interests of participants with those of the Company and Shareholders by providing such participants with the opportunity to acquire proprietary interests in the Company and become Shareholders; and (3) to encourage participants to contribute to the long-term growth, performance and profits of the Company and to enhance the value of the Company and its Shares for the benefit of the Company and Shareholders as a whole.

A summary of the 2025 H Share Option Incentive Scheme is set out below:

- (a) The Participants of the 2025 H Share Option Incentive Scheme include employee participant(s) and related entity participant(s). The basis of eligibility of any participants to the grant of any H Share Options shall be determined by the Board or the scheme administrator from time to time.
- (b) The total number of H Shares which may be issued in respect of H Share Option(s) to be granted under the 2025 H Share Option Incentive Scheme and other Shares which may be issued under any other effective share scheme(s) of the Company is up to 10% of the total Shares (excluding treasury shares) in issue as at the adoption date (the “**Scheme Mandate Limit**”).

As at the date of this report, the Company has 1,025,874,000 issued Shares (excluding 815,871 treasury shares). The maximum number of H Shares which may be issued in respect of all H Share Options which may be granted pursuant to the 2025 H Share Option Incentive Scheme, together with the Shares which may be issued in respect of share options and awards which may be granted under any other effective share scheme(s) of the Company (including under the 2025 A Share Option Incentive Scheme) will be 102,587,400 Shares, representing approximately 10% of the total number of Shares in issue (excluding treasury shares) as at the date of this report.

- (c) Subject to early termination by the Board of Directors, the 2025 H Share Option Incentive Scheme shall remain in effect for a period of ten (10) years commencing from the Adoption Date, unless terminated earlier in accordance with the rules of the 2025 H Share Option Incentive Scheme.
- (d) The vesting period, being the minimum period for which a H Share Option must be held before it can be exercised, is determined by the Board or the scheme administrator as authorised by the Board, which shall not be less than twelve (12) months, except that H Share Options granted to employee participants may be subject to a shorter vesting period under certain circumstances.

OTHER INFORMATION

- (e) The exercise price of H Share Options shall be such price determined by the Board of Directors or the scheme administrator in its absolute discretion and notified to the participant in the grant letter, provided that the exercise price of H Share Options shall in any event be no less than the highest of: (1) the closing price of the H Shares as stated in the daily quotations sheet issued by the Hong Kong Stock Exchange on the grant date, which must be a business day; and (2) the average closing price of the H Shares as stated in the daily quotations sheets issued by the Hong Kong Stock Exchange for the five business days immediately preceding the grant date. There is no amount payable on application or acceptance of the option and there is no time requirement for which payments must or may be made.

On 2 September 2025, in accordance with the Hong Kong Listing Rules, the Articles of Association and the 2025 H Share Option Incentive Scheme, the Board resolved to conditionally grant a total of 13,210,000 H Share Options to 10 grantees, which took effect upon the 2025 H Share Option Incentive Scheme being approved and adopted by the Shareholders at the 2025 first extraordinary general meeting of the Company held on 29 September 2025. For further details, please refer to the Company's announcement dated 2 September 2025.

The 2025 H Share Option Incentive Scheme shall be valid for a period of ten years commencing from (and including) its date of adoption unless terminated earlier in accordance with rules of the 2025 H Share Option Incentive Scheme.

Details of the movements of the H Share Options during the Reporting Period are as follows:

						Movement of H Share Options during the Reporting Period					
Name or category of grantee	Date of grant ⁽¹⁾	Date of commencement of the exercise period ⁽²⁾	Date of expiry of the exercise period ⁽²⁾	Grant Price (HK\$) ⁽³⁾	Number of H Share Options granted	Number of H Share Options that have not been exercised as at 31 December 2025	Granted	Exercised	Lapsed	Cancelled	Number of H Share Options that have not been exercised as at 30 June 2026
First Grant											
Li Ning (Executive Director and Vice Chairman)	2 September 2025	2 September 2026	2 September 2030	32.30	1,200,000	1,200,000	–	–	–	–	1,200,000
Zou Jianjun (Executive Director, Chief Executive Officer and General Manager)	2 September 2025	2 September 2026	2 September 2030	32.30	5,000,000	5,000,000	–	–	–	–	5,000,000
Li Cong (Executive Director and Co-Chief Executive Officer)	2 September 2025	2 September 2026	2 September 2030	32.30	1,200,000	1,200,000	–	–	–	–	1,200,000
Zhang Zhuobing (Executive Director)	2 September 2025	2 September 2026	2 September 2030	32.30	1,200,000	1,200,000	–	–	–	–	1,200,000
Yao Sheng (Non-executive Director)	2 September 2025	2 September 2026	2 September 2030	32.30	1,200,000	1,200,000	–	–	–	–	1,200,000

OTHER INFORMATION

Name or category of grantee	Date of grant ⁽¹⁾	Date of commencement of the exercise period ⁽²⁾	Date of expiry of the exercise period ⁽²⁾	Grant Price (HK\$) ⁽³⁾	Number of H Share Options granted	Movement of H Share Options during the Reporting Period					Number of H Share Options that have not been exercised as at 30 June 2026
						Number of H Share Options that have not been exercised as at 31 December 2025	Granted	Exercised	Lapsed	Cancelled	
First Grant											
Wang Gang (Executive Director)	2 September 2025	2 September 2026	2 September 2030	32.30	1,200,000	1,200,000	–	–	–	–	1,200,000
Li Xin (Executive Director)	2 September 2025	2 September 2026	2 September 2030	32.30	1,200,000	1,200,000	–	–	–	–	1,200,000
Three other employee participants	2 September 2025	2 September 2026	2 September 2030	32.30	1,010,000	1,010,000	–	–	–	–	1,010,000
Total					13,210,000	13,210,000	–	–	–	–	13,210,000

Notes:

- (1) The grant of H Share Options was conditionally made on 2 September 2025, and took effect upon the 2025 H Share Option Incentive Scheme being approved and adopted by the Shareholders at the 2025 first extraordinary general meeting of the Company held on 29 September 2025.
- (2) All the H Shares Options granted shall vest in two equal installments on each of the first and second anniversaries of the date of the conditional grant (i.e., 2 September 2025). The specific arrangements are as follows: (1) the first batch (50% of the H Share Options granted) on the first anniversary of the date of the conditional grant (i.e., 2 September 2026); (2) the second batch (50% of the H Share Options granted) on the second anniversary of the date of the conditional grant (i.e., 2 September 2027).
- (3) Subject to the vesting of the H Share Options, the exercise period of the H Share Options granted shall be not more than five (5) years commencing on the date of the conditional grant.
- (4) The grant price is HK\$32.30 per H Share, which represents the higher of (i) the closing price of the H Shares as stated in the daily quotations sheet issued by the Hong Kong Stock Exchange on the date of conditional grant; or (ii) the average closing price of the H Shares as stated in the daily quotations sheets issued by the Hong Kong Stock Exchange for the five business days immediately preceding the date of the conditional grant. The closing price of the H Shares immediately before the grant date is HK\$32.98.

The number of H Share Options available for grant under the 2025 H Share Option Incentive Scheme as at 1 June 2026 and 30 June 2026 is 64,677,400. The number of H Share Options available for grant under the 2025 H Share Option Incentive Scheme represents 6.30% of the total issued Shares (excluding treasury shares) as at the date of this report.

OTHER INFORMATION

Further details of the 2025 H Share Option Incentive Scheme and the conditional grant are set out in the circulars dated 5 September 2025 and 15 September 2025, the announcement dated 2 September 2025 of the Company, and note 24 to the Unaudited Condensed Consolidated Financial Statements of this report.

2026 A Share Employee Stock Ownership Scheme

On 27 April 2026, the Board resolved to approve the 2026 A Share Employee Stock Ownership Scheme, which would be subject to the approval at the Shareholders' meeting of the Company.

On 26 August 2026, in order to better safeguard the interests of the Company, its shareholders, and its employees, after due consideration, the Board resolved to terminate the 2026 A Share Employee Stock Ownership Scheme, the Administrative Measures for the 2026 A Share Employee Stock Ownership Scheme and all other ancillary documents accordingly.

Competing interest and other interest

None of the Directors or any entity connected with them has any material interest, either directly or indirectly, in any contract, transaction or arrangement of significance to the Group's business to which the Company, any of its holding companies, any of its subsidiaries, fellow subsidiaries was a party subsisted at any time during the Reporting Period.

During the Reporting Period, none of the Directors and their respective associates had an interest in a business which causes or may cause any significant competition with the business of the Group and any other conflicts of interest which any such person has or may have with the Group.

Changes of Information of the Directors

During the Reporting Period, save as disclosed below, the Directors confirmed that there is no information which is discloseable pursuant to Rule 13.51B(1) of the Hong Kong Listing Rules.

As at the date of this report, changes in information since the date of publication of the 2025 Annual Report which are required to be disclosed by the Directors pursuant to Rule 13.51B(1) of the Listing Rules are set out as below:

Updated Biographical Details of Directors

Name of Director	Details of Change	Effective Date
Mr. Zhang Zhuobing	Serving as a director and the legal representative of Suzhou Junyi'an Biotechnology Co., Ltd.* (蘇州君益安生物科技有限公司), a wholly-owned subsidiary of the Company	2 March 2026
Mr. Xiong Jun	Serving as a director and the legal representative of Guangdong Hengqin Juntuo Biomedical Technology Co., Ltd.* (廣東橫琴君拓生物醫藥科技有限公司), a non-wholly-owned subsidiary of the Company	5 June 2026
Dr. Yao Sheng	Resigned as the deputy general manager of the Company and a director of Suzhou Junao Precision Medicine Co., Ltd.* (蘇州君奧精準醫學有限公司), a subsidiary of the Company, and re-designated from an executive Director to a non-executive Director	5 June 2026
Dr. Zou Jianjun	Resigned as a director of TopAlliance, a subsidiary of the Company	5 June 2026
Dr. Wang Gang	Resigned as a director of TopAlliance, a subsidiary of the Company	5 June 2026
Dr. Li Xin	Resigned as a director of TopAlliance, a subsidiary of the Company	5 June 2026
Mr. Li Zhongxian	Appointed as the chairman of each of the Audit Committee and the Remuneration and Appraisal Committee and a member of the Strategic and ESG Committee	26 June 2026
Mr. Chen Liang	Appointed as an independent non-executive Director, and a member of each of the Audit Committee and the Compliance Committee	26 June 2026

OTHER INFORMATION

Name of Director	Details of Change	Effective Date
Mr. Zhang Chun	Retired as an independent non-executive Director, and a member of each of the Audit Committee, the Remuneration and Appraisal Committee, the Strategic and ESG Committee and the Compliance Committee	26 June 2026

Directors' and Chief Executive's Interests and Short Position in Shares, Underlying Shares and Debentures

As at 30 June 2026, the interests or short positions of the Directors and chief executive of the Company in the Shares, underlying Shares or debentures of the Company or any of its associated corporations (within the meaning of Part XV of the SFO) which were required to be notified to the Company and the Hong Kong Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions in which they are taken or deemed to have under such provisions of the SFO), or which were required, pursuant to section 352 of the SFO, to be entered in the register referred to therein, or which were required to be notified to the Company and Hong Kong Stock Exchange pursuant to the Model Code were as follows:

Interests in the Company

Name of Director/ Chief Executive	Nature of interests	Class of Shares	Number of Shares/ Underlying Shares ⁽¹⁾	Approximate percentage in relevant class of Shares ⁽¹⁾	Approximate percentage in total share capital ⁽¹⁾
Xiong Jun	Beneficial owner ⁽²⁾	A Shares	98,218,913 (L)	12.82%	9.57%
		H Shares	897,200 (L)	0.34%	0.09%
	Parties acting in concert ⁽²⁾ Interest in controlled corporations ⁽²⁾	A Shares	96,126,568 (L)	12.54%	9.36%
		A Shares	105,413,768 (L)	13.75%	10.27%
Li Ning	Beneficial owner ⁽³⁾	A Shares	50,000 (L)	0.01%	0.00%
		H Shares	1,200,000 (L)	0.46%	0.12%
Zou Jianjun	Beneficial owner ⁽⁴⁾	H Shares	5,000,000 (L)	1.92%	0.49%
Li Cong	Beneficial owner ⁽⁵⁾	A Shares	127,020 (L)	0.02%	0.01%
		H Shares	1,200,000 (L)	0.46%	0.12%
Zhang Zhuobing	Beneficial owner ⁽⁶⁾	A Shares	40,000 (L)	0.01%	0.00%
		H Shares	1,200,000 (L)	0.46%	0.12%

OTHER INFORMATION

Name of Director/ Chief Executive	Nature of interests	Class of Shares	Number of Shares/ Underlying Shares ⁽¹⁾	Approximate percentage in relevant class of Shares ⁽¹⁾	Approximate percentage in total share capital ⁽¹⁾
	Interest of spouse ⁽⁶⁾	A Shares	8,608,000 (L)	1.12%	0.84%
		H Shares	2,097,200 (L)	0.81%	0.20%
	Parties acting in concert ⁽⁶⁾	A Shares	106,826,913 (L)	13.94%	10.40%
Yao Sheng	Beneficial owner ⁽⁷⁾	H Shares	1,200,000 (L)	0.46%	0.12%
Wang Gang	Beneficial owner ⁽⁸⁾	A Shares	10,000 (L)	0.00%	0.00%
		H Shares	1,200,000 (L)	0.46%	0.12%
Li Xin	Beneficial owner ⁽⁹⁾	A Shares	12,060 (L)	0.00%	0.00%
	Beneficial owner ⁽⁹⁾	H Shares	1,241,200 (L)	0.48%	0.12%
	Interest in controlled corporations ⁽⁹⁾	H Shares	41,654 (L)	0.02%	0.00%
Tang Yi	Beneficial owner ⁽¹⁰⁾	A Shares	7,774,500 (L)	1.01%	0.76%
	Interest in controlled corporations ⁽¹⁰⁾	A Shares	48,184,000 (L)	6.29%	4.69%

Notes:

- The letter "L" denotes the long position in the Shares, the letter "S" denotes short position in the Shares and the letter "P" denotes lending pool. As at 30 June 2026, the Company had 1,026,689,871 issued Shares, comprising 766,394,171 A Shares and 260,295,700 H Shares.
- As at 30 June 2026, Mr. Xiong directly held 90,218,913 A Shares and 897,200 H Shares. Pursuant to the 2025 A Share Option Incentive Scheme, he was interested in 8,000,000 A share options.

Pursuant to (i) a concert party agreement dated 25 December 2017 entered into among Mr. Xiong Jun, Mr. Xiong Fengxiang, Suzhou Ruiyuan Shengben Biological Medicine Management Partnership (LP)* ("Suzhou Ruiyuan"), Suzhou Benyu Tianyuan Biological Technology Partnership (LP)* ("Suzhou Benyu"), Shanghai Baoying Asset Management Co., Ltd.* ("Shanghai Baoying"), Mr. Xiong Jun was deemed to be interested in the A Shares held by the other parties to the 2017 Concert Party Agreement; and (ii) a concert party agreement dated 26 July 2019 entered into between Mr. Xiong Jun and Ms. Zhou Yuqing (the "2019 Concert Party Agreement"), Mr. Xiong Jun was further deemed to be interested in the 21,680,800 A Shares held by the other party to the 2019 Concert Party Agreement as at 30 June 2026 under the SFO; (iii) the entering into of the supplemental agreement to the 2017 Concert Party Agreement ("Supplemental Agreement") and a concert party agreement among Mr. Xiong, Ms. Liu Xiaoling and Ms. Wang Lifang on 11 April 2025 (the "2025 Concert Party Agreement"), Suzhou Ruiyuan, Suzhou Benyu and Zhao Yun have ceased to be parties acting in concert with Mr. Xiong Jun, Mr. Xiong Jun has ceased to be interested in the shares held by Suzhou Ruiyuan, Suzhou Benyu and Zhao Yun, and Mr. Xiong has formed a concert party group with Xiong Fengxiang, Shanghai Baoying, Meng Xiaojun, Gao Shufang, Zhuhai Huapu Investment Co., Ltd.* (the "New 2017 Concert Party Group"), and another concert party group with Liu Xiaoling and Wang Lifang (the "2025 Concert Party Group", together with the New 2017 Concert Party Group and 2019 Concert Party Group, the "New Concert Parties Groups"). Mr. Xiong Jun was deemed to be interested in an aggregate of 96,126,568 A Shares held by the other members of the New Concert Parties Groups as at 30 June 2026 under the SFO.

OTHER INFORMATION

As at 30 June 2026, Mr. Xiong Jun (i) was an executive director and was directly interested in 20% of the equity share capital of Shanghai Baoying, which directly held 4,372,144 A Shares; Shanghai Baoying was also a party to the 2017 Concert Party Agreement and was deemed to be interested in the 52,857,624 A Shares held by the New 2017 Concert Party Group other than Mr. Xiong; (ii) was the chairman of the board of directors and was directly interested in 40% of the equity share capital of Shenzhen Qianhai Yuanben Equity Investment Fund Management Co., Ltd.* (“**Shenzhen Yuanben**”), which was the general partner of each of Suzhou Benyu and Suzhou Ruiyuan, which in turn directly held 4,600,000 A Shares and 43,584,000 A Shares, respectively. Shenzhen Yuanben also held a limited partner interest of approximately 86.28% of Suzhou Benyu. Mr. Xiong Jun was deemed to be interested in an aggregate of 105,413,768 A Shares held by the corporations he controlled under the SFO as at 30 June 2026.

3. As at 30 June 2026, Dr. Li Ning directly held 50,000 A Shares. Pursuant to the 2025 H Share Option Incentive Scheme, he was interested in 1,200,000 H share options.
4. As at 30 June 2026, pursuant to the 2025 H Share Option Incentive Scheme, Dr. Zou Jianjun was interested in 5,000,000 H share options.
5. As at 30 June 2026, Mr. Li Cong directly held 127,020 A Shares. Pursuant to the 2025 H Share Option Incentive Scheme, he was interested in 1,200,000 H share options.
6. As at 30 June 2026, Mr. Zhang Zhuobing directly held 40,000 A Shares. Pursuant to the 2025 H Share Option Incentive Scheme, he was interested in 1,200,000 H share options.

Mr. Zhang Zhuobing’s spouse, Ms. Liu Xiaoling, directly held 8,608,000 A Shares. Ms. Liu Xiaoling, being a party to the 2025 Concert Party Agreement, is deemed to be interested in the 106,826,913 A Shares and 897,200 H Shares held by the other parties to the 2025 Concert Party Agreement. Ms. Liu Xiaoling is also deemed to be interested in the 1,200,000 H share options held by Mr. Zhang Zhuobing. Mr. Zhang Zhuobing, as the spouse of Ms. Liu Xiaoling is further deemed to be interested in the 106,826,913 A Shares and 897,200 H Shares that Ms. Liu Xiaoling was interested in under the SFO.

7. As at 30 June 2026, pursuant to the 2025 H Share Option Incentive Scheme, Dr. Yao Sheng was interested in 1,200,000 H share options.
8. As at 30 June 2026, Dr. Wang Gang was deemed to be interested in 10,000 A Shares. Pursuant to the 2025 H Share Option Incentive Scheme, he was interested in 1,200,000 H share options.
9. As at 30 June 2026, Dr. Li Xin directly held 12,060 A Shares and 41,200 H Shares. She also indirectly held 41,654 H Shares through an investment fund. Pursuant to the 2025 H Share Option Incentive Scheme, she was interested in 1,200,000 H share options.
10. As at 30 June 2026, Mr. Tang Yi directly held 7,774,500 A Shares. Mr. Tang Yi was a director of and directly interested in 60% of the equity share capital of Shenzhen Yuanben, which was the general partner of each of Suzhou Benyu and Suzhou Ruiyuan. Shenzhen Yuanben also held a limited partner interest of approximately 86.28% of Suzhou Benyu. Therefore, he was deemed to be interested in Shares in which Suzhou Benyu and Suzhou Ruiyuan were interested under the SFO.

Save as disclosed above, as at 30 June 2026, none of the Directors and the chief executive of the Company had or was deemed to have any interests or short positions in the Shares, underlying Shares or debentures of the Company or its associated corporations (within the meaning of Part XV of the SFO) that was required to be recorded in the register of the Company required to be kept under Section 352 of the SFO, or as otherwise notified to the Company and Hong Kong Stock Exchange pursuant to the Model Code.

OTHER INFORMATION

Interests in Associated Corporations

Save as disclosed above, as at 30 June 2026, none of the Directors or the chief executive of the Company had or was deemed to have any interests or short positions in the Shares, underlying Shares or debentures of the Company or its associated corporations (within the meaning of Part XV of the SFO) that was required to be recorded in the register of the Company required to be kept under Section 352 of the SFO, or as otherwise notified to the Company and Hong Kong Stock Exchange pursuant to the Model Code.

Substantial Shareholders' Interests and Short Positions in Shares and Underlying Shares

As at 30 June 2026, to the best knowledge of the Directors, the following persons/entities (not being a Director or chief executive of the Company) had interests or short positions in the Shares or underlying Shares of the Company which fall to be disclosed to the Company and the Hong Kong Stock Exchange under the provisions of Divisions 2 and 3 of Part XV of the SFO and recorded in the register required to be kept under Section 336 of the SFO were as follows:

Name of Shareholder	Nature of interests	Class of Shares	Number of Underlying Shares ⁽¹⁾	Approximate percentage in relevant class of Shares ⁽²⁾	Approximate percentage in total share capital ⁽²⁾
Xiong Fengxiang	Beneficial owner	A Shares	41,060,000 (L)	5.36%	4.00%
熊鳳祥 ⁽³⁾⁽⁴⁾	Parties acting in concert	A Shares	114,388,681 (L)	14.93%	11.14%
Suzhou Ruiyuan Shengben Biological Medicine Management Partnership (LP)*	Beneficial owner	A Shares	43,584,000 (L)	5.69%	4.25%
蘇州瑞源盛本生物醫藥管理合夥企業(有限合夥)					
Shanghai Baoying Asset Management Co., Ltd*	Beneficial owner	A Shares	4,372,144 (L)	0.57%	0.42%
上海寶盈資產管理有限公司 ⁽⁴⁾	Parties acting in concert	A Shares	151,076,537 (L)	20.28%	15.14%
Meng Xiaojun	Beneficial owner	A Shares	4,288,400 (L)	0.56%	0.42%
孟曉君 ⁽⁴⁾	Parties acting in concert	A Shares	151,160,281 (L)	19.72%	14.72%
Gao Shufang	Beneficial owner	A Shares	3,789,720 (L)	0.49%	0.37%
高淑芳 ⁽⁴⁾	Parties acting in concert	A Shares	151,658,961 (L)	19.79%	14.77%
Zhuhai Huapu Investment Co., Ltd.*	Beneficial owner	A Shares	3,719,504 (L)	0.49%	0.36%
珠海華樸投資有限公司 ⁽⁴⁾	Parties acting in concert	A Shares	151,729,177 (L)	19.80%	14.78%
Zhou Yuqing	Beneficial owner	A Shares	21,680,800 (L)	2.83%	2.11%
周玉清 ⁽⁵⁾	Parties acting in concert	A Shares	98,218,913 (L)	12.52%	9.35%
Lin Lijun	Interest in controlled	A Shares	50,305,326 (L)	6.56%	4.90%
林利軍 ⁽⁶⁾	corporations				
	Founder of discretionary trust	H Shares	15,758,673 (L)	6.05%	1.53%
Shanghai Tanying Investment Partnership (LP)*	Beneficial owner	A Shares	50,305,326 (L)	6.56%	4.90%
上海檀英投資合夥企業(有限合夥) ⁽⁶⁾					

OTHER INFORMATION

Name of Shareholder	Nature of interests	Class of Shares	Number of Underlying Shares ⁽¹⁾	Approximate percentage in relevant class of Shares ⁽²⁾	Approximate percentage in total share capital ⁽²⁾
Shanghai Lejin Investment Partnership (LP)* 上海樂進投資合夥企業(有限合夥) ⁽⁶⁾	Interest in controlled corporations	A Shares	50,305,326 (L)	6.56%	4.90%
Shanghai Zhengxingu Investment Management Co., Ltd.* 上海正心谷投資管理有限公司 ⁽⁶⁾	Interest in controlled corporations	A Shares	50,305,326 (L)	6.56%	4.90%
Liu Xiaoling 劉小玲 ⁽⁷⁾	Beneficial owner	A Shares	8,608,000 (L)	1.12%	0.84%
	Parties acting in concert	A Shares	106,826,913 (L)	13.94%	10.40%
	Interest of spouse	A Shares	40,000 (L)	0.01%	0.00%
Wang Lifang 王莉芳 ⁽⁷⁾	Beneficial owner	A Shares	8,608,000 (L)	1.12%	0.84%
	Parties acting in concert	A Shares	106,826,913 (L)	13.94%	10.40%
LVC Innovate Limited ⁽⁸⁾	Interest in controlled corporations	H Shares	15,758,673 (L)	6.05%	1.53%
Jovial Champion Investments Limited ⁽⁸⁾	Interest in controlled corporations	H Shares	15,758,673 (L)	6.05%	1.53%
Vistra Trust (Singapore) Pte. Limited ⁽⁸⁾	Interest in controlled corporations	H Shares	15,758,673 (L)	6.05%	1.53%
Greenland Holdings Corporation Limited 綠地控股集團股份有限公司	Interest in controlled corporations	H Shares	51,386,400 (L)	19.74%	5.01%
	Interest in controlled corporations	H Shares	16,000,000 (S)	6.15%	1.56%
Greenland Digital Technology Co., Ltd. 綠地數字科技有限公司	Interest in controlled corporations	H Shares	51,386,400 (L)	19.74%	5.01%
	Interest in controlled corporations	H Shares	16,000,000 (S)	6.15%	1.56%

OTHER INFORMATION

Notes:

1. The letter "L" denotes the long position in the Shares, the letter "S" denotes short position in the Shares and the letter "P" denotes lending pool.
2. As at 30 June 2026, the Company had 1,026,689,871 issued Shares, comprising 766,394,171 A Shares and 260,295,700 H Shares.
3. As at 30 June 2026, Mr. Xiong Fengxiang directly held 41,060,000 A Shares. Pursuant to the Supplemental Agreement, Mr. Xiong Fengxiang, being a member of the New Concert Parties Group, was deemed to be interested in the A Shares in which the other members of the New Concert Parties Group are interested under the SFO (including the 90,218,913 A Shares directly held by Mr. Xiong Jun, son of Mr. Xiong Fengxiang).
4. Each of them is a party to the 2017 Concert Party Agreement and the Supplemental Agreement, and was therefore deemed to be interested in the A Shares in which the other members of the New 2017 Concert Party Group are interested under the SFO.
5. Ms. Zhou Yuqing is a party to the 2019 Concert Party Agreement, and was therefore deemed to be interested in the A Shares in which Mr. Xiong Jun (who was the other party to the 2019 Concert Party Agreement) are interested under the SFO.
6. As at 30 June 2026, Shanghai Tanying Investment Partnership (LP)* (上海檀英投資合夥企業(有限合夥)) ("**Shanghai Tanying**") was directly interested in 50,305,326 A Shares. Mr. Lin Lijun was a director and wholly interested in Shanghai Zhengxing Investment Management Co., Ltd.* (上海正心谷投資管理有限公司) (formerly Shanghai Shengge Asset Management Co., Ltd.*) ("**Shanghai Loyal Valley**"), which was the general partner of Shanghai Tanying. Shanghai Loyal Valley was the general partner of Shanghai Lejin Investment Partnership (LP)* (上海樂進投資合夥企業(有限合夥)) ("**Shanghai Lejin**"), which in turn held 99.99% interest in Shanghai Tanying. Therefore, Mr. Lin Lijun was deemed to be interested in the Shares held by Shanghai Tanying under the SFO. Each of Shanghai Loyal Valley and Shanghai Lejin was deemed to be interested in the 50,305,326 A Shares held by Shanghai Tanying under the SFO.
7. Each of them is a party to the 2025 Concert Party Agreement, and was therefore deemed to be interested in the Shares in which the other parties to the 2025 Concert Party Agreement was interested under the SFO.
8. As at 30 June 2026, Loyal Valley Capital Advantage Fund II LP ("**LVC Fund II**") and LVC Renaissance Fund LP ("**LVC Renaissance Fund**"), directly held 7,842,673 H Shares and 7,916,000 H Shares, respectively. Loyal Valley Capital Advantage Fund II Limited ("**LVC Fund II GP**") was the general partner of LVC Fund II and was deemed to be interested in the H Shares held by it. LVC Renaissance Limited ("**LVC Renaissance GP**") was the general partner of LVC Renaissance Fund and was deemed to be interested in the H Shares held by it. LVC Fund II GP was wholly-owned by LVC Holdings Limited, which was wholly-owned by LVC Management Holdings Limited. Therefore, LVC Management Holdings Limited was deemed to be interested in the H Shares held by LVC Fund II. Each of LVC Fund II GP and LVC Renaissance GP was directly or indirectly controlled by LVC Innovate Limited (previously known as LVC Bytes Limited), which was wholly-owned by Jovial Champion Investments Limited, which was in turn wholly-owned by Vistra Trust (Singapore) Pte. Limited, which was controlled by Mr. Lin Lijun. Therefore, each of LVC Innovate Limited (previously known as LVC Bytes Limited), Jovial Champion Investments Limited and Vistra Trust (Singapore) Pte. Limited was deemed to be interested in the H Shares held by LVC Fund II and LVC Renaissance Fund under the SFO. Vistra Trust (Singapore) Pte. Limited was controlled by Mr. Lin Lijun. Also, Mr. Lin Lijun was deemed to be interested in an aggregate of 15,758,673 H Shares held by LVC Fund II and LVC Renaissance Fund under the SFO.

OTHER INFORMATION

RISK FACTORS

1. Risks related to pending profitability

A long profit cycle is one of the most salient features of the biopharmaceutical industry. It typically takes a relatively long period for a biopharmaceutical company at the R&D stage to grow before it becomes profitable. As an innovative biopharmaceutical company, the Company is currently in an important R&D investment phase, and our R&D investment is expected to increase consistently in line with the expansion of R&D pipeline and acceleration of domestic and overseas drug clinical trial activities. Our future profitability depends on the pace of the launch and the conditions of post-launch sales of our drug candidates. On the other hand, R&D investments and marketing and operating costs will add uncertainties to the Company's profitability. Therefore, the Company is exposed to the risk of not being able to become profitable in the short term.

A total of four drugs (TUOYI®, JUNMAIKANG, MINDEWEI and JUNSHIDA) are being commercialized by the Company, and various drug candidates in the late stage of research and development close to commercialization. The accelerated development of more and more drug candidates, the successive completion of registrational clinical trials for more indications of the approved products as well as the increased number of products approved for marketing will further improve the Company's financial position and help create conditions for a turnaround in the profitability of the Company as soon as possible.

2. Risks related to significant decline in performance or loss

The Company is committed to the discovery, development and commercialization of innovative therapies. The Company actively deploys a product pipeline that covers various therapeutic areas. In the future, it will maintain a corresponding scale of investment in R&D for the pre-clinical research, global clinical trials and preparation for NDAs of drug candidates and other drug development. Besides, the Company's NDA and registration efforts, post-launch marketing and promotion activities and other aspects will incur expenses, which may result in greater losses for the Company in the short run, thereby adversely affecting the Company's daily operations and financial position. During the Reporting Period, there were no material adverse changes in the principal business and core competitiveness of the Company.

3. Risks related to core competitiveness

Classified as technical innovation, the R&D of new drugs is characterized by long R&D cycles, significant investment, high risks and low success rate. From laboratory research to obtaining approval, new drugs go through a lengthy process with complicated stages, including preclinical study, clinical trial, registration and marketing of new drugs and after-sales supervision. Any of the above stages is subject to the risk of failure. The Company will strengthen its forward-looking strategic research, and determine the direction of new drug R&D according to the needs of clinical drug use. The Company will also formulate reasonable new drug technology solutions, continuously increase the investment in R&D of new drugs, and prudently launch R&D projects for new drugs. In particular, the Company implements phase-based assessment on drug candidates in the course of R&D. If it is found that the expected results cannot be achieved, the subsequent R&D of such product will be terminated immediately, so as to minimize the R&D risks of new drugs.

OTHER INFORMATION

4. Risks related to operations

The Company's business operations require certain R&D technical services and raw materials supply. Currently, the relationship between the Company and existing suppliers are stable. If the price of R&D technical services or raw materials increased significantly, the Company's profitability may be adversely affected. At the same time, the Company's suppliers may not be able to keep up with the rapid development of the Company, such that they may have to reduce or terminate the supply of the Company's R&D services or raw materials. If such R&D technical services or the supply of raw materials were disrupted, and thus the Company's business operations may be adversely affected. Furthermore, some of the Company's raw materials, equipment and consumables for production are directly or indirectly imported. If there are significant changes in the international trade situation, the Company's production and operation may be affected to a certain extent.

The Company's commercialized products toripalimab injection, adalimumab injection, deuremidevir hydrobromide tablets and ongericimab injection are all included in the NRDL. The reduction in price after being included into the drug list can effectively improve the accessibility and affordability of the Company's products, which is conducive to a significant increase in product sales. However, if the increase in sales is less than expected, it may adversely affect the Company's revenue.

5. Finance risks

During the Reporting Period, the exchange rate risks of the Company primarily arose from the assets and liabilities held by the Company and its subsidiaries which were denominated in the foreign currencies other than the book-keeping base currency. If significant fluctuations occur in the exchange rates between these foreign currencies to be kept by the Company and RMB in the future, the Company will continue to experience exchange gains or losses, which could affect the operating performance of the Company.

During the Reporting Period, the Company's capital sources included revenue from sales of marketed products as well as external financing. If the Company is unable to achieve profitability or secure sufficient funds to cover operating expenses within a certain period in the future, the Company may have to delay, reduce or cancel R&D projects, affecting the commercialization progress of its drug candidates, which may in turn have an adverse impact on the business prospects, financial position and operating performance of the Company.

During the Reporting Period, when assessing the risk of inventory impairment, the Company recognized the provisions for inventory impairment upon identifying indications that the estimated net realizable value of the purchased inventories was lower than its carrying value, such as inventory becoming fully or partially obsolete or a decline in selling prices. When estimating the net realizable value of inventories, the Company comprehensively considers factors such as future market competition, pricing, further processing costs and selling expenses to recognize asset impairment losses, thereby accurately reflecting the carrying value of inventories as of the end of the period. In the future, if changes in market conditions or intensified competition occur, the Company may face risks of asset impairment, which may adversely affect its operations to a certain extent.

OTHER INFORMATION

6. Risks related to the industry

In view of the constant reforms in the medical and health system, encouraging pharmaceutical enterprises to be innovative and reduce prices of drugs have become a trend, and the industry landscape is about to be reshaped. If the Company fails to keep up with industry trends and continue with its innovation in the future, or if there are adverse changes in relevant industry policies, the Company's development may be adversely affected.

The Company's development goal has always been "innovation". Our pipeline focuses on innovative drugs. In response to the above industry and policy risks, the Company will adapt to changes in external policies, continue to improve our innovation capabilities and our ability to continuously develop new products, increase our R&D investments, accelerate the process of innovative drugs entering clinical trial phase and the market, and respond to challenges with innovation. On this basis, the Company will further expand our production capacity, and reduce the unit cost of our products while strictly maintaining the quality of our products, so as to address the possible price reduction of drugs in future. At the same time, we will comply with relevant laws and regulations and adapt our business operations to the changes in regulatory policies to avoid possible policy risks.

7. Risks related to the macro environment

Future changes in the international, political, economic and market environment, especially the uncertainty of trade relations between China and the United States, as well as the additional tariffs or other restrictions that may be imposed by China and the United States on cross-border technology transfer, investment and trade, may have a certain adverse impact on the Company's overseas business operations.

SHARE CAPITAL

Details of movements in the share capital of the Company during the Reporting Period are set out in note 22 to the condensed consolidated financial statements.

As at 30 June 2026, 1,026,689,871 Shares were in issue (comprising 766,394,171 A Shares (including 815,871 treasury shares) and 260,295,700 H Shares).

OTHER INFORMATION

PURCHASE, SALE OR REDEMPTION OF LISTED SECURITIES

Save as disclosed herein, neither the Company nor any of its subsidiaries had purchased, sold or redeemed any of the Company's listed securities (including sale of treasury shares) during the Reporting Period.

CORPORATE GOVERNANCE

The Board is committed to maintaining high corporate governance standards. The Board believes that high corporate governance standards are essential in providing a framework for the Group to safeguard the interests of shareholders, enhance corporate value, formulate its business strategies and policies, and enhance its transparency and accountability.

The Company has applied the principles and code provisions as set out in the CG Code contained in Appendix C1 of the Hong Kong Listing Rules. The Board is of the view that, during the Reporting Period, the Company has complied with all code provisions as set out in the CG Code in force during the Reporting Period.

COMPLIANCE WITH THE MODEL CODE FOR SECURITIES TRANSACTIONS BY DIRECTORS

The Company has adopted the Model Code for Securities Transactions by Directors of Listed Issuers in Appendix C3 of the Hong Kong Listing Rules as its own code of conduct regarding Directors' securities transactions. Having made specific enquiry with each of the Directors, they have confirmed that they had complied with such code of conduct during the Reporting Period.

USE OF PROCEEDS

Use of Proceeds from the Issuance of A Shares

As approved by the China Securities Regulatory Commission (Zheng Jian Xu Ke [2022] No. 2616) (證監許可[2022]2616 號文), the Company issued 70,000,000 ordinary shares (A Shares) with a nominal value of RMB1.00 to 17 target subscribers (including securities investment fund management companies, securities firms, trust investment companies, finance companies, insurance institutional investors, qualified foreign institutional investors, and other domestic legal persons investors and natural persons, who/which satisfy the relevant requirements of the China Securities Regulatory Commission) on 2 December 2022 at the issue price of RMB53.95 per share. The gross proceeds amounted to approximately RMB3,777 million. After deducting issuance expenses of approximately RMB32 million in accordance with the related requirements, the net proceeds amounted to approximately RMB3,745 million. The net proceeds from the issuance of A Shares have been used and will be used in accordance with the uses disclosed in the Company's circular dated 7 March 2022, announcements dated 7 March 2022 and 14 June 2022, 30 May 2024 and 29 May 2025. The market price of A Shares on 2 December 2022 was RMB61.23 per A share. The Company considered that the projects funded by the proceeds involved in the issuance of A Shares would accelerate the Company's clinical research work and promote the marketing process of relevant products in the PRC and overseas, enhance the synergy between pre-clinical and clinical research, and relieve tensions in R&D and operation funds of the Company to a certain extent, which are conducive to the realization of the Company's core development strategy and the sustainable and sound development of the production and operation of the Company.

OTHER INFORMATION

Purpose of the proceeds	Intended use of the net proceeds (Approx. RMB million)	Unutilized proceeds as at 31 December 2025 (Approx. RMB million)	Proceeds utilized during the Reporting Period (Approx. RMB million)	Proceeds utilized as at 30 June 2026 (Approx. RMB million)	Unutilized proceeds as at 30 June 2026 (Approx. RMB million)	Expected timeline for application of the unutilized proceeds
R&D projects of innovative drugs	3,464	2,321	169	1,312	2,152	Expected to be fully utilized by 31 December 2028
Shanghai Junshi Biotech headquarters and R&D base project	281	31	31	281	–	Was fully utilized by 30 June 2026
	3,745	2,352	200	1,593	2,152	

Note: The unutilized proceeds and utilized proceeds shown in the above table exclude bank charges, foreign exchange losses/gains and interests generated from bank saving accounts.

Placing of H Shares under General Mandate

To further expand the layout and investment in next-generation drug platforms and R&D technologies, and to optimize the shareholding structure of the Company, on 20 June 2025, the Company completed the placing of an aggregate of 41,000,000 new H share(s) under general mandate (“**Placing**”) pursuant to a placing agreement dated 12 June 2025 entered into by the Company and UBS AG Hong Kong Branch (as sole placing agent). The Placing Shares represented approximately 15.75% of all issued H shares of the Company and 3.99% of all issued shares of the Company as enlarged by the allotment and issue of the Placing Shares and the price of the Placing Shares was HK\$25.35 per H Share. The closing price of the shares of the Company quoted on the Hong Kong Stock Exchange on 12 June 2025 was HK\$28.65 per H Share. The net price (after deduction of the commissions and estimated expenses) raised per H Share is approximately HK\$25.02 per H Share. The aggregate nominal value of the Placing Shares is RMB41,000,000. The Placing Shares were issued to not less than six placees who are independent professional, institutional and/or other investors and who are independent of, and not connected with the Company and its connected persons (as defined in the Hong Kong Listing Rules).

OTHER INFORMATION

The aggregate gross proceeds from the Placing are approximately HK\$1,039 million and the aggregate net proceeds from the Placing to be received by the Company (after deduction of the commissions and estimated expenses) are approximately HK\$1,026 million (equivalent to RMB937 million). The Group intends to use 70% of the net proceeds from the Placing for innovative drug development and 30% of the net proceeds from the Placing for general corporate purposes such as replenishment of working capital. For further details, please refer to the Company's announcements dated 13 June 2025 and 20 June 2025.

As at 30 June 2026, approximately RMB394 million of the net proceeds from the Placing has been utilized. The Company will gradually utilize the net proceeds from the placing in accordance with such intended purposes based on the estimate of future market conditions and business operations of the Company, and will remain subject to change based on current and future development of market conditions and actual business needs.

The following table sets out the intended use and actual usage of the net proceeds from the Placing as at 30 June 2026:

Purpose of the proceeds	Intended use of the net proceeds (Approx. RMB million)	Unutilized proceeds as at 31 December 2025 (Approx. RMB million)	Proceeds utilized during the Reporting Period (Approx. RMB million)	Proceeds utilized as at 30 June 2026 (Approx. RMB million)	Unutilized proceeds as at 30 June 2026 (Approx. RMB million)	Expected timeline for application of the unutilized proceeds
R&D projects of innovative drugs	656	585	46	113	531	Expected to be fully utilized by 31 December 2027
General corporate purpose	281	–	–	281	–	Was fully utilized by 31 December 2025
	937 ^(Note)	585	46	394 ^(Note)	531 ^(Note)	

Note: The difference between (i) the sum of utilized proceeds and the unutilized proceeds and (ii) the net proceeds from the issuance represents bank charges, foreign exchange losses and interests generated from bank saving accounts.

OTHER INFORMATION

Subsequent Events after the Reporting Period

- In July 2026, the indications of toripalimab for the first-line treatment of ESCC and the second-line or later treatment of NPC were approved for marketing in Saudi Arabia.
- In July 2026, the indications of toripalimab for the first-line, second-line or later treatment of NPC were approved for marketing in Thailand.
- In July 2026, three indications of toripalimab for the first-line, second-line or later treatment of NPC and the first-line treatment of ESCC were approved for marketing in Vietnam.
- In July 2026, the supplemental application for the revised indication of toripalimab in combination with chemotherapy for the treatment of adult patients with resectable stage II-III NSCLC was accepted.
- In July 2026, the Company successfully completed the issuance of the 2026 second tranche of technology innovation bonds of RMB300 million in aggregate, and received the proceeds raised on 22 July 2026.
- In August 2026, the Company successfully completed the issuance of the 2026 third tranche of technology innovation bonds of RMB700 million in aggregate, and received the proceeds raised on 21 August 2026.

AUDIT COMMITTEE

The Audit Committee comprises two independent non-executive Directors, namely Mr. Li Zhongxian (chairman of the Audit Committee) and Mr. Chen Liang, and one non-executive Director, namely Mr. Tang Yi. The primary duties of the Audit Committee are to assist the Board by providing an independent view of the effectiveness of the financial reporting process, internal control and risk management systems of the Group and overseeing the audit process.

The Audit Committee has reviewed, together with the management and external auditors, the accounting principles and policies adopted by the Group and the condensed consolidated financial statements for the Reporting Period.

AUDITOR

The interim financial report for the six months ended 30 June 2026 is unaudited, but has been reviewed by Deloitte Touche Tohmatsu.

All references above to other sections, reports or notes in this interim report form part of this report.

By order of the Board

Shanghai Junshi Biosciences Co., Ltd.*

Mr. Xiong Jun

Chairman

26 August 2026

* For identification purpose only

REPORT ON REVIEW OF CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

TO THE BOARD OF DIRECTORS OF SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*

上海君實生物醫藥科技股份有限公司

(incorporated in the People's Republic of China with limited liability)

INTRODUCTION

We have reviewed the condensed consolidated financial statements of Shanghai Junshi Biosciences Co., Ltd.* 上海君實生物醫藥科技股份有限公司 (the "Company") and its subsidiaries (collectively referred to as the "Group") set out on pages 64 to 102, which comprise the condensed consolidated statement of financial position as of 30 June 2026 and the related condensed consolidated statement of profit or loss and other comprehensive income, condensed consolidated statement of changes in equity and condensed consolidated statement of cash flows for the six-month period then ended, and notes to the condensed consolidated financial statements. The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited require the preparation of a report on interim financial information to be in compliance with the relevant provisions thereof and International Accounting Standard 34 "Interim Financial Reporting" ("IAS 34") as issued by the International Accounting Standards Board. The directors of the Company are responsible for the preparation and presentation of these condensed consolidated financial statements in accordance with IAS 34. Our responsibility is to express a conclusion on these condensed consolidated financial statements based on our review, and to report our conclusion solely to you, as a body, in accordance with our agreed terms of engagement, and for no other purpose. We do not assume responsibility towards or accept liability to any other person for the contents of this report.

SCOPE OF REVIEW

We conducted our review in accordance with Hong Kong Standard on Review Engagements 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" as issued by the Hong Kong Institute of Certified Public Accountants. A review of these condensed consolidated financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Hong Kong Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

CONCLUSION

Based on our review, nothing has come to our attention that causes us to believe that the condensed consolidated financial statements are not prepared, in all material respects, in accordance with IAS 34.

Deloitte Touche Tohmatsu

Certified Public Accountants

Hong Kong

26 August 2026

CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

FOR THE SIX MONTHS ENDED 30 JUNE 2026

	NOTES	For the six months ended 30 June	
		2026 RMB'000 (Unaudited)	2025 RMB'000 (Unaudited)
Revenue	3	1,696,211	1,168,384
Cost of sales and services		(416,780)	(244,359)
Gross profit		1,279,431	924,025
Other income	4	42,190	34,947
Other gains and losses	5	197,399	67,825
Impairment losses (including reversals of impairment losses or impairment gains) on financial assets		(4,110)	2,361
Research and development expenses		(643,935)	(744,931)
Selling and distribution expenses		(507,169)	(487,343)
Administrative expenses		(279,359)	(208,761)
Share of losses of joint ventures		(30,466)	(11,183)
Share of losses of associates		(12,739)	(14,026)
Finance costs		(57,248)	(38,696)
Other expenses		(13,536)	(10,165)
Loss before tax		(29,542)	(485,947)
Income tax (expense) credit	6	(7,444)	19,538
Loss for the period	7	(36,986)	(466,409)
Other comprehensive income (expense) for the period			
Item that will not be reclassified subsequently to profit or loss:			
Fair value loss on financial asset designated as at fair value through other comprehensive income ("FVTOCI")		(1,111)	(16,089)
Item that may be reclassified subsequently to profit or loss:			
Exchange differences arising on translation of foreign operations		3,102	173
Other comprehensive income (expense) for the period		1,991	(15,916)
Total comprehensive expense for the period		(34,995)	(482,325)

CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

FOR THE SIX MONTHS ENDED 30 JUNE 2026

	NOTE	For the six months ended 30 June	
		2026 RMB'000 (Unaudited)	2025 RMB'000 (Unaudited)
Profit (loss) for the period attributable to:			
– Owners of the Company		25,501	(413,431)
– Non-controlling interests		(62,487)	(52,978)
		(36,986)	(466,409)
Total comprehensive income (expense) for the period attributable to:			
– Owners of the Company		27,492	(429,347)
– Non-controlling interests		(62,487)	(52,978)
		(34,995)	(482,325)
EARNINGS (LOSS) PER SHARE	9		
– Basic and diluted (RMB yuan)		0.02	(0.42)

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

AS AT 30 JUNE 2026

	NOTES	As at 30 June 2026 RMB'000 (Unaudited)	As at 31 December 2025 RMB'000 (Audited)
Non-current assets			
Property, plant and equipment	10	5,041,339	4,819,215
Right-of-use assets	10	493,096	468,848
Intangible assets		158,469	170,519
Interests in joint ventures	11	497,412	208,478
Interests in associates	12	260,985	299,299
Deferred tax assets	13	86,336	88,309
Other assets, prepayments and other receivables	15	539,260	505,056
Other financial assets	16	1,935,342	1,381,556
		9,012,239	7,941,280
Current assets			
Inventories		498,818	573,110
Trade and bill receivables	14	743,754	506,747
Other assets, prepayments and other receivables	15	266,509	162,490
Other financial assets	16	963,885	600,782
Restricted bank deposits	17	26,337	20,575
Bank balances and cash	17	2,705,943	2,594,000
		5,205,246	4,457,704
Current liabilities			
Trade and other payables	18	1,381,832	1,456,728
Income tax payable		5,185	4,769
Borrowings	19	1,398,507	1,262,590
Deferred income		29,600	33,700
Contract liabilities	20	62,011	22,184
Provisions and other liabilities		3,451	–
Lease liabilities		43,619	32,008
		2,924,205	2,811,979
Net current assets		2,281,041	1,645,725
Total assets less current liabilities		11,293,280	9,587,005

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

AS AT 30 JUNE 2026

	NOTES	As at 30 June 2026 RMB'000 (Unaudited)	As at 31 December 2025 RMB'000 (Audited)
Non-current liabilities			
Other payables	18	30,000	30,000
Borrowings	19	4,419,369	2,793,608
Deferred income		127,531	133,471
Contract liabilities	20	86,136	93,570
Other financial liabilities	21	410,493	406,490
Lease liabilities		52,367	56,616
		5,125,896	3,513,755
Net assets		6,167,384	6,073,250
Capital and reserves			
Share capital	22	1,026,690	1,026,690
Treasury share		(30,892)	(30,892)
Reserves		4,963,860	5,051,292
Equity attributable to owners of the Company		5,959,658	6,047,090
Non-controlling interests		207,726	26,160
Total equity		6,167,384	6,073,250

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

FOR THE SIX MONTHS ENDED 30 JUNE 2026

	Attributable to owners of the Company									Non-controlling interests	Total
	Share capital	Treasury share	Share premium	Share payments reserve	Other reserve	Revaluation reserve	Translation reserve	Accumulated losses	Sub-total		
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000		
As at 1 January 2026 (Audited)	1,026,690	(30,892)	15,778,700	76,456	526,913	(208,931)	42,244	(11,164,090)	6,047,090	26,160	6,073,250
Profit (loss) for the period	-	-	-	-	-	-	-	25,501	25,501	(62,487)	(36,986)
Exchange differences arising on translation of foreign operations	-	-	-	-	-	-	3,102	-	3,102	-	3,102
Fair value loss on financial asset designated as at FVTOCI	-	-	-	-	-	(1,111)	-	-	(1,111)	-	(1,111)
Total comprehensive (expense) income for the period	-	-	-	-	-	(1,111)	3,102	25,501	27,492	(62,487)	(34,995)
Recognition of equity settled share-based payment expenses-share option (Note 24)	-	-	-	127,301	-	-	-	-	127,301	1,292	128,593
Acquisition of non-controlling interests (Note a)	-	-	-	-	(52,246)	-	-	-	(52,246)	51,646	(600)
Capital injection in a subsidiary of the Group (Note b)	-	-	-	-	(191,811)	-	-	-	(191,811)	191,811	-
Others	-	-	-	-	1,832	-	-	-	1,832	(696)	1,136
As at 30 June 2026 (Unaudited)	1,026,690	(30,892)	15,778,700	203,757	284,688	(210,042)	45,346	(11,138,589)	5,959,658	207,726	6,167,384

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

FOR THE SIX MONTHS ENDED 30 JUNE 2026

	Attributable to owners of the Company									Non-controlling interests	Total
	Share capital	Treasury share	Share-based		Other reserve	Revaluation reserve	Translation reserve	Accumulated losses	Sub-total		
			premium	payments reserve							
As at 1 January 2025 (Audited)	985,690	(30,892)	14,882,670	–	524,201	(202,154)	42,216	(10,323,180)	5,878,551	71,706	5,950,257
Loss for the period	–	–	–	–	–	–	–	(413,431)	(413,431)	(52,978)	(466,409)
Exchange differences arising on translation of foreign operations	–	–	–	–	–	–	173	–	173	–	173
Fair value loss on financial asset designated as at FVTOCI	–	–	–	–	–	(16,089)	–	–	(16,089)	–	(16,089)
Total comprehensive (expense) income for the period	–	–	–	–	–	(16,089)	173	(413,431)	(429,347)	(52,978)	(482,325)
H shares issued	41,000	–	908,270	–	–	–	–	–	949,270	–	949,270
Transaction costs attributable to issuance of H shares	–	–	(12,240)	–	–	–	–	–	(12,240)	–	(12,240)
Others	–	–	–	–	3,492	–	–	–	3,492	1,054	4,546
As at 30 June 2025 (Unaudited)	1,026,690	(30,892)	15,778,700	–	527,693	(218,243)	42,389	(10,736,611)	6,389,726	19,782	6,409,508

Notes:

- (a) During the period ended 30 June 2026, the Company acquired all equity interests held by a non-controlling shareholder of the subsidiary at nil consideration. Upon the completion of transaction, the equity interests in this subsidiary held by the Company increased from 50% to 100%.

During the period ended 30 June 2026, the Company acquired all equity interests held by a non-controlling shareholder of the subsidiary at consideration of RMB600,000. Upon the completion of transaction, the equity interests in this subsidiary held by the Company increased from 99.4% to 100%.

- (b) Pursuant to a shareholder resolution passed on 31 March 2026, the Company made a capital injection to a non-wholly owned subsidiary of the Company, by converting the debt owing by this subsidiary to the Company amounting to RMB800,000,000.

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

FOR THE SIX MONTHS ENDED 30 JUNE 2026

	For the six months ended 30 June	
	2026 RMB'000 (Unaudited)	2025 RMB'000 (Unaudited)
NET CASH USED IN OPERATING ACTIVITIES	(62,801)	(361,029)
INVESTING ACTIVITIES		
Interest received	16,170	13,671
Purchases of property, plant and equipment	(337,161)	(312,503)
Proceeds on disposal of property, plant and equipment	139	16
Proceeds on disposal of intangible assets	–	8,000
Payments for rental deposits	(85)	(1,151)
Refund of rental deposits	1,753	–
Refund of other deposits	–	32,826
Purchases of other financial assets	(2,853,631)	(1,376,795)
Proceeds from disposal of other financial assets	2,019,573	1,185,105
Purchases of intangible assets	(26)	(1,252)
Placement of restricted bank deposits	(6,320)	(1,654)
Release of restricted bank deposits	558	469
Investment in associates	(6,118)	(14,000)
Proceeds on disposal of an associate	51,000	–
Investments in joint ventures	(319,400)	(35,000)
Net cash inflow on acquisition of subsidiaries	–	823
Net cash outflow on disposal of a subsidiary (Note 26)	(7,511)	(20,918)
Others	(1,400)	–
NET CASH USED IN INVESTING ACTIVITIES	(1,442,459)	(522,363)

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

FOR THE SIX MONTHS ENDED 30 JUNE 2026

	For the six months ended 30 June	
	2026 RMB'000 (Unaudited)	2025 RMB'000 (Unaudited)
FINANCING ACTIVITIES		
Net proceeds received from issuance of H shares	–	939,583
New borrowings raised	1,542,422	1,700,523
Repayments of borrowings	(795,761)	(1,181,404)
Proceeds from issuance of technology innovation bonds	1,000,000	–
Transaction costs paid for the issuance of technology innovation bonds	(3,000)	–
Payment for acquisition of non-controlling interests	(600)	–
Repayments for lease liabilities	(39,830)	(25,278)
Interest paid	(60,485)	(47,910)
NET CASH FROM FINANCING ACTIVITIES	1,642,746	1,385,514
NET INCREASE IN CASH AND CASH EQUIVALENTS	137,486	502,122
CASH AND CASH EQUIVALENTS AT 1 JANUARY	2,594,000	2,486,679
Effect of foreign exchange rate changes	(25,543)	376
CASH AND CASH EQUIVALENTS AT 30 JUNE	2,705,943	2,989,177

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED 30 JUNE 2026

1. GENERAL INFORMATION AND BASIS OF PREPARATION

Shanghai Junshi Biosciences Co., Ltd.* (the “Company”) was established in the People’s Republic of China (the “PRC”) on 27 December 2012 and converted into a joint stock company with limited liability in May 2015. In August 2015, the Company’s domestic shares became listed on the National Equities Exchange and Quotations (“NEEQ”) (stock code: 833330). On 24 December 2018, the Company’s H shares became listed on the Main Board of The Stock Exchange of Hong Kong Limited (stock code: 1877). The domestic shares of the Company were delisted from NEEQ since 8 May 2020 and were converted into A shares and listed on the STAR Market of the Shanghai Stock Exchange on 15 July 2020 (stock code: 688180). The respective addresses of the registered office and principal place of business of the Company are disclosed in the “Corporate Information” section to the interim report.

The principal activities of the Company and its subsidiaries (the “Group”) are mainly discovery, development and commercialisation of innovative drugs.

The condensed consolidated financial statements are presented in Renminbi (“RMB”), which is also the functional currency of the Company.

The condensed consolidated financial statements have been prepared in accordance with International Accounting Standard (“IAS”) 34 *Interim Financial Reporting* issued by the International Accounting Standards Board (“IASB”) as well as the applicable disclosure requirements of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The directors of the Company have, at the time of approving the condensed consolidated financial statements, a reasonable expectation that the Group has adequate resources to continue in operational existence for the foreseeable future. Thus they continue to adopt the going concern basis of accounting in preparing the condensed consolidated financial statements.

2. ACCOUNTING POLICIES

The condensed consolidated financial statements have been prepared on the historical cost basis, except for certain financial instruments, which are measured at fair values, as appropriate.

Other than additional/change in accounting policies resulting from application of amendments to IFRS Accounting Standards, the accounting policies and methods of computation used in the condensed consolidated financial statements for the six months ended 30 June 2026 are the same as those presented in the Group’s annual consolidated financial statements for the year ended 31 December 2025.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED 30 JUNE 2026

2. ACCOUNTING POLICIES (Continued)

Application of amendments to IFRS Accounting Standards

In the current interim period, the Group has applied the following amendments to IFRS Accounting Standards issued by the IASB, for the first time, which are mandatorily effective for the Group's annual period beginning on 1 January 2026 for the preparation of the Group's condensed consolidated financial statements:

Amendments to IFRS 9 and IFRS 7	Amendments to the Classification and Measurement of Financial Instruments
Amendments to IFRS 9 and IFRS 7	Contracts Referencing Nature-dependent Electricity
Amendments to IFRS Accounting Standards	Annual Improvements to IFRS Accounting Standards – Volume 11

The application of the amendments to IFRS Accounting Standards in the current period has had no material impact on the Group's financial positions and performance for the current and prior periods and/or on the disclosures set out in these condensed consolidated financial statements.

3. REVENUE AND SEGMENT INFORMATION

The Group derives its revenue from the transfer of goods and services over time and at a point in time in the following major revenue sources:

	For the six months ended 30 June	
	2026 RMB'000 (Unaudited)	2025 RMB'000 (Unaudited)
Timing of revenue recognition		
<i>At a point in time</i>		
Sale of pharmaceutical products	1,407,315	1,059,372
Licensing income	249,552	98,930
Others	3,917	621
	1,660,784	1,158,923
<i>Over time</i>		
Licensing income (Note 20)	4,606	3,183
Service income	30,821	6,278
	1,696,211	1,168,384

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED 30 JUNE 2026

3. REVENUE AND SEGMENT INFORMATION (Continued)

For the purposes of resource allocation and assessment, the Group's management, being the chief operating decision maker, reviews the consolidated results when making decisions about allocating resources and assessing performance of the Group as a whole. No other discrete financial information is provided other than the Group's results and financial position as a whole. Accordingly, only entity-wide disclosures are presented.

During the period ended 30 June 2026, the Group recognised non-refundable upfront payment of RMB201,921,000 (six months ended 30 June 2025: RMB3,587,000) upon the grant of the license, sales-based royalty income amounting to RMB47,631,000 (six months ended 30 June 2025: RMB27,136,000), milestone payment of nil (six months ended 30 June 2025: RMB68,207,000) upon the achievement of certain milestone pursuant the licensing agreements.

Geographical information

The Group's operations are mainly located in the PRC and the United States of America (the "USA").

Information about the Group's revenue from external customers is presented based on the operating location of customers.

	For the six months ended 30 June	
	2026 RMB'000 (Unaudited)	2025 RMB'000 (Unaudited)
The PRC	1,575,782	1,074,357
The USA	69,419	40,311
Others	51,010	53,716
	1,696,211	1,168,384

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED 30 JUNE 2026

4. OTHER INCOME

	For the six months ended 30 June	
	2026 RMB'000 (Unaudited)	2025 RMB'000 (Unaudited)
Bank interest income	16,170	13,671
Government grants related to property, plant and equipment (<i>Note a</i>)	7,038	8,000
Other subsidies (<i>Note b</i>)	18,982	13,276
	42,190	34,947

Notes:

- (a) Amounts represent subsidies from the PRC government specifically for the capital expenditure incurred for the acquisition of buildings situated on leasehold land in the PRC and machineries, which is recognised as other income over the estimated useful life of the respective assets.
- (b) Amounts mainly represent subsidies from PRC government for research and development activities, which are recognised as other income upon meeting specific conditions and incentives which have no specific conditions attached to the grants.

5. OTHER GAINS AND LOSSES

	For the six months ended 30 June	
	2026 RMB'000 (Unaudited)	2025 RMB'000 (Unaudited)
Fair value change of other financial assets measured at fair value through profit or loss ("FVTPL"), net	29,193	58,923
Exchange losses, net	(32,771)	(203)
Gain on disposal of a subsidiary (<i>Note 26</i>)	8,266	1,337
Gain on disposal of an associate (<i>Note a</i>)	137,815	—
Gain on deemed disposal of an associate	4,572	—
Gain (loss) on disposal of property, plant and equipment (<i>Note b</i>)	394	(169)
Gain on termination of leases	333	34
Other gains (<i>Note b</i>)	47,837	7,547
Others	1,760	356
	197,399	67,825

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED 30 JUNE 2026

5. OTHER GAINS AND LOSSES (Continued)

Notes:

- (a) During the period ended 30 June 2026, the Group disposed of the entire interest in Shanghai Junshi Runjia Pharmaceutical Co., Ltd.*君實潤佳(上海)醫藥科技有限公司("Junshi Runjia"), the associate of the Group, to an independent third party for cash proceeds of RMB170,000,000, and recognised a gain of RMB137,815,000.
- (b) During the period ended 30 June 2026, the Group transferred certain pipelines, patents, technical know-how and machinery to Shanghai Zhiyu Biomedicine Co., Ltd.*上海致域生物醫藥有限公司("Shanghai Zhiyu") in exchange of certain equity interests in Shanghai Zhiyu and recognised a gain of RMB47,837,000 on the transfer of pipelines, patents and technical know-how and a gain of RMB1,906,000 on transfer of machinery.

6. INCOME TAX (EXPENSE) CREDIT

	For the six months ended 30 June	
	2026 RMB'000 (Unaudited)	2025 RMB'000 (Unaudited)
Current tax		
United States Corporate Income Tax ("CIT")	–	(431)
Hong Kong Profits Tax	(1,457)	(254)
	(1,457)	(685)
Withholding tax	(4,014)	18,353
Deferred tax	(1,973)	1,870
	(7,444)	19,538

During the period ended 30 June 2026, the Company is subject to withholding tax on licensing income received from various customers located in different countries where withholding tax is required. The withholding tax rate was 10%.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED 30 JUNE 2026

7. LOSS FOR THE PERIOD

	For the six months ended 30 June	
	2026 RMB'000 (Unaudited)	2025 RMB'000 (Unaudited)
Loss for the period has been arrived at after charging (crediting) the following items:		
Amortisation for intangible assets	12,077	10,622
Less: amounts included in the cost of properties under construction	(3)	–
	12,074	10,622
Depreciation for property, plant and equipment	125,466	127,681
Less: amounts included in the cost of inventories	(17,325)	(19,899)
amounts included in the cost of properties under construction	(834)	–
	107,307	107,782
Depreciation of right-of-use assets	23,998	25,004
Less: amounts included in the cost of properties under construction	(3,067)	–
	20,931	25,004
Expenses relating to short-term leases and low-value assets	5,868	4,246
Impairment losses reversed/recognised on other assets and prepayments included in cost of sales	–	(5,990)
included in research and development expenses	–	7,500
Impairment losses recognised on intangible assets included in research and development expenses	–	31,853
Cost of inventories recognised as expense (including write-down of inventories amounting to RMB130,701,000 (six months ended 30 June 2025: RMB17,376,000))		
– Cost of sales	380,009	237,613
– Research and development expenses	78,831	171,641
Staff costs (including directors' emoluments):		
– Salaries and other benefits	641,693	533,934
– Retirement benefit scheme contributions	56,006	48,174
– Share-based payment expenses	128,593	–
	826,292	582,108
Less: amounts included in the cost of inventories	(27,812)	(33,922)
amounts included in the cost of properties under construction	(10,582)	(3,236)
	787,898	544,950

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED 30 JUNE 2026

8. DIVIDENDS

No dividends were paid, declared or proposed during the six months ended 30 June 2026 and 2025.

9. EARNINGS (LOSS) PER SHARE

The calculation of the basic and diluted earnings (loss) per share attributable to owners of the Company is based on the following data:

Profit (loss)

	For the six months ended 30 June	
	2026 RMB'000 (Unaudited)	2025 RMB'000 (Unaudited)
Profit (loss) for the period attributable to owners of the Company for the purpose of basic and diluted earnings (loss) per share	25,501	(413,431)

Number of shares

	For the six months ended 30 June	
	2026 (Unaudited)	2025 (Unaudited)
Weighted average number of ordinary shares for the purpose of basic and diluted earnings (loss) per share	1,025,874,000	987,365,713

In June 2025, the Company issued 41,000,000 ordinary shares (H Shares). The weighted average number of ordinary shares for the purpose of basic loss per share for the six months ended 30 June 2025 has been adjusted for the issuance of new H shares.

The computation of diluted earnings per share for the six months ended 30 June 2026 does not assume the exercise of the Company's outstanding A share options and H share options as set out in Note 24. These share options were not dilutive as their exercise prices were higher than the Company's average share price during the six months ended 30 June 2026.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED 30 JUNE 2026

10. MOVEMENTS IN PROPERTY, PLANT AND EQUIPMENT AND RIGHT-OF-USE ASSETS

During the current interim period, the additions to of the Group's property, plant and equipment were RMB349,007,000 (six months ended 30 June 2025: RMB157,211,000) in the PRC in order to upgrade its manufacturing capacities, including capitalisation of interest expense of RMB21,020,000 (six months ended 30 June 2025: RMB13,774,000).

During the current interim period, the Group renewed several lease agreements and entered into several new lease agreements with lease terms ranged from 1 to 3 years (six months ended 30 June 2025: 2 to 9 years). The Group is required to make fixed payments on the usage of the assets during the contract period. On the date of lease commencement, the Group recognised right-of-use assets of RMB48,850,000 (six months ended 30 June 2025: RMB50,184,000) and lease liabilities of RMB46,353,000 (six months ended 30 June 2025: RMB50,184,000).

11. INTERESTS IN JOINT VENTURES

	As at 30 June 2026 RMB'000 (Unaudited)	As at 31 December 2025 RMB'000 (Audited)
Cost of investments in joint ventures	586,900	267,500
Share of post-acquisition losses	(89,488)	(59,022)
	497,412	208,478

During the period ended 30 June 2026, the Group formed a new joint venture entity with investment cost of RMB290,000,000 and RMB29,400,000 was further injected to an existing joint venture.

12. INTERESTS IN ASSOCIATES

	As at 30 June 2026 RMB'000 (Unaudited)	As at 31 December 2025 RMB'000 (Audited)
Cost of investments in associates	324,235	390,083
Share of post-acquisition losses	(89,967)	(112,928)
Gain on deemed disposal of associates	42,744	38,171
Less: elimination of unrealised downstream transactions	(16,027)	(16,027)
	260,985	299,299

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED 30 JUNE 2026

13. DEFERRED TAX ASSETS

As at 30 June 2026, deferred tax assets of RMB86,336,000 (31 December 2025: RMB88,309,000) mainly in relation to unused tax losses has been recognised in the Group's condensed consolidated statement of financial position. No deferred tax asset has been recognised on the remaining tax losses due to the unpredictability of future profit streams. The realisability of the deferred tax asset mainly depends on whether sufficient future profits or taxable temporary differences will be available in the future. In cases where the actual future taxable profits generated are less or more than expected or change in facts and circumstances which result in revision of future taxable profits estimation, a material reversal or further recognition of deferred tax assets may arise, which would be recognised in profit or loss for the period in which such a reversal or further recognition takes place.

14. TRADE AND BILL RECEIVABLES

	As at 30 June 2026 RMB'000 (Unaudited)	As at 31 December 2025 RMB'000 (Audited)
Trade receivables	748,895	507,476
Bills receivables	–	302
Less: Allowance for credit losses	(5,141)	(1,031)
	743,754	506,747

The Group allows a normal credit period of 30 to 60 days (31 December 2025: 30 to 60 days) to its trade customers.

The following is an analysis of trade receivables by age (net of allowance for credit losses) presented based on invoice dates, which approximated the revenue recognition date, at the end of the reporting period.

	As at 30 June 2026 RMB'000 (Unaudited)	As at 31 December 2025 RMB'000 (Audited)
0 to 90 days	706,437	490,887
91 to 180 days	26,833	5,078
Over 180 days	10,484	10,782
	743,754	506,747

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED 30 JUNE 2026

15. OTHER ASSETS, PREPAYMENTS AND OTHER RECEIVABLES

	As at 30 June 2026 RMB'000 (Unaudited)	As at 31 December 2025 RMB'000 (Audited)
Deposits		
– current	4,062	5,192
– non-current	8,902	9,447
Prepayments		
– current (<i>Note a</i>)	141,144	143,908
– non-current (<i>Note b</i>)	127,907	126,386
Other receivables		
– current	1,232	–
– non-current	40,485	38,703
Value added tax (“VAT”) recoverable (<i>Note c</i>)		
– current	1,071	13,390
– non-current	361,966	330,520
Consideration receivables arising from disposal of an associate (<i>Note 12</i>)	119,000	–
	805,769	667,546
Analysed as		
– current	266,509	162,490
– non-current	539,260	505,056
	805,769	667,546

Notes:

- (a) Prepayments mainly include fee paid for research and development services for the clinical and non-clinical study of the drugs. Prepayments also include other prepaid operating expenses and prepayments for purchase of raw materials. During the period ended 30 June 2026, impairment losses of nil (six months ended 30 June 2025: RMB1,510,000) was recognised on prepayments relating to purchase of raw materials.
- (b) Amount represents prepayments for construction in progress and acquisition of property, plant and equipment.
- (c) VAT recoverable of RMB1,071,000 (31 December 2025: RMB13,390,000) are presented as current assets as at 30 June 2026 since they are expected to be deducted from future VAT payable arising on the Group's revenue which are expected to be generated within the next twelve months from 30 June 2026. The remaining VAT recoverable of RMB361,966,000 (31 December 2025: RMB330,520,000) are expected to be recovered after twelve months from the end of reporting period and therefore presented as non-current assets at the end of reporting period.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED 30 JUNE 2026

16. OTHER FINANCIAL ASSETS

	As at 30 June 2026 RMB'000 (Unaudited)	As at 31 December 2025 RMB'000 (Audited)
Current assets		
Financial assets measured at FVTPL		
– Financial products	963,885	600,782
Non-current assets		
Financial assets measured at FVTPL		
– Unlisted equity investments in partnership	237,353	226,708
– Unlisted equity investments	210,314	368,001
– Listed equity investments	415,768	–
– Investments in preference shares	964,150	731,060
Financial assets designated as at FVTOCI (Note)	107,757	55,787
	1,935,342	1,381,556

Note: The investments are not held for trading, instead, these are held for long-term strategic purposes. The management of the Group have elected to designate these investments in equity instruments as at FVTOCI as they believe that recognising short-term fluctuations in these investments' fair value in profit or loss would not be consistent with the Group's strategy of holding the investments for long-term purposes and realising the performance potential in the long run.

17. RESTRICTED BANK DEPOSITS/BANK BALANCES AND CASH

Restricted bank deposits mainly represent the deposits restricted for the bank borrowings and for construction contract. The restricted bank deposits amounting to RMB26,337,000 (31 December 2025: RMB20,575,000) will be released in one year and are therefore classified as current assets.

Bank balances carry interest at market rates which ranged from 0.0001% to 3.60% per annum as at 30 June 2026 (31 December 2025: 0.0001% to 3.73% per annum).

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED 30 JUNE 2026

18. TRADE AND OTHER PAYABLES

	As at 30 June 2026 RMB'000 (Unaudited)	As at 31 December 2025 RMB'000 (Audited)
Trade payables	83,588	111,044
Accrued expenses in respect of		
– construction cost of properties under construction	517,189	509,233
– research and development expenses (Note a)	314,550	291,963
– selling and distribution expenses	133,247	155,430
– payables under collaboration agreement	68	55
– others	64,795	74,991
Salary and bonus payables	208,834	252,624
Other tax payables	28,082	22,377
Other payables (Note b)	61,479	69,011
	1,411,832	1,486,728
Analysed as		
– current	1,381,832	1,456,728
– non-current	30,000	30,000
	1,411,832	1,486,728

Notes:

- (a) Amounts include service fees payable to outsourced service providers including contract research organisations and clinical trial centres.
- (b) Included in the balance, amount of RMB30,000,000 (31 December 2025: RMB35,000,000) is non-trade in nature, unsecured and interest-free, and amount of RMB15,000,000 (31 December 2025: RMB15,000,000) is non-trade in nature, unsecured, and carrying interest rate of 5% (31 December 2025: 5%) per annum and will mature within one year.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED 30 JUNE 2026

18. TRADE AND OTHER PAYABLES (Continued)

Payment terms with suppliers are mainly with credit term of 0 to 90 days (2025: 0 days to 90 days) from the time when the goods and services are received from the suppliers. The following is an aging analysis of trade payables presented based on invoice date at the end of the reporting period:

	As at 30 June 2026 RMB'000 (Unaudited)	As at 31 December 2025 RMB'000 (Audited)
0 to 30 days	63,282	71,167
31 to 60 days	717	1,768
61 to 180 days	2,853	16,744
Over 180 days	16,736	21,365
	83,588	111,044

19. BORROWINGS

	As at 30 June 2026 RMB'000 (Unaudited)	As at 31 December 2025 RMB'000 (Audited)
Bank borrowings		
– secured	2,265,466	2,077,250
– unsecured	2,543,307	1,978,948
	4,808,773	4,056,198
Other borrowings		
– unsecured	1,009,103	-
	5,817,876	4,056,198

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED 30 JUNE 2026

19. BORROWINGS (Continued)

	As at 30 June 2026 RMB'000 (Unaudited)	As at 31 December 2025 RMB'000 (Audited)
The maturity profile of borrowings is as follows:		
– within one year	1,398,507	1,262,590
– within a period of more than one year but not exceeding two years	1,625,880	1,139,312
– within a period of more than two years but not exceeding five years	1,799,245	708,681
– within a period of more than five years	994,244	945,615
	5,817,876	4,056,198
Less: amount due within one year shown under current liabilities	(1,398,507)	(1,262,590)
Amount shown under non-current liabilities	4,419,369	2,793,608

As at 30 June 2026, the Group's variable-rate borrowings of RMB3,634,210,000 (31 December 2025: RMB2,757,491,000) carry interest at loan prime rate minus a margin, ranging from 2.11% to 3.05% (31 December 2025: 2.24% to 3.05%) per annum.

As at 30 June 2026, the Group's fixed-rate borrowings of RMB2,183,666,000 (31 December 2025: RMB1,298,707,000) carry interest at around 1.17% to 2.70% (31 December 2025: 1.17% to 2.79%) per annum.

In January 2026, the Company completed the issuance of the 2026 first tranche of technology innovation bonds and received a total proceed of RMB1,000,000,000. The bonds bear a coupon rate of 2.7% per annum payable at the end of each year and have a term of 3+2 years, maturing in January 2031. The bonds have a fixed term of 3 years. At the end of the third year, the Company has an option to adjust the coupon rate and the bondholders of the bonds have an option to extend the term for a further two years or to redeem the bonds.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED 30 JUNE 2026

19. BORROWINGS (Continued)

The Group has pledged the following assets as securities for the Group's bank borrowings at the end of reporting period:

	As at 30 June 2026 RMB'000 (Unaudited)	As at 31 December 2025 RMB'000 (Audited)
Restricted bank deposits	20,000	20,000
Property, plant and equipment	2,474,337	2,409,148
Right-of-use assets	208,833	212,798
	2,703,170	2,641,946

20. CONTRACT LIABILITIES

	As at 30 June 2026 RMB'000 (Unaudited)	As at 31 December 2025 RMB'000 (Audited)
Service income	9,851	8,903
Licensing income	97,693	105,417
Sale of pharmaceutical products	40,603	1,434
	148,147	115,754
Analysis as:		
– current	62,011	22,184
– non-current	86,136	93,570
	148,147	115,754

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED 30 JUNE 2026

20. CONTRACT LIABILITIES (Continued)

During the period ended 30 June 2025, the Group entered into a license agreement with an independent third party granting exclusive right to store, distribute, promote, market and sell toripalimab in European Union, European Economic Area, Switzerland and United Kingdom of Great Britain and Northern Ireland. The agreement has a fixed term. Pursuant to the agreement, the Group is entitled to an upfront payment, additional milestone payments, if any, and revenue sharing amount based on the net sales as stipulated in the agreement. In March 2025, the Group received the non-refundable upfront payment amounting to Euro15,000,000 (equivalent to RMB112,709,000).

During the period ended 30 June 2026, RMB4,606,000 (six months ended 30 June 2025: RMB3,183,000) was amortised and recognised in revenue. As of 30 June 2026, the contract liability of RMB9,067,000 was recognised as current portion and the remaining contract liabilities amounting to RMB86,136,000 was recognised as non-current portion.

21. OTHER FINANCIAL LIABILITIES

	As at 30 June 2026 RMB'000 (Unaudited)	As at 31 December 2025 RMB'000 (Audited)
Financial liabilities measured at amortised cost (<i>Note a</i>)	259,954	255,490
Financial liabilities measured at FVTPL (<i>Note b</i>)	150,539	151,000
	410,493	406,490

Notes:

- (a) The amounts represent capital injection received from other limited partners of Wuxi Runyuan Biomedical Venture Capital Investment Partnership (Limited Partnership) * 無錫潤元生物醫藥創業投資合夥企業(有限合夥) ("Wuxi Runyuan"), a subsidiary of the Company. The amount is measured at amortised cost based on the terms stipulated in the investment agreement.
- (b) The amounts represent capital injection received from other limited partners of Ningbo Yongyuan Xinglun Junjin Venture Capital Investment Partnership (Limited Partnership)* 寧波甬元興倫君金創業投資合夥企業(有限合夥) ("Ningbo Yongyuan") and Wenzhou Renze Kaidi Venture Capital Partnership (Limited Partnership) * 溫州仁澤凱狄創業投資合夥企業(有限合夥)("Wenzhou Renze"), subsidiaries of the Company. The amount is measured at FVTPL based on the terms stipulated in the investment agreements.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED 30 JUNE 2026

22. SHARE CAPITAL

	Total number of shares	Amount RMB'000
Registered, issued and fully paid at RMB1.0 per share:		
At 1 January 2025 (Audited)	985,689,871	985,690
H shares issued	41,000,000	41,000
At 30 June 2025 (Unaudited)	1,026,689,871	1,026,690
At 1 January 2026 (Audited) and 30 June 2026 (Unaudited)	1,026,689,871	1,026,690

The new shares rank pari passu with the existing shares of the same class in all respects.

23. CAPITAL AND OTHER COMMITMENTS

At the end of the reporting period, the Group had the following capital and other commitments:

	As at 30 June 2026 RMB'000 (Unaudited)	As at 31 December 2025 RMB'000 (Audited)
Capital expenditure contracted for but not provided in the condensed consolidated financial statements:		
– acquisition of property, plant and equipment	796,443	885,558
Other commitments in respect of investments:	357,500	357,500

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED 30 JUNE 2026

24. SHARE-BASED PAYMENT TRANSACTIONS

A Share Option Scheme

In September 2025, in order to provide incentives to eligible persons for their contributions to the Group, the Company's A share incentive scheme ("A Share Option Scheme") was approved and adopted. Under the A Share Option Scheme, the Company granted 25,150,000 share options to eligible grantees which include directors and employees in September 2025. The exercise price of each option is RMB46.67 per A share. The options are vested as follows:

On 1st anniversary of the first trading day following the end of the 12 months from grant date	50% vest
On 2nd anniversary of the first trading day following the end of the 24 months from grant date	remaining 50% vest

The share options are also subject to performance vesting conditions, including the fulfilment of both personal and the Group's performance targets.

Subject to the respective terms of issue, options may be exercised before the expiry date. If the employees choose not to exercise the options before the expiry date, the options will expire at the end of the date and no longer exercisable.

As at 30 June 2026, the number of options which remain outstanding under the A Share Option Scheme was 24,700,000 which, if exercise in full, representing 2.35% of the shares of the Company in issue at that date.

The table below discloses movement of the Company's A share options held by the Group's employees for the period ended 30 June 2026:

	Date of grant	Exercise price RMB	Vesting date	Expiry date	Number of A share incentive options				Outstanding at 30 June 2026
					Outstanding at 1 January 2026	Granted during the period	Exercised during the period	Forfeited during the period	
Tranche 1	September 2025	46.67	29 September 2026	28 September 2027	12,350,000	-	-	-	12,350,000
Tranche 2	September 2025	46.67	29 September 2027	28 September 2028	12,350,000	-	-	-	12,350,000
					24,700,000	-	-	-	24,700,000
Exercisable at the end of the period									-
Weighted average exercise price (RMB)					46.67	-	-	-	46.67

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED 30 JUNE 2026

24. SHARE-BASED PAYMENT TRANSACTIONS (Continued)

A Share Option Scheme (Continued)

The share options outstanding at 30 June 2026 had a weighted average remaining contractual life of 1.92 years.

The estimated weighted average fair value of the options granted on grant date is RMB7.69. The fair value of share options was estimated as at the date of grant, using a binomial model, taking into account the terms and conditions upon which the options were granted. The following table lists the inputs to the model used:

Key assumptions	Tranche 1	Tranche 2
Grant date share price	RMB41.09	RMB41.09
Exercise price	RMB46.67	RMB46.67
Option life	2 years	3 years
Volatility rate	40.18%	40.82%
Expected dividend yield	0%	0%
Risk-free interest rate	1.51%	1.53%

During the period ended 30 June 2026, total share-based payment expenses of RMB60,850,000 (net of RMB217,000 capitalized in property, plant and equipment) (six months ended 30 June 2025: nil) have been recognised in profit or loss.

H Share Option Scheme

In September 2025, in order to provide incentives to eligible persons for their contribution to the Group, the Company's H share incentive scheme ("H Share Option Scheme") was approved and adopted. Under the H Share Option Scheme, the Company granted 13,210,000 share options to eligible grantees which include directors and employees in September 2025. The exercise price of each option is Hong Kong dollar ("HK\$")32.30 per H share. The options are vested as follows:

On 1st anniversary of the first trading day following the end of the 12 months from grant date	50% vest
On 2nd anniversary of the first trading day following the end of the 24 months from grant date	remaining 50% vest

The share options are also subject to performance vesting conditions, including the fulfilment of both personal and the Group's performance targets.

Subject to the respective terms of issue, options may be exercised before the expiry date. If the employees choose not to exercise the options before the expiry date, the options will expire at the end of the date and no longer exercisable.

As at 30 June 2026, the number of options which remain outstanding under the H Share Option Scheme was 13,210,000 which, if exercise in full, representing 1.27% of the shares of the Company in issue at that date.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED 30 JUNE 2026

24. SHARE-BASED PAYMENT TRANSACTIONS (Continued)

H Share Option Scheme (Continued)

The table below discloses movement of the Company's H share options held by the Group's employees for the period ended 30 June 2026:

	Date of grant	Exercise price HK\$	Vesting date	Expiry date	Number of H share incentive options				Outstanding at 30 June 2026
					Outstanding at 1 January 2026	Granted during the period	Exercised during the period	Forfeited during the period	
Tranche 1	September 2025	32.30	2 September 2026	2 September 2030	6,605,000	–	–	–	6,605,000
Tranche 2	September 2025	32.30	2 September 2027	2 September 2030	6,605,000	–	–	–	6,605,000
					13,210,000	–	–	–	13,210,000
Exercisable at the end of the period									–
Weighted average exercise price (HK\$)					32.30	–	–	–	32.30

The share options outstanding at 30 June 2026 had a weighted average remaining contractual life of 4.17 years.

The estimated weighted average fair value of the options granted on grant date is HK\$15.47.

The fair value of equity-settled share options granted in September 2025 was estimated as at the date of grant, using a binomial model, taking into account the terms and conditions upon which the options were granted. The following table lists the inputs to the model used:

Key assumptions	Tranche 1	Tranche 2
Grant date share price	HK\$32.30	HK\$32.30
Exercise price	HK\$32.30	HK\$32.30
Option life	5 years	5 years
Volatility rate	56.93%	56.93%
Expected dividend yield	0%	0%
Risk-free interest rate	2.50%	2.50%

During the period ended 30 June 2026, total share-based payment expenses of RMB67,526,000 (six months ended 30 June 2025: nil) have been recognised in profit or loss.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED 30 JUNE 2026

25. FAIR VALUE MEASUREMENTS OF FINANCIAL INSTRUMENTS

Fair value measurements and valuation process

In estimating the fair value of an asset or a liability, the Group uses market-observable data to the extent it is available. For instruments with significant unobservable inputs under Level 3, the Group engages third party qualified valuers to perform the valuation. The management of the Group works closely with the qualified external valuers to establish the appropriate valuation techniques and inputs to the model.

The fair values of these financial assets and financial liabilities are determined (in particular, the valuation technique(s) and inputs used), as well as the level of the fair value hierarchy into which the fair value measurements are categorised (Levels 1 to 3) based on the degree to which the inputs to the fair value measurements is observable.

- Level 1 fair value measurements are based on quoted prices (unadjusted) in active market for identical assets or liabilities that the entity can access at the measurement date;
- Level 2 fair value measurements are those derived from inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and
- Level 3 fair value measurements are those derived from valuation techniques that include the lowest level inputs which are significant to the fair value measurement for the asset or liability that are not based on observable market data (significant unobservable inputs).

Fair value of the Group's financial assets and financial liabilities that are measured at fair value on a recurring basis

	Fair value as at		Fair value hierarchy	Valuation techniques and key inputs	Significant unobservable inputs
	30 June 2026 RMB'000 (Unaudited)	31 December 2025 RMB'000 (Audited)			
Financial assets					
Financial assets at FVTPL					
Unlisted equity investments	20,122	16,898	Level 3	Back-solve from recent transaction price	Redemption/Liquidation/IPO probability/risk – free rate/expected volatility/liquidity discount
Unlisted equity investments	190,192	190,192	Level 2	Recent transaction price	N/A
Investments in preference shares	334,669	162,585	Level 3	Back-solve from recent transaction price	Redemption/Liquidation/IPO probability/risk – free rate/expected volatility/liquidity discount

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED 30 JUNE 2026

25. FAIR VALUE MEASUREMENTS OF FINANCIAL INSTRUMENTS (Continued)

Fair value of the Group's financial assets and financial liabilities that are measured at fair value on a recurring basis (Continued)

	Fair value as at		Fair value hierarchy	Valuation techniques and key inputs	Significant unobservable inputs
	30 June 2026 RMB'000 (Unaudited)	31 December 2025 RMB'000 (Audited)			
Financial assets					
Investments in preference shares	–	2,874	Level 3	2026: Discounted cash flow -Future cash flows are estimated based on expected return 2025: Back-solve from recent transaction price	2026: Expected return 2025: Redemption/Liquidation/IPO probability/risk – free rate/expected volatility/liquidity discount
2026: Listed equity investments 2025: Unlisted equity investments	247,788	84,131	2026: Level 1 2025: Level 3	2026: Quoted bid prices in an active market 2025: Back-solve from recent transaction price	2026: N/A 2025: Redemption/Liquidation/IPO probability/risk – free rate/expected volatility/liquidity discount
Investments in preference shares	125,430	162,382	Level 3	2026: Back-solve from recent transaction price 2025: Market comparison approach – in this approach, fair value was determined with reference to Price-to-cumulative Research & Development Expenses multiple ("P/R&D multiple")	2026: Redemption/Liquidation/IPO probability/risk – free rate/expected volatility/liquidity discount 2025: Discount rate of 27% and P/R&D multiple of 3.6, taking into account management's experience and knowledge of market conditions
Investments in preference shares	139,803	182,849	Level 3	Market comparison approach – in this approach, fair value was determined with reference to P/R&D multiple	2026: Discount rate of 15% and P/R&D multiple of 6.17, taking into account management's experience and knowledge of market conditions 2025: Discount rate of 18% and P/R&D multiple of 8.88, taking into account management's experience and knowledge of market conditions
2026: Listed equity investments 2025: Unlisted equity investments	53,172	76,780	2026: Level 1 2025: Level 2	2026: Quoted bid prices in an active market 2025: Recent transaction price	N/A
Listed equity investments	114,808	–	Level 1	Quoted bid prices in an active market	N/A
Investments in preference shares	323,370	180,370	Level 2	Recent transaction price	N/A
Investments in preference shares	40,878	40,000	2026: Level 3 2025: Level 2	2026: Back-solve from recent transaction price 2025: Recent transaction price	2026: Redemption/Liquidation/IPO probability/risk – free rate/expected volatility/liquidity discount 2025: N/A

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED 30 JUNE 2026

25. FAIR VALUE MEASUREMENTS OF FINANCIAL INSTRUMENTS (Continued)

Fair value of the Group's financial assets and financial liabilities that are measured at fair value on a recurring basis (Continued)

	Fair value as at		Fair value hierarchy	Valuation techniques and key inputs	Significant unobservable inputs
	30 June 2026 RMB'000 (Unaudited)	31 December 2025 RMB'000 (Audited)			
Financial assets					
Investments in unlisted equity investments in partnership	237,353	226,708	Level 3	The fair value is determined based on the share of fair value of the underlying net assets held by the investee	The fair value of the underlying net assets of the investee
Financial products	963,885	600,782	Level 2	Discounted cash flow – Future cash flows are estimated based on expected return	N/A
	2,791,470	1,926,551			
Financial assets at FVTOCI					
Listed equity investments	23,761	24,872	Level 1	Quoted bid prices in an active market	N/A
Unlisted equity investments	30,915	30,915	Level 3	Back-solve from recent transaction price	Redemption/Liquidation/IPO probability/risk – free rate/expected volatility/liquidity discount
Unlisted equity investments	53,081	–	Level 2	Recent transaction price	N/A
	2,899,227	1,982,338			

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED 30 JUNE 2026

25. FAIR VALUE MEASUREMENTS OF FINANCIAL INSTRUMENTS (Continued)

Fair value of the Group's financial assets and financial liabilities that are measured at fair value on a recurring basis (Continued)

	Fair value as at		Fair value hierarchy	Valuation techniques and key inputs	Significant unobservable inputs
	30 June 2026 RMB'000 (Unaudited)	31 December 2025 RMB'000 (Audited)			
Financial liabilities					
Other financial liabilities	150,539	151,000	Level 2	The fair value is determined based on the share of fair value of the underlying net assets held by the investee	N/A

For the sensitivity analysis of significant unobservable inputs of other investments, the management of the Group considers that the impacts are immaterial, and such relevant information is not disclosed.

The Group owns 2.32% and 2.80% equity interests in two investee companies that are classified as financial assets at FVTPL and are measured at fair value at each reporting date. The fair value of these investments as at 30 June 2026 amounts to RMB53,172,000 and RMB247,788,000 respectively (31 December 2025: RMB76,780,000 and RMB84,131,000). The fair value of one investment as at 31 December 2025 was measured using a valuation technique derived from inputs other than quoted prices included within Level 1 that are observable and hence was classified as Level 2 of the fair value hierarchy. The fair value of the other investment as at 31 December 2025 was measured using a valuation technique with significant unobservable inputs and hence was classified as Level 3 of the fair value hierarchy. These two investee companies have become listed entities on the Main Board of The Stock Exchange of Hong Kong Limited since 23 June 2026 and 13 May 2026 respectively, with their shares traded in an active market. Therefore, the fair value of these investments as at 30 June 2026 were determined based on published price quotations available on the Main Board of The Stock Exchange of Hong Kong Limited and was classified as Level 1 of the fair value hierarchy.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED 30 JUNE 2026

25. FAIR VALUE MEASUREMENTS OF FINANCIAL INSTRUMENTS (Continued)

Reconciliation of Level 3 fair value measurements

	Unlisted equity investments RMB'000	Unlisted equity investments in partnership RMB'000	Investments in preference shares RMB'000	Total RMB'000
At 1 January 2026 (Audited)	131,944	226,708	510,690	869,342
Additions	–	26,400	170,000	196,400
Transfer into Level 3 due to change of valuation technique	–	–	40,879	40,879
Transfer out of Level 3 due to change of valuation technique (Note a)	(245,357)	–	–	(245,357)
Dividend received	–	(1,341)	–	(1,341)
Total gains (losses):				
– in profit or loss	164,450	(14,414)	(80,789)	69,247
At 30 June 2026 (Unaudited)	51,037	237,353	640,780	929,170
At 1 January 2025 (Audited)	54,742	188,869	529,738	773,349
Additions	–	28,794	–	28,794
Transfer in from investments in preference shares	84,131	–	–	84,131
Transfer out to unlisted equity investments	–	–	(84,131)	(84,131)
Transfer out of Level 3 due to change of valuation technique (Note b)	–	–	(65,999)	(65,999)
Dividend received	–	(1,639)	–	(1,639)
Total gains (losses):				
– in profit or loss	–	(10,843)	54,881	44,038
– in other comprehensive income	(4,414)	–	–	(4,414)
At 30 June 2025 (Unaudited)	134,459	205,181	434,489	774,129

Note a: These investments were measured by quoted bid prices in an active market at the end of reporting period as these investee companies were listed during this period.

Note b: These investments were measured by market comparison approach as at December 31, 2024.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED 30 JUNE 2026

26. DISPOSAL OF A SUBSIDIARY

During the period ended 30 June 2026, the Group disposed the entire 87.91% equity interest in RadAlliance Therapeutics, Inc. ("RadAlliance") to an independent third party at cash proceeds of United States Dollar ("USD")1,600. Upon completion of the disposal, RadAlliance ceased to be a subsidiary of the Group. The net liabilities of RadAlliance at the date of disposal were as follows:

	As at 31 May 2026 RMB'000
Trade receivables	2,386
Other assets, prepayments and other receivables	20,044
Bank balances and cash	7,522
Trade and other payables	(39,149)
Net liabilities on the date of disposal	(9,197)
Reclassification of cumulative translation reserve upon disposal of RadAlliance to profit or loss	(193)
	(9,390)
Carrying amount of the equity interest in RadAlliance	(8,255)
Total consideration received	11
Gain on disposal	8,266
Net cash outflow arising on disposal:	
Total cash consideration received	11
Cash and cash equivalents disposed of	(7,522)
	(7,511)

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED 30 JUNE 2026

27. RELATED PARTIES DISCLOSURES

Except as disclosed elsewhere in the condensed consolidated financial statements, the Group had also entered into the following transactions with related parties:

(a) Related party transactions

		For the six months ended 30 June	
		2026 RMB'000 (Unaudited)	2025 RMB'000 (Unaudited)
Joint ventures:			
Shanghai Ruotuo Biotechnology Co., Ltd. *			
上海倬妥生物科技有限公司("Ruotuo Bio") (Note a)	R&D expenses incurred	2,795	3,440
	Interest expenses on lease liabilities	46	65
	Service income	5,407	—
Hainan Junshi Phase II Venture Capital Investment Fund Partnership Enterprise (Limited Partnership) *			
海南君實二期創業投資基金合夥企業(有限合夥)			
("Junshi Phase II Fund")	Management fee income	560	—
Nanjing Ningze Innovation and Entrepreneurship Investment Partnership (Limited Partnership) *			
南京寧澤創新創業投資合夥企業(有限合夥)			
("Nanjing Ningze")	Management fee income	567	—
Anhui Gaotou Guotai Haitong Health M&A Equity Investment Fund Partnership (Limited Partnership)*			
安徽高投國泰海通健康併購股權投資基金合夥企業(有限合夥)("Anhui Gaotou")	Executive Partner fee income	561	—
Shanghai Junyu Biotechnology Development Co., Ltd.*			
上海君峪生物科技發展有限公司("SHJY") (Note b)	Service income	—	594

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED 30 JUNE 2026

27. RELATED PARTIES DISCLOSURES (Continued)

(a) Related party transactions (Continued)

		For the six months ended 30 June	
		2026	2025
		RMB'000	RMB'000
		(Unaudited)	(Unaudited)
Associates and their subsidiaries:			
Excellmab Pte Ltd.	Sale of pharmaceutical products	133	–
Shanghai Kelaijie Biotechnology Co., Ltd.*	Lease income	29	29
上海科睐傑生物技術有限公司("KLJ")	Service income	1,764	–
Hainan Junshi Phase I Equity Investment Fund Partnership Enterprise (Limited Partnership) *			
海南君實一期股權投資基金合夥企業(有限合夥)			
("Junshi Phase I Fund")	Management fee income	477	501
Anwita Biosciences, Inc.	R&D expenses incurred	–	1,199
Shanghai Junkang Litai Biomedical Technology Co., Ltd.*	Service and license		
上海君康立泰生物醫藥科技有限公司 ("JKLT") (Note c)	income	–	6,098
Other entities:			
Shanghai Zhiyu (Note d)	Transfer pipelines, patents, technical know-how and machinery in exchange of an investment	53,081	–
Shanghai Allink Biopharmaceutical Co., Ltd.*			
上海安領科生物醫藥有限公司("Allink") (Note e)	Service income	–	962

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED 30 JUNE 2026

27. RELATED PARTIES DISCLOSURES (Continued)

(a) Related party transactions (Continued)

Note a: During the current interim period, the Group renewed a lease agreement with Ruotuo Bio and recognised right-of-use assets of RMB3,066,000 on the date of lease commencement. As at 30 June 2026, the carrying amount of lease liabilities was RMB3,113,000.

Note b: SHJY is a joint venture of the Group before 21 May 2025. The service income represents the amount incurred before SHJY becoming a subsidiary of the Group.

Note c: JKLT is an associate of the Group after 28 March 2025. The amount represents transactions when JKLT is an associate of the Group.

Note d: One of the Company's non-executive directors is the controlling shareholder of Shanghai Zhiyu. The amount represents the tax-inclusive transaction consideration.

Note e: One of the Company's non-executive directors, who resigned on 21 June 2024, is the chairman of Allink. It is still regarded as a related party for 12 months following his resignation.

(b) Related party balances

		As at 30 June 2026 RMB'000 (Unaudited)	As at 31 December 2025 RMB'000 (Audited)
Joint ventures:			
Ruotuo Bio (<i>Note f</i>)	Trade receivable	7,581	2,920
Ruotuo Bio	Trade payable	932	–
Junshi Phase II Fund	Trade receivable	594	–
Nanjing Ningze	Trade receivable	952	345
Anhui Gaotou	Trade receivable	595	112
Associates and their subsidiaries:			
Shanghai Junze Chuangyao Biotechnology Co., Ltd.* 上海筠澤創曜生物科技有限公司	Other receivable	26,485	24,703
Junshi Phase I Fund	Trade receivable	3,566	3,060
KLJ	Trade receivable	1,764	–
JKLT	Trade receivable	–	2,460
Junshi Runjia (Xuzhou) Pharmaceutical Technology Co., Ltd.* 君實潤佳(徐州)醫藥科技有限公司 ("Junshi Runjia XZ") (<i>Note g</i>)	Trade receivable	–	6,380

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED 30 JUNE 2026

27. RELATED PARTIES DISCLOSURES (Continued)

(b) Related party balances (Continued)

		As at 30 June 2026 RMB'000 (Unaudited)	As at 31 December 2025 RMB'000 (Audited)
Other entities:			
Jiangsu Ruihe Environmental Engineering Research Centre Co., Ltd. *			
江蘇瑞河環境工程研究院有限公司("Ruihe")			
(Note h)	Trade payable	1,497	1,497
Key management personnel:			
Wang Zhengyu	Other payable	–	10

Note f: Trade receivables are presented net of allowance for credit losses.

Note g: Junshi Runjia XZ is a wholly-owned subsidiary of Junshi Runjia. Junshi Runjia is an associate of the Group before January 2026. The amount represents balances when Junshi Runjia is an associate of the Group.

Note h: One of the Company's non-executive directors is a director of Ruihe.

(c) Compensation of directors and key management personnel

The remuneration of directors of the Company and other members of key management during both periods were as follows:

	For the six months ended 30 June	
	2026 RMB'000 (Unaudited)	2025 RMB'000 (Unaudited)
Short-term benefits and performance bonus	19,321	17,218
Post-employment benefits	266	274
Share-based payment expenses	83,243	-
	102,830	17,492

The remuneration of key management personnel is determined by the management of the Company having regard to the performance of individuals and market trends.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED 30 JUNE 2026

28. SUBSEQUENT EVENTS

In July 2026, the Company completed the issuance of the 2026 second tranche of technology innovation bonds with an aggregate principal amount of RMB300,000,000. The bonds bear a coupon rate of 2.59% per annum and have a fixed term of 3 years, maturing in July 2029.

In August 2026, the Company completed the issuance of the 2026 third tranche of technology innovation bonds with an aggregate principal amount of RMB700,000,000. The bonds bear a coupon rate of 2.55% per annum and have a fixed term of 3 years, maturing in August 2029.

In August 2026, the Company proposed to enter into a share transfer agreement with certain investors pursuant to which the Company will transfer 656,250 shares of its wholly-owned subsidiary, TopAlliance Biosciences Inc., to the investors at a consideration of USD15 million. Concurrently, the investors will subscribe for the shares to be issued by TopAlliance Biosciences Inc. at an aggregate consideration of USD5 million. Upon completion of these transactions, the Company will hold a 20% equity interest in TopAlliance Biosciences Inc. and TopAlliance Biosciences Inc. will no longer be consolidated in the Group's financial statements.

DEFINITIONS

<i>A Share(s)</i>	ordinary share(s) in the share capital of the Company, with a nominal value of RMB1.00 each, which are subscribed for and paid for in Renminbi and have been issued and listed on the STAR Market since 15 July 2020
<i>A Shareholder(s)</i>	holder(s) of A Share(s)
<i>AACR</i>	American Association for Cancer Research
<i>ADC</i>	antibody-drug conjugate
<i>AGA</i>	actionable genomic aberration
<i>Articles of Association</i>	articles of association of the Company
<i>AS</i>	ankylosing spondylitis
<i>ASCO</i>	American Society of Clinical Oncology
<i>ASH</i>	American Society of Hematology
<i>Audit Committee</i>	the audit committee of the Company
<i>B-NHL</i>	B-cell non-Hodgkin lymphoma
<i>Board or Board of Directors</i>	the Company's board of Directors
<i>Bochuang Pharmaceuticals</i>	Chongqing Bochuang Pharmaceuticals Co., Ltd.*
<i>CG Code</i>	Corporate Governance Code in Part 2 of Appendix C1 to the Hong Kong Listing Rules
<i>Companies Ordinance</i>	the Companies Ordinance, Chapter 622 of the Laws of Hong Kong
<i>Coherus</i>	Coherus Oncology, Inc.
<i>Company or we</i>	Shanghai Junshi Biosciences Co., Ltd.* (上海君實生物醫藥科技股份有限公司)
<i>COVID-19</i>	coronavirus disease 2019

DEFINITIONS

<i>CRR</i>	complete response rate
<i>CRS</i>	cytokine release syndrome
<i>CSCO</i>	Chinese Society of Clinical Oncology
<i>DCR</i>	disease control rate
<i>Director(s)</i>	director(s) of the Company
<i>DLBCL</i>	diffuse large B-cell lymphoma
<i>DLT</i>	dose-limiting toxicity
<i>Dr. Reddy's</i>	Dr. Reddy's Laboratories Limited
<i>EC</i>	the European Commission
<i>EEA</i>	European Economic Area
<i>EFS</i>	event-free survival
<i>EGFR</i>	epidermal growth factor receptor
<i>ELCC</i>	European Lung Cancer Congress
<i>ESCC</i>	esophageal squamous cell carcinoma
<i>ESMO</i>	European Society for Medical Oncology
<i>ES-SCLC</i>	extensive-stage small cell lung cancer
<i>EU</i>	the European Union
<i>EULAR</i>	European Congress of Rheumatology
<i>FDA</i>	the United States Food and Drug Administration
<i>FIH</i>	first-in-human
<i>Fosun Pharma</i>	Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (上海復星醫藥(集團)股份有限公司)

DEFINITIONS

<i>Fosun Wanbang</i>	Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd.* (復星萬邦(江蘇)醫藥集團有限公司)
<i>G/GEJA</i>	gastric or gastroesophageal junction adenocarcinoma
<i>GMP</i>	the Good Manufacturing Practice
<i>Group</i>	the Company and its subsidiaries
<i>HCC</i>	hepatocellular carcinoma
<i>HeFH</i>	heterozygous familial hypercholesterolemia
<i>HER2</i>	human epidermal growth factor receptor 2
<i>HER3</i>	human epidermal growth factor receptor 3
<i>H Share(s)</i>	overseas-listed share(s) in the share capital of the Company, with a nominal value of RMB1.00 each, which are traded in Hong Kong dollars and are listed on Hong Kong Stock Exchange
<i>H Share Listing</i>	the listing of the Company's H Shares on the Hong Kong Stock Exchange on 24 December 2018
<i>H Shareholder(s)</i>	holder(s) of H Share(s)
<i>Hikma</i>	Hikma MENA FZE
<i>HKD or HK\$</i>	Hong Kong dollars, the official currency of Hong Kong
<i>Hong Kong</i>	Hong Kong Special Administrative Region of PRC
<i>Hong Kong Listing Rules or Listing Rules</i>	the Rules Governing the Listing of Securities on the Hong Kong Stock Exchange
<i>ICANS</i>	immune effector cell-associated neurotoxicity syndrome
<i>IO</i>	immune-oncology
<i>IFRSs</i>	International Financial Reporting Standards
<i>IND</i>	Investigational New Drug

DEFINITIONS

<i>irAEs</i>	immune-related adverse events
<i>JunTop Biosciences</i>	Shanghai JunTop Biosciences Co., Ltd.* (上海君拓生物醫藥科技有限公司)
<i>LEO Pharma</i>	LEO Pharma A/S
<i>Model Code</i>	the Model Code for Securities Transactions by Directors of Listed Issuers in Appendix C3 to the Hong Kong Listing Rules
<i>mPFS</i>	median progression-free survival
<i>MPR</i>	major pathological response
<i>MSS/pMMR</i>	microsatellite stable or mismatch repair proficient
<i>MTD</i>	maximum tolerated dose
<i>NCCN</i>	the National Comprehensive Cancer Network
<i>NDA</i>	new drug application
<i>NEJM</i>	New England Journal of Medicine
<i>NMPA</i>	National Medical Products Administration of China
<i>NPC</i>	nasopharyngeal carcinoma
<i>NRDL</i>	the National Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance (Year 2025) (《國家基本醫療保險、工傷保險和生育保險藥品目錄(2025 年)》)
<i>NSCLC</i>	non-small cell lung cancer
<i>Nomination Committee</i>	the nomination committee of the Company
<i>ORR</i>	objective response rate
<i>OS</i>	overall survival
<i>PFS</i>	progression free survival
<i>Placing Shares</i>	the placing of an aggregate of 41,000,000 new H Shares
<i>PK</i>	pharmacokinetics

DEFINITIONS

<i>PR</i>	partial response
<i>PRC or China</i>	the People's Republic of China
<i>pCR</i>	pathological complete response
<i>PsO</i>	psoriasis
<i>R&D</i>	research and development
<i>RCC</i>	renal cell carcinoma
<i>RdRp</i>	RNA-dependent RNA polymerase
<i>Remuneration and Appraisal Committee</i>	the remuneration and appraisal committee of the Company
<i>RFS</i>	relapse-free survival
<i>RP2D</i>	recommended phase II dose
<i>R/R</i>	relapsed or refractory
<i>Reporting Period</i>	the six months ended 30 June 2026
<i>RMB</i>	Renminbi
<i>SCLC</i>	small cell lung cancer
<i>SD</i>	stable disease
<i>SFO</i>	the Securities and Futures Ordinance, Chapter 571 of the laws of Hong Kong
<i>Share(s)</i>	ordinary share(s) in the share capital of the Company with a nominal value of RMB1.00 each, comprising H Shares and A Shares
<i>Shareholder(s)</i>	holder(s) of the Share(s)
<i>SITC</i>	Society for Immunotherapy of Cancer
<i>sNDA</i>	supplemental new drug application

DEFINITIONS

STAR Market	the STAR Market of the Shanghai Stock Exchange
STAR Market Listing	the listing of the Company's A Shares on the STAR Market on 15 July 2020
Stock Exchange or Hong Kong Stock Exchange	The Stock Exchange of Hong Kong Limited
Strategic and ESG Committee	the strategic and ESG committee of the Company
TEAEs	treatment-emergent adverse events
TNBC	triple-negative breast cancer
TopAlliance	TopAlliance Biosciences Inc.*(拓普艾萊生物技術有限公司), a wholly-owned subsidiary of the Company. As of the date of this report, the Company proposed to transfer the shares of TopAlliance, while TopAlliance proposed to issue new shares; upon completion of such transactions, the Company's shareholding in TopAlliance will change to 20%
TRAEs	treatment-related adverse events
UAE	United Arab Emirates
UC	urothelial carcinoma
UK	United Kingdom
USD	United States dollars
WCLC	World Conference on Lung Cancer
%	per cent

In this interim report, the terms "associate", "close associate", "connected person", "connected transaction", "controlling shareholder", "core connected person", "subsidiary" and "substantial shareholder" shall have the meanings given to such terms in the Hong Kong Listing Rules, unless the context otherwise requires.

The English translation of the PRC entities, enterprises, nationals, facilities, regulations in Chinese are translations of the Chinese names. To the extent there is any inconsistency between the Chinese names of the PRC entities, enterprises, nationals, facilities, regulations and their English translations, the Chinese names shall prevail.

* For identification purpose only